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It is not by muscle, speed, or physical dexterity that great things are achieved, but by 
reflection, force of character, and judgement; in these qualities old age is usually not 
only not poorer, but is even richer.  
 
~ Marcus Tullius Cicero (106-43 BC) 
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ABSTRACT 
 
Background: Many factors contribute to age-related changes in cognitive functioning. 
There is no single defined profile of factors that is clearly associated with the presence, 
or rate of progression, of cognitive changes in older adults. Stress, both psychosocial 
and physiological, may play a role. Aims: The general aim of this study was to explore 
the relationships between cognitive functioning and cognitive decline, on the one hand, 
and psychosocial and physiological stress, as well as a range of sociodemographic, 
psychosocial and physiological factors, on the other, in older adults with a range of 
cognitive function including healthy and impaired. Methods: Both cross-sectional 
(Study 1) and longitudinal (Study 2) designs addressed these aims. Study 1 examined 
the contribution of stress and sociodemographic, psychosocial, and physiological 
factors to cognition. Participants were 69 cognitively healthy older adults and 65 
possible or probable Alzheimer’s disease (AD) patients. They were all over the age of 
60 and resided in the greater Cape Town metropolitan region of South Africa. Cognitive 
functioning was assessed using a battery of neuropsychological tests. Salivary cortisol 
levels, apolipoprotein E (APOE) genotype, and plasma beta-amyloid levels were 
determined at baseline. A subset of participants underwent magnetic resonance imaging 
to determine brain hippocampal volumes. Study 2 investigated whether any of the 
variables measured at baseline were significant predictors of cognitive change and 
cognitive decline over a three-year period. Results: In the cross-sectional study, a 
hierarchical regression model showed that older age, fewer years of education, and the 
presence of the APOE є4 allele were predictors of poorer cognitive function. Although 
cognitive function was not significantly associated with either psychosocial stress or 
morning salivary cortisol levels (a physiological marker of stress), AD patients had 
significantly higher levels of self-perceived psychosocial stress. Secondary statistical 
analyses also showed a moderately positive association between morning salivary 
cortisol levels and the ratio of beta-amyloid 1-42/-40 concentrations. Furthermore, AD 
patients had smaller hippocampal volumes than controls, and AD patients with the є4 
allele had smaller hippocampal volumes than patients without. Across the entire 
sample, hippocampal volumes were associated with cognitive functioning. In the 
longitudinal study, baseline cognitive measures (as taken in Study 1) were compared 
with two subsequent annual assessments (Time 1 and Time 2). Across the entire 
sample, only age and education predicted cognitive change across time, and none of the 
predictor variables was associated with cognitive decline across the same time period. 
Conclusions: The profile of factors associated with cognitive functioning in this sample 
of older South African adults was similar to that found in studies from high-income 
countries. In this study, stress was not related to baseline cognitive function or to 
subsequent cognitive decline. This study is novel for South Africa and contributes to 
our knowledge of cognitive ageing and AD in low- and middle-income countries. It 
highlights the importance of age-associated cognitive disorders for public health on a 
continent in which they have largely been ignored. 
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CHAPTER ONE: GENERAL INTRODUCTION 
 
The central theme of this doctoral dissertation is the contribution of stress to 
cognitive functioning in South African older adults across a spectrum of cognition in 
healthy older adults and in those with cognitive impairment in Alzheimer’s disease 
(AD). The effects of biological factors on age-related cognitive functioning have been 
widely studied. However, the role of psychosocial factors such as stress for cognitive 
functioning is less well known. Stress, and the experience of traumatic life events, have 
negative consequences for mental health (Williams et al., 2007). More specifically, the 
experience of stress appears to be associated with mild cognitive impairment (MCI) and 
with risk for developing Alzheimer’s disease (Catania et al., 2009; Peavy et al., 2012; 
Wilson et al., 2007).  
Investigating the contribution of stress to age-related cognitive functioning is 
especially relevant in the South African context. South Africa has a turbulent socio-
political history, high levels of crime and violence, and elevated rates of exposure to 
traumatic life events and psychosocial stress (Finchilescu & Dawes, 1999; Williams et 
al., 2007). South African adults are likely to have experienced multiple traumatic events 
during their life which may have enduring effects on cognition. Thus it is pertinent to 
examine the effects of such psychosocial stress on cognitive functioning in these older 
adults. 
Although my core focus was on stress, I also aimed to explore the relationships 
of several factors with cognitive impairment and subsequent cognitive decline in older 
South African adults. These factors were chosen because they have previously been 
identified as risk factors for AD. However, the aim of this thesis was not to explore 
these factors in terms of their risk for cognitive impairment and AD, but rather to 
examine their associations with cognitive functioning and cognitive change/decline 
across a spectrum of healthy cognition to impaired cognition such as in AD. To this 
end, I embarked upon two studies: one cross-sectional (Study 1) and the other 
longitudinal (Study 2).  
The aim of Study 1 was to investigate the relationship between psychosocial 
stress, cortisol, the apolipoprotein E (APOE) є4 allele, beta-amyloid (Aβ), hippocampal 
volume, and cognitive functioning in a sample of cognitively healthy older adults and 
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AD patients. I chose to examine the relationships between factors that previous research 
has shown to be associated with (a) cognitive impairment in AD and (b) the experience 
of stress. Such an examination allowed me to perform integrative research to advance 
understanding of numerous factors that might affect cognitive functioning in older 
adults. Undertaking this exploration required an interdisciplinary approach, and so my 
research methods spanned the fields of psychology, physiology, biochemistry, and 
neuroradiology. By looking at different types of stress (e.g., recent, remote, and total 
psychosocial stress, and physiological stress as measured by cortisol), and their 
relationships with one another and with other physiological variables, I hoped to further 
current knowledge of stress and its impact on cognitive functioning in normal ageing 
and in AD. 
The aim of Study 2 was to identify variables associated with cognitive change 
and cognitive decline. That is to say, I sought to explore factors measured at baseline 
and their association with subsequent cognitive change/decline. 
An important note here is that a definitive diagnosis of AD can only be made 
with post-mortem histopathological confirmation of the disease (Chintamaneni & 
Bhaskar, 2012). Thus, all references in this dissertation to AD and AD patients refer to 
possible or probable AD, according to the clinical criteria stipulated by the National 
Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s 
Disease and Related Disorders Association (NINCDS/ADRDA) (McKhann et al., 
1984), and by the fourth edition (text revision) of the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV-TR) (American Psychiatric Association, 2003). 
Ultimately, I aimed to integrate results from the cross-sectional and longitudinal 
studies to provide a picture of factors that (a) were associated with baseline cognitive 
functioning in older South African adults, (b) predicted subsequent cognitive 
change/decline, and (c) were associated with both baseline cognitive functioning and 
subsequent cognitive change/decline. Thus, I begin with a general introduction 
(Chapter One) in which I discuss the concept of stress and provide an overview of AD. 
I then move on to discuss the literature, methods, and results for Study 1, followed by a 
brief summary of those results (Chapter Two). I then discuss the literature, methods, 
and results for Study 2, followed by a brief summary of those results (Chapter Three). 
Finally, I interpret and discuss the findings from both studies in a general discussion 
(Chapter Four).  
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Such investigation of the combination of these factors provides a novel 
contribution to the literature. These factors and their relation to cognition have been 
explored either on their own, or alongside only a few other factors. To my knowledge, 
no single study has attempted simultaneous investigation of all of these factors and their 
relationship to cognition in older adults. This contribution to knowledge is especially 
relevant in low- or middle-income countries (LAMICs), where little data regarding age-
related diseases in older adults are available. The 10/66 Dementia Research Group 
estimates that two-thirds of the world’s estimated 24 million people with dementia live 
in LAMICs, but that less than one-tenth of all population-based research into dementia 
and AD has been performed in developing countries (Prince, 2000). Although some 
such data do exist for LAMICs (e.g., in India, China and southeast Asia, Latin America 
and the Caribbean, and Africa; (Chandra et al., 1998; Hendrie et al., 1995; Mathuranath 
et al., 2012; Prince, Acosta, Chiu, Scazufca, & Varghese, 2003; Scazufca et al., 2008; 
Shaji, Bose, & Verghese, 2005), there is a paucity of this kind of research in South 
Africa. Such research is important in South Africa, because, despite the high prevalence 
of HIV/AIDS and other infectious diseases (Corbett et al., 2002; Muula, 2008), the 
South African population is ageing rapidly (Joubert & Bradshaw, 2006) and the country 
has one of the highest proportions of older persons in Africa (Kinsella & Ferreira, 
1997). 
 
What is Stress? 
Providing a concise definition of stress is problematic because the current 
scientific literature contains varying explanations. Broadly speaking, however, stress 
can be considered as a stimulus, as a reaction to a stimulus, or as the physiological 
effects of that reaction (Kemeny, 2013). 
Within one frequently cited framework, the neurobiological stress response 
occurs as a result of stressors (i.e., life experiences that threaten a primary goal). By this 
definition, stressors are categorized as being either physiological (i.e., presenting a 
threat to one’s physical integrity) or psychological (i.e., presenting a threat to one’s 
mental well-being) in nature (Dickerson, Gruenewald, & Kemeny, 2004; Stawski, 
Sliwinski, & Smyth, 2006). 
A key figure in stress research, Hans Selye, a distinguished physician and 
endocrinologist, coined the word “stress”. In his book, ‘The Stress of Life” Selye 
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provides a more functional definition of stress stating that it is “the state manifested by 
a specific syndrome which consists of all the nonspecifically-induced changes within a 
biologic system” (Selye, 1976, p. 64). Hence, he suggests that stress has its own 
constitution, but without one particular cause, that produces visible changes in response 
to stress. Selye writes about the General Adaptation Syndrome, in which he describes 
the stereotypical response pattern that occurs in situations of stress. Stated simply, this 
pattern includes an initial shock phase and an alarm reaction, followed by adaptation to 
the stressor, followed by an exhaustion phase, where persistent aversive stimulation can 
overcome an organism’s ability to resist the stressor (Selye, 1976).  
Stress is linked to disease because it disrupts one’s natural balance, homeostasis, 
which is vital for health and well-being (Perry & Pollard, 1998). An American 
physiologist, Cannon (1932, pg. 24), described homeostasis as “a condition which may 
vary, but which is relatively constant”. Homeostasis is considered to be incorporated by 
allostasis in relation to the life cycle of an organism and its individual experiences and 
responses to the surrounding environment (McEwen & Wingfield, 2010). The concept 
of allostasis, which means “maintaining stability or homeostasis through change”, was 
introduced by Sterling and Eyer (1988). It essentially relates to adaptive processes that 
sustain homeostasis through facilitators that include, primarily, adrenalin and cortisol 
(McEwen, 2005). These chemical messengers, adrenalin and cortisol, encourage 
adaptation in the response to acute stress; however, they can also result in allostatic 
load. Allostatic load, an indicator of the cumulative toll taken on the body, refers to 
wear and tear as a result of repeated exposure to chronic stress (McEwen & Seeman, 
1999). A high allostatic load might result from chronic overactivation of the stress 
system (Juster, McEwen, & Lupien, 2010; McEwen, 1998; McEwen & Stellar, 1993). 
When an organism is exposed to prolonged stress and can no longer resist the effects of 
a stressor, irreversible physiological damage can occur affecting both the brain and the 
body causing loss of bone minerals, immunosuppression, and changes in the neural 
circuitry of the hippocampus (McEwen, 2004b; Sapolsky, 1996). Because stress lowers 
one’s resistance, and because repeated stress results in repeated wear and tear on the 
body in general, the organism facing prolonged bouts of stress is at increased risk for 
disease.  
Psychosocial stress refers to acute or chronic stressors that may be of 
psychological (internal) or social (external) origin. An acute stressor (e.g., having a 
near-miss motor vehicle accident) triggers an immediate stress response that usually 
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subsides shortly after the stressor itself has ceased to exist or is no longer present in the 
individual’s life. On the other hand, a chronic stressor (e.g., ongoing financial problems 
or a lengthy illness) occurs over a prolonged period of time, where a simple or quick 
solution is not available (Baum, Cohen, & Hall, 1993). Both acute and chronic stressors 
may lead to a range of behavioural and physiological impairments (Lupien, McEwen, 
Gunnar, & Heim, 2009; McEwen, 2004a; McEwen, 2007). 
 
Stress: Its Impact on Cognition 
The experience of stress is associated with adverse effects on both physical and 
mental health. Recent research focus is especially on the effects of excessive stress on 
human cognition (Lupien et al., 2009; Sandi, 2013). The fields of psychology and 
medicine have provided strong evidence to support the notion that stress has a negative 
impact on human cognitive performance, and that this negative impact is aggravated in 
old age (Stawski et al., 2006; Sterlemann et al., 2010). Additionally, empirical evidence 
suggests that the negative effects of stress contribute to the development of AD (Peavy 
et al., 2012; Wang, Wahlberg, Karp, Winblad, & Fratiglioni, 2012). 
At this point, there must be a digression to acknowledge the fact that there are 
numerous risk factors for AD, many of which may interact with one another, further 
accelerating disease progression (Qiu, 2012; Vagelatos & Eslick, 2013). Thus, this 
dissertation takes a biopsychosocial approach to understanding the interplay of 
biological, psychological, and social factors that underlie cognitive functioning, and 
cognitive decline, in older adults.  
More than three decades ago, George Engel (Engel, 1977), an American 
psychiatrist, suggested that physicians should consider adopting a biopsychosocial 
model as an alternative to the prevailing biomedical model. The premise underlying this 
argument was that although the biomedical model played a significant role in 
identifying physiological and biochemical deficiencies in the body, one could not 
ignore the considerable influence that biological, psychosocial, and social factors could 
also have on human functioning in the context of disease and illness. For the purposes 
of this research, adopting the biopsychosocial approach was appropriate because this 
study was descriptive and relational. Hence, pursuing a true experimental approach 
would not have been feasible. It was not my intention to isolate all potential 
confounding variables in order to examine the influence of one particular variable on an 
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outcome. Rather, to align my research with the multifactorial nature of AD, I wished to 
explore the influence of several factors on cognitive functioning and on one another. 
Returning from the digression: To my knowledge, there are no studies that have 
investigated the combination of different types of psychosocial stress, cortisol, 
apolipoprotein є4, Aβ, hippocampal volume together, considering their relationships 
with one another and with cognitive function in normal ageing and in AD. 
The next section will focus specifically on AD, discussing briefly its 
epidemiology, pathology, symptoms, course and prognosis, clinical assessment, 
diagnosis, and treatment. I do not aim to provide an all-encompassing discussion of AD 
(for such discussion, see works by Ballard et al., (2011); Minati et al., (2009); and Perry 
et al., (2013)), but rather an introductory overview suited to the scope and constraints of 
a doctoral dissertation in psychology. The factors in which I am particularly interested, 
and that are investigated in Study 1, will be discussed in more detail in the Introduction 
to Study 1. 
 
Alzheimer’s Disease: A Brief Introduction 
AD is the leading cause of dementia worldwide and is the sixth-leading cause of 
death in high income countries (HIC) (Alzheimer's Association, 2013). DSM-IV-TR 
criteria specify that the term ‘dementia’ refers to a memory deficit demonstrated on 
objective cognitive testing, along with impairment in at least one other cognitive 
domain (e.g., language, thinking, planning, or reasoning), to such an extent that it 
interferes with an individual’s daily life and activities (American Psychiatric 
Association, 2003). AD is a progressive, irreversible brain disease that is characterized 
by a gradual onset, continuing cognitive and functional decline, and personality changes 
(Braak & Braak, 1995).  
The characteristics of AD were first described by a German neurologist and 
psychiatrist, Alois Alzheimer, in his 1907 paper, “Über eine eigenartige Erkankung der 
Hirnrinde”. In his paper, which was subsequently translated into English, (Alzheimer, 
Stelzmann, Schnitzlein, & Murtagh, 1995; Strassnig & Ganguli, 2005), Alzheimer 
documented the case of a 51-year-old woman whom he saw in a psychiatric institution 
in Frankfurt am Main. The first symptom with which she presented was jealousy of her 
husband. There followed rapid memory loss, disorientation, misplacing objects, 
delusions of persecution, and behavioural changes; these symptoms progressed with 
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time until her death four-and-a-half years later. Following her death, Alzheimer 
examined her brain and identified abnormal plaques and entangled bundles of fibres. 
These plaques have since become known as amyloid plaques; the twisted fibres are now 
called neurofibrillary tangles. The plaques consist largely of Aβ and the tangles of 
hyperphosphorylated tau protein (Sheng, Sabatini, & Sudhof, 2012).  
More than 100 years since that initial description of the disease, AD has a 
prominent place in scientific research. We now have a far better understanding of the 
disease process, and neuroscientists are making good headway in understanding the 
roles different factors may play in the pathogenesis of the disease. That said, however, 
the cause of AD remains unknown in most cases. (Some rare, inherited forms of the 
disease are known to be caused by specific mutations in the gene for amyloid precursor 
protein (APP) on chromosome 21 and the presenilin 1 (PS1) and presenilin 2 (PS2) 
genes on chromosomes 1 and 14 respectively; (Petrella, Coleman, & Doraiswamy, 
2003). There is much that we still do not understand about the sporadic form of the 
disease, particularly with regard to how certain factors may interact with one another to 
cause or worsen disease progression, or with regard to which individuals are at the 
highest risk for developing the disease.  
Epidemiology. A recent study using the latest data from the 2010 United States 
Census and the Chicago Health and Aging Project estimated that 5.2 million Americans 
of all ages will be living with AD in 2013 (Hebert, Weuve, Scherr, & Evans, 2013). 
Half of these people may not, because of lack of awareness or access to appropriate 
healthcare services, even know they have the disease (Alzheimer’s Association, 2013).  
An earlier Delphi consensus study estimated that the global prevalence of 
dementia in 2001 was in the region of 24 million people, of which 70% were cases of 
AD (Ferri et al., 2005). The study noted that that number was predicted to double every 
20 years, to 42 million by 2020 and to 81 million by 2040. These estimates were based 
on the assumptions of no changes in mortality and of no effective preventative or 
curative strategies. A global increase in numbers of people with dementia will 
undoubtedly lead to an even more costly burden of disease in the years to come. The 
Delphi consensus study also estimated that 60% of patients with dementia live in 
LAMICs, and that the rates of increase in people with dementia will be much higher by 
2040 in those countries than in HICs.  
It is, however, advisable to interpret the findings regarding LAMICs with 
caution, as relatively few studies of AD have been performed in these regions. 
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Nonetheless, data from studies in India, China and southeast Asia, Latin America and 
the Caribbean, and Africa (Chandra et al., 1998; Mathuranath et al., 2012; Prince et al., 
2003; Scazufca et al., 2008; Shaji, Bose, & Verghese, 2005) are fairly reliable. These 
studies present prevalence and incidence rates of AD and dementia. The three studies 
performed in regions of India reported prevalence and incidence rates of AD and 
dementia that were generally lower than those reported for HICs, and the study in 
Brazil reported a prevalence of dementia similar to that reported for African countries. 
Currently, there are no South African epidemiological data regarding AD. 
However, anecdotal evidence from local memory and geriatric clinics suggests that the 
presence of AD is not uncommon. (I discuss prevalence studies in Africa towards the 
end of the Introduction to Study 1, under the title Alzheimer’s disease in the South 
African context.)  
Risk factors. Empirical research has identified numerous risk factors for the 
development of AD. These risk factors have been identified via either observational 
studies (such as case-control and cross-sectional studies) or experimental studies (such 
as clinical trials; (Reitz, Brayne, & Mayeux, 2011)). Advancing age is a risk factor for 
AD, although AD is not a characteristic of normal ageing. The onset of AD before the 
age of 60 years is rare and is the result of either a mutation in the gene coding for APP 
or, more frequently, the PS1 or PS2 genes (Petrella et al., 2003). 
Currently, the only other confirmed risk factors for increasing the risk of 
developing AD include having a first-degree family member with dementia (Green et 
al., 2002), and presence of the є4 allele of the APOE gene (Lindsay et al., 2002; 
Notkola et al., 1998; Sando et al., 2008b). Some other potential risk factors that have 
been identified in the scientific literature include risk factors that increase the possibility 
of cardiovascular disease such as hypertension, obesity, and high cholesterol 
(Luchsinger et al., 2005; Reitz et al., 2011); traumatic brain injury (Jellinger, Paulus, 
Wrocklage, & Litvan, 2001; Sivanandam & Thakur, 2012); psychosocial stress 
(Alkadhi, 2012; Wang et al., 2012); low levels of education (Evans et al., 1997; Gatz et 
al., 2001); and lower socioeconomic status (Evans et al., 1997). 
MCI has also been shown to be a risk factor for AD (Damian et al., 2013; 
Levey, Lah, Goldstein, Steenland, & Bliwise, 2006). MCI represents a midway point 
between healthy cognition and a diagnosis for AD (Petersen, 2011). The original 
clinical criteria for MCI included concern about a change in cognition, impairment in 
one or more cognitive domains, normal general cognitive functioning, intact activities 
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of daily living, and no dementia (Petersen et al., 2001). Some researchers argue that 
MCI is a prodromal stage of AD (Drago et al., 2011); while others propose that it is a 
separate entity that may be representing something different, such as 
microvasculopathy. It has been demonstrated that not all cases of MCI progress to AD; 
some remain MCI and others may even revert back to healthy cognition (Britt et al., 
2011). 
Pathology. AD-type pathology is a significant predictor of dementia throughout 
the lifespan (Dolan et al., 2010). Usually, the pathological process of AD begins in the 
entorhinal cortex; at this stage, the disease is asymptomatic; i.e. there are no clinical 
symptoms. The pathology then progresses to the limbic system, including the 
hippocampus, and spreads further to associated regions of the neocortex (Braak & 
Braak, 1991). A magnetic resonance imaging (MRI) scan of the brain of a patient with 
early AD usually shows medial temporal, including hippocampal, atrophy, and 
enlargement of the temporal horn of the lateral ventricle (Apostolova et al., 2012). The 
medial temporal structures and temporal poles, as well as the temporoparietal junction, 
are the brain regions predominantly affected in AD (Frisoni et al., 2005; Harasty, 
Halliday, Kril, & Code, 1999; Krasuski et al., 1998). The frontal lobes are also involved 
later in the disease process (Scahill, Schott, Stevens, Rossor, & Fox, 2002). 
Microscopically, the hallmark neuropathological characteristics of AD, as seen 
on histological examination of postmortem brain tissue, include extreme formations of 
the amyloid plaques and neurofibrillary tangles, as well as eventual atrophy of the 
temporal, frontal, and parietal lobes. Plaques and tangles appear initially and primarily 
in hippocampal areas (Serrano-Pozo, Frosch, Masliah, & Hyman, 2011). 
The Aβ protein represents a cleaved fragment of the larger molecule, APP. The 
latter is a normal component of nerve cells (Selkoe, 2003). In the brains of healthy 
individuals, amyloid protein fragments are broken down and eliminated. In individuals 
with AD, however, these fragments accumulate, aggregate, and form hard, insoluble 
plaques in the brain parenchyma. Scientists consider these plaques to be central for 
neurodegeneration in the disease; this abnormal metabolism of APP is referred to as the 
“amyloid cascade hypothesis” (Karran, Mercken, & De, 2011). 
Neurofibrillary tangles are intracellular insoluble twisted protein fibres located 
within nerve cells. These fibres consist of a protein called tau that normally occurs in 
neurones. However, when processed abnormally, as is the case in AD, tau molecules 
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clump together, become hyperphosphorylated, and form tangles, which lead to neuronal 
death (Iqbal & Grundke-Iqbal, 2006). 
Both neuritic plaques and neurofibrillary tangles which may also be found in 
smaller amounts in the brains of healthy elderly persons may interfere in some way with 
normal cellular functioning. One hypothesis regarding this abnormal cellular 
functioning is that these plaques and tangles may stimulate a neuritic inflammatory 
response (Wilcock, 2012). The formation and aggregation of plaques and tangles often 
precede a loss of synaptic connections and neuronal death. However, neuroscientists 
still debate whether the plaques and tangles are a cause or a consequence of the disease. 
Clinical symptoms, course, and prognosis. AD is characterized by a gradual 
onset and progression of episodic memory impairment that is disproportionate to 
functioning in other cognitive domains (Salmon & Bondi, 2009). In most cases, 
common symptoms include misplacing everyday items such as keys and wallets, 
difficulty keeping track of details such as dates, problems performing multiple and/or 
complex tasks, and increasing repetitiveness in behaviour and speech. 
In the early stages of the disease, patients usually have only a relatively 
circumscribed cognitive deficit (typically, of episodic memory). With disease 
progression, cognitive impairment becomes more generalized. Late stages of the disease 
are often marked by gait disturbances, motor and sensory abnormalities, and seizures. 
The course of the disease is progressive over several years. A study investigating 
survival of people with a clinical diagnosis of dementia, including Alzheimer’s disease, 
found that the median survival of people diagnosed at age 60-69 was 6.7 (interquartile 
range 3.1-10.8) years. This median number decreased to 1.9 (0.7-3.6) years for those 
diagnosed at age 90 or over (Rait et al., 2010). In the absence of other serious medical 
conditions, death usually occurs in a state of extreme cognitive impairment, and is often 
secondary to cardiovascular disease, neoplasms, or complications (e.g., pneumonia or 
deep vein thrombosis) associated with being immobile and bed-bound (Beard et al., 
1996). 
Clinical assessment. This assessment usually includes at least a clinical 
interview and neuropsychological assessment, but ideally includes all four elements 
described below. 
Interview. The clinical history, taken by a healthcare practitioner, plays an 
integral role in the diagnosis of AD. This history should be obtained from both the 
patient and a knowledgeable informant who has regular contact with the patient and 
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who can provide objective collateral information. Using a systematic clinical approach, 
which includes a thorough interview, assists in defining the diagnosis through collecting 
pertinent information for creating a future care plan for patients with AD and their 
families and caregivers (Galasko, Golde, & Scheltens, 2013).   
The purpose of the interview is to ascertain information regarding changes in the 
status of the patient’s cognitive, behavioural, mood, and motor functioning, and any 
recent limitations in their ability to perform activities of daily living. The healthcare 
practitioner should enquire about the patient’s past, particularly with regard to 
educational and occupational attainment. Other important information that the 
healthcare practitioner should ascertain as part of the clinical interview includes the 
patient’s current medications and their side effects, alcohol and drug substance intake, 
symptoms of depression and/or anxiety, appetite and nutrition, sleep disturbance, and 
pain (Alom, Llinares, & Fajardo, 2012). 
Neuropsychological assessment of Alzheimer’s disease. Neuropsychological 
testing plays an important role in the diagnostic assessment of older adults with 
cognitive impairment in early disease stages (Chapman et al., 2010; McKhann et al., 
1984). Neuropsychological testing may be useful for differentiating cognitive changes 
associated with normal ageing from those associated with a neurodegenerative disease, 
and it helps to distinguish different types of dementia (Weintraub, Wicklund, & 
Salmon, 2012). The neuropsychological profile of AD is best recognized in the 
beginning stages of the disease, when the symptoms relate to the brain regions most 
affected in early AD (e.g., amnesia with hippocampal involvement). With disease 
progression and particularly in later disease, distinct neuropsychological profiles are 
more difficult to discern because of the more widespread and generalised 
neuroanatomical involvement (Salmon & Bondi, 2009).    
Although the neuropsychological presentation of AD may vary across patients, 
there are certain cognitive symptoms that are almost always present. Frequently, the 
neuropathology of AD targets, initially, the limbic regions (Serrano-Pozo et al., 2011) 
involved in episodic memory functioning (i.e., the ability to learn and recall recent 
information). Hence, pathological changes in this region manifest in the hallmark 
neuropsychological feature of AD, namely a deficit in episodic memory (Salmon & 
Bondi, 2009). As the disease and its associated pathology progress, other neocortical 
regions become affected, resulting in additional cognitive symptoms. These symptoms 
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often include deficits in language, semantic knowledge, visuospatial abilities, executive 
functioning, attention, working memory, and praxis (Weintraub et al., 2012). 
Although the focus of early cognitive deficits in AD has largely fallen on 
episodic memory (Gold & Budson, 2008), a recent meta-analysis proposes that a 
predominantly nonspecific cognitive decline can also occur prior to a diagnosis of 
dementia, during a preclinical phase (Backman, Jones, Berger, Laukka, & Small, 2005). 
Even though a decline in episodic memory functioning is the most common feature of 
AD in the early stage of the disease, studies have also demonstrated deficits in the 
domains of executive functioning, visuospatial ability, perceptual speed, attention, and 
verbal skills (Backman & Small, 2007). This decline in cognitive functioning across a 
variety of domains provides support for the notion that several brain regions (including 
the medial temporal lobes, frontal lobes, and anterior cingulate gyrus) are impaired in 
preclinical AD (Small, Mobly, Laukka, Jones, & Backman, 2003). 
Laboratory studies. It is standard practice where dementia is considered a 
possible diagnosis to perform routine blood tests to identify possible systemic factors. 
Cognitive impairment can sometimes be caused by a vitamin B12 deficiency, thiamine 
deficiency, or hypothyroidism. Additionally, metabolic problems such as diabetes (Xu, 
von, Qiu, Winblad, & Fratiglioni, 2009) and hyperinsulinemia (Luchsinger, Tang, Shea, 
& Mayeux, 2004) should be investigated because they can affect the progression of AD 
and are associated with concomitant cerebrovascular disease. Hyperlipidemia has also 
been proposed as a possible risk factor for AD, but empirical evidence is controversial 
and the relationship between cholesterol and AD remains unclear (Chui, Zheng, Reed, 
Vinters, & Mack, 2012). 
Neuroimaging. Structural neuroimaging scans such as computed tomography 
(CT) or MRI can be useful additional tests for excluding other possible causes of 
cognitive impairment (e.g., brain tumours, stroke, or subdural haemorrhage). In AD, 
structural MRI may demonstrate widespread cortical and hippocampal atrophy with 
ventricular enlargement (Frisoni, Fox, Jack, Jr., Scheltens, & Thompson, 2010). For 
instance, Moghekar and colleagues (2012) reported that MRI-detected cerebral white 
matter disease was associated with AD-type brain pathology at autopsy in a sample of 
50 participants from the Baltimore Longitudinal Study of Aging Autopsy Program. 
These researchers proposed that this relationship may explain, at least partly, the 
association between cerebral white matter disease and cognitive decline in older adults. 
In some cases, the use of cerebral perfusion single photon emission computed 
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tomography scans may also aid diagnosis of AD (Matsuda, 2007; O'Brien, 2007; 
Soonawala et al., 2002).  
Diagnosis. As detailed above, the diagnosis of AD is dependent on a detailed 
history from the patient and his or her relative or informant, including an account of 
previous and current level of functioning, a physical examination, cognitive testing, 
blood tests, and neuroimaging. Of all these factors, the most important one is to obtain a 
reliable history of the illness, including time of onset and nature of the progression 
(Ropper & Brown, 2005). 
Based on the results from these different methods of investigation, the diagnosis 
is largely made by exclusion of other causes of progressive dementia. Probable AD, 
following the NINCDS/ADRDA criteria, is defined by deficits in at least two areas of 
cognitive ability, including memory, in an individual demonstrating progressive 
deterioration, whose activities of daily living are also significantly impaired and where 
there is no evidence of an alternative cause for the symptoms (McKhann et al., 1984).  
The NINCDS/ADRDA (McKhann et al., 1984) and the DSM-IV-TR (American 
Psychiatric Association, 2003) criteria for the clinical diagnosis of possible or probable 
AD include progressive memory impairment, and one (or more) of the following 
cognitive disturbances: aphasia (language problems), apraxia (decline in ability to 
perform learned, purposeful movements), agnosia (inability to identify objects despite 
operational sensory function), disturbances in executive functioning (i.e., difficulty with 
planning, organizing, sequencing, problem-solving, and/or abstract reasoning), and 
perceptual difficulties. To meet diagnostic criteria, these memory impairments and 
other cognitive disturbances must produce major difficulties in social or occupational 
functioning, and must also represent a considerable decline from a previous level of 
functioning. Other clinical features that contribute to a diagnosis of probable AD after 
excluding other causes of dementia include neurological abnormalities such as 
increased muscle tone and a shuffling gait (McKhann et al., 1984). Patients with AD are 
also known to have a high prevalence of non-cognitive symptoms (Fernandez, Gobartt, 
& Balana, 2010); thus, the diagnosing healthcare professional should also enquire about 
the presence of affective and behavioural symptoms such as depression, insomnia, 
incontinence, delusions, hallucinations, weight loss, sex problems, and substantial 
verbal, emotional, and physical outbursts.  
From experience acquired recently by clinicians and researchers, it has emerged 
that often the diagnosis of AD can be identified in a prodromal phase, as the 
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pathophysiological process of AD is thought to commence years prior to diagnosis 
(Sperling et al., 2011). With this experience in mind, there have been several reviews of 
the NINCDS/ADRDA criteria (Dubois et al., 2007). The National Institute on Aging 
and the Alzheimer’s Association assembled an international workgroup to evaluate the 
currently available biomarker, epidemiological, and neuropsychological data. This 
group was also tasked with forming recommendations to identify factors that predict 
most strongly the risk of progression from “normal” cognition to MCI (Petersen, 2004; 
Petersen, 2011) and AD. The workgroup compiled two sets of criteria (Albert et al., 
2011); the first set is core clinical criteria that could be used by healthcare providers 
without access to advanced imaging techniques or cerebrospinal fluid (CSF) analysis. 
The second set of criteria integrates the use of biomarkers based on imaging and CSF 
measures. Currently, these recommendations are exclusively intended for the purposes 
of research and do not have any clinical applications. However, the aim is to validate 
the criteria that use biomarkers and to standardize biomarker analysis for clinical use in 
community settings (Albert et al., 2011). 
Differential diagnosis. When an older adult presents with cognitive change, AD 
is a possible diagnosis and can be determined fairly accurately based on the 
aforementioned criteria (Braaten, Parsons, McCue, Sellers, & Burns, 2006). In some 
cases, however, patients may present with unexpected or additional clinical features; 
this situation raises the possibility of other differential diagnoses or AD combined with 
other conditions. Clinical symptoms can also overlap in the presentation of different 
dementias such as AD, fronto-temporal dementia, and vascular dementia.  
Cerebrovascular disease often accompanies AD; its presence is known to 
increase the burden of AD, and can also affect the clinical expression of AD (Helzner et 
al., 2009). Vascular risk factors are known to have negative effects on the brain and 
cognitive functioning (O'Brien et al., 2003). Consideration of vascular risk factors is 
particularly relevant in South Africa and other LAMICs, as populations of these 
countries frequently show high levels of hypertension, cholesterol, and diabetes 
mellitus, in conjunction with poorer nutrition and less access to healthcare resources. 
Additionally, in South Africa one must consider the effect of infection on cognitive 
functioning because rates of systemic infection, primarily arising from HIV/AIDS, are 
high.  
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Treatment. Currently, there is no cure for AD and treatment is symptomatic, 
i.e. it only treats the symptoms and not the cause. Both pharmacologic and non-
pharmacologic interventions are available, but neither prevents or cures the disease. 
Over the past two decades, the main pharmacologic treatments for AD have 
targeted the brain’s underlying deficiency of acetylcholine. Acetylcholinesterase 
inhibitors raise brain levels of acetylcholine by blocking the enzyme responsible for its 
degradation. These drugs, namely donepezil, rivastigmine, and galantamine, are used 
for specific symptomatic treatment of cognition and behaviour in mild to moderate AD 
(Birks & Harvey, 2006). A systematic review and meta-analysis of placebo-controlled 
data support these drugs’ modest overall benefits for stabilizing or slowing decline in 
cognition, function, behaviour, and clinical global change (Hansen et al., 2008). 
However, although cognitive function may improve and remain above the pre-treatment 
baseline for the first year, it subsequently declines. Memantine, a drug labelled for 
moderate to severe AD, operates via a different mechanism of action; it regulates the 
effects of the neurotransmitter glutamate and can slow the progression of symptoms. 
Reportedly, this drug benefits cognitive, ADL, and global functioning (Rainer et al., 
2011; Schmitt & Wichems, 2006).  
Non-pharmacologic interventions aim to address behavioural and psychiatric 
symptoms of the disease (Gauthier et al., 2010). These interventions include, for 
example, simplifying tasks, reducing excess stimulation, and adapting the caregiving 
environment, with a focus on person-centered care (Brooker, 2003).  
 
Conclusion 
The actual cause of cognitive impairment and AD is unknown, but research 
suggests that several factors may be responsible and that these factors may act 
synergistically to precipitate or accelerate its progression. Thus, an approach exploring 
a range of factors associated with cognitive functioning in a multi-disciplinary way is 
both logical and necessary. Both the cross-sectional and longitudinal studies reported in 
this dissertation aim to explore cognitive functioning and AD in South African older 
adults. They also aim to contribute new knowledge about such associations in a LAMIC 
in which age-related diseases are largely ignored. Improved knowledge and factors 
related to cognitive functioning in older adults is particularly relevant for those factors 
that appear to be modifiable, to a certain degree (e.g., vascular or stress-related risk 
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factors). Understanding the contributory role of such factors in the development and 
progression of cognitive impairment may pave the way for future preventative and 
treatment strategies.  
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CHAPTER TWO: STUDY 1 – A CROSS-SECTIONAL STUDY 
 
Introduction 
 
Factors Associated with Changes in Cognitive Functioning 
The purpose of this introductory section is to provide an overview of the major 
factors associated with the presence of age-related changes in cognitive functioning. 
These are factors that have been identified previously as risk factors for the 
development of AD. This section will not provide an exhaustive review of all risk 
factors associated with Alzheimer’s disease. Rather, it will discuss the risk factors for 
AD, previously identified as such by prior studies, which were the focus of the current 
research. Important to note is that the focus of this study is not on risk factors for AD. 
Rather, these factors are explored in relation to cognitive functioning and as such they 
were selected because of their association with and risk for the development of AD, and 
therefore their contribution to cognitive impairment. 
This chapter provides a brief review of recent literature on physiological, 
psychosocial, and sociodemographic factors that have been found to be associated with 
the presence of AD. Specifically, the physiological factors include changes in the 
hypothalamic-pituitary-adrenal (HPA) axis functioning, the APOE-є4 allele, Aβ, and 
hippocampal volume. The psychosocial factors include traumatic life experiences, 
perceived psychosocial stress, and resilience. The sociodemographic factors include 
age, sex, and education. All of these factors may be grouped together as affecting, and 
being affected by, the experience of stress; hence, one might regard stress as the 
overarching factor of interest in the current research. Below, I discuss each of these 
factors in terms of their relationships with cognitive functioning and with AD, as well 
as their associations with the general concept of stress.  
Although various studies may refer to risk factors for the development of AD, it 
is important to note that the term “risk factors” does not necessarily imply causation. 
Instead, the term implies that a particular variable is associated with increased 
likelihood of disease occurrence. Additionally, in cross-sectional studies, association 
does not necessarily imply causation, as the symptoms may be a consequence of the 
disease itself and may not have preceded the disease at all.  
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 Physiological factors. The physiological factors of interest in this study include 
changes in HPA-axis functioning, APOE-є4 carrier status, Aβ, and hippocampal 
volume. Each of these is discussed below in terms of their relationship to cognitive 
functioning, AD, and stress.  
Changes in HPA-axis functioning. When humans are exposed to stressors of 
any kind, the body responds via two major effector systems, namely the HPA system 
and the locus-coeruleus-norepinephrine/sympathetic nervous system. These two 
systems work together and connect the brain with the periphery (Tsigos & Chrousos, 
2002). Activation of the latter leads to stimulation of the sympathetic nervous system 
which prepares the body for the classic “fight or flight” response which was first 
described by Cannon (1932). Such preparation includes, for example, increasing the 
availability of glucose and oxygen delivered to the muscles and brain, increasing heart 
rate and blood pressure, and vasoconstriction (Romero & Butler, 2007).  
However, the stress response system of interest in this study is the HPA axis. 
The HPA axis responds to stress by activating a neuroendocrine response (see Figure 1) 
and is a key intermediary of the effects of stress on the brain and behaviour. Activity in 
this system is associated with a range of hormonal, neurochemical, and physiological 
alterations (Foley & Kirschbaum, 2010). Activation of the HPA axis system after 
encountering a stressor enables the organism to adapt to increased demands and to 
sustain homeostasis after a stressful event (Kudielka & Kirschbaum, 2005).  
When an individual experiences a stressor, the HPA axis reacts via a series of 
physiological events; these are depicted in Figure 1. With the occurrence of a stressor, 
the hypothalamus is triggered to secrete corticotrophin-releasing hormone (CRH); the 
latter stimulates the anterior pituitary to produce adrenocorticotrophic hormone 
(ACTH), which, in turn, stimulates the adrenal cortex to release glucocorticoids into the 
bloodstream (Dickerson & Kemeny, 2004).  
The principal human glucocorticoid is cortisol. The release of this hormone is 
the best characterized marker of the HPA axis response to psychosocial stress. Cortisol 
is regulated by a negative feedback system (Tasker & Herman, 2011). In this system, 
high circulating glucocorticoids down-regulate the ACTH and CRH secretions from the 
pituitary and hypothalamus respectively (Lachize et al., 2009). As part of the acute 
stress effect, glucocorticoids interact with corticosteroid receptors located throughout 
the brain; these regulate gene transcription and cellular function subsequent to the 
impact of the acute stress effects (Phuc et al., 2005).  
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The hippocampus is a site for two types of corticosteroid receptors, Type I 
(mineralocorticoid receptors) and Type II (glucocorticoid receptors) (Webster, Knable, 
O'Grady, Orthmann, & Weickert, 2002). Both types of receptors are also abundant in 
the amygdala and in the prefrontal cortex (de Kloet, Datson, Revsin, Champagne, & 
Oitzl, 2008; Sanchez, Young, Plotsky, & Insel, 2000). These receptors are responsible 
for moderating the neural circuits and neuroendocrine systems that initiate behavioural 
responses to stress (Russo, Murrough, Han, Charney, & Nestler, 2012). Glucocorticoid 
receptors have been implicated in both short- and long-term neurobiological adaptations 
found in response to stressors (Maletic et al., 2007). For example, early-life 
environmental circumstances permanently alter (a) the development of glucocorticoid 
expression in the hippocampus, and (b) HPA-axis responses to chronic stress (Weaver, 
Diorio, Seckl, Szyf, & Meaney, 2004). Glucocorticoids can affect the hippocampus in 
several ways: They can diminish the excitability of some hippocampal neurones, they 
can initiate atrophy of dendritic branches in pyramidal cells within the CA3 area, and 
they can reduce the growth of new neurones in the dentate gyrus (McEwen & Sapolsky, 
1995).  
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        Stimulates  Releases   Inhibits  Impairs 
 
Figure 1. The negative feedback loop of the HPA axis. CRH = corticotrophin-releasing 
hormone. ACTH = adrenocorticotrophic hormone. The body experiences a stressor; this 
triggers the hypothalamus to release CRH, which stimulates the anterior lobe of the 
pituitary gland to release ACTH. The adrenal cortex of the adrenal glands responds to 
stimulation by the ACTH and produces cortisol. Cortisol has a negative feedback on the 
hypothalamus and the pituitary gland, inhibiting CRH and ACTH secretion.  
 
Glucocorticoids aid the body in preparing for survival during stressful 
situations; for instance, they play a role in altering heart rate, blood pressure, and 
muscle tone. However, if exceptionally high or low quantities of glucocorticoids are 
released, cognitive and neural processes may be impaired (Welberg, 2009). Findings 
from animal studies indicate that prolonged stress is associated with elevated 
glucocorticoid levels and, consequently, with enduring effects on certain brain circuits 
and systems (McEwen & Sapolsky, 1995). There is general consensus that exposure to 
stress can cause and/or exaggerate several diseases. For example, in humans, sustained 
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elevated levels of cortisol have been linked to a variety of medical and psychiatric 
conditions including hypertension, abdominal adiposity, hyperglycaemia, insulin 
resistance, dyslipidaemia, and depression (Epel, Lapidus, McEwen, & Brownell, 2001; 
Herbert, 2013; Whitworth, Williamson, Mangos, & Kelly, 2005). A proposed 
mechanism behind the harmful effect of stress is that HPA-axis functioning is a marker 
of allostatic load. A high allostatic load might arise from prolonged overactivation of 
the stress system (Juster et al., 2010; McEwen, 1998; McEwen & Stellar, 1993).  
The effects of chronic stress can therefore accumulate over the course of a 
lifetime, and may represent a risk factor for cognitive decline and for AD. If individuals 
experience chronic stress, then they are constantly releasing cortisol. This effect is 
exacerbated in older adults, whose biological systems become dysregulated and are not 
shut off as effectively as in young adults (Goldman, Glei, Seplaki, Liu, & Weinstein, 
2005; Gouin, Hantsoo, & Kiecolt-Glaser, 2008). Thus, in ageing, cortisol levels 
increase and are sustained at higher levels for a longer period of time. 
Peavy et al. (2007) explored the effects of chronic elevations in cortisol 
associated with prolonged stress, and found an association with a decline in memory 
performance. In their study of 91 non-demented elderly participants, they found that 
those individuals with high stress as a result of recent life events demonstrated higher 
cortisol concentrations and poorer memory performance than those with low stress. 
Elevated levels of circulating cortisol are not only associated with the 
development of cognitive impairment; they may also play a role in the progression of 
AD. For instance, Csernansky et al. (2006) assessed, on an annual basis for up to 4 
years, 33 subjects with very mild Alzheimer-type dementia and 21 subjects without 
dementia. They found that higher plasma cortisol levels were related to faster disease 
progression in AD patients. Consistent with these findings, Bemelmans et al., (2007) 
showed that plasma cortisol was (a) negatively correlated with concerted retrieval 
efforts during memory tasks, and (b) positively associated with AD progression. 
Furthermore, Lupien et al. (1998) detected a direct and significant relationship between 
elevated cortisol levels, hippocampal shrinkage, and hippocampal-based memory 
deficits in older adults. I shall discuss the hippocampus, its role in AD, and its link to 
stress, in more detail later on in this chapter. 
Genetics and apolipopoprotein E. As noted previously, there may be a genetic 
predisposition to developing AD (Farrer et al., 1997). A large twin study (Gatz et al., 
2006) using the Swedish Twin Registry provides support for the role of genes in the 
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development of AD. The study involved 11 884 twin pairs aged 65 years or older, 
among whom were 392 pairs in which one or both members had AD. Results from this 
study suggested that heritability for AD is high (reported at 58%) and that the same 
genetic factors were influential for both men and women. High rates of heritability for 
cognitive impairment have also been confirmed in a sample of African-Americans. 
Whitfield, Kiddoe, Gamaldo, Andel, and Edwards (2009) determined concordance rates 
and heritability for cognitive impairment in 95 same-sexed pairs of older African-
American twins from the Carolina African-American Twin Study of Aging. They 
demonstrated that the heritability for cognitive impairment in their sample was 54%, a 
number comparable to that reported for the European sample studied by Gatz and 
colleagues (2006).  
One gene that has been strongly linked with the development of AD, and more 
generally with some aspects of cognitive decline in elderly cohorts, is apolipoprotein E, 
and, more particularly, its є4 allele. Apolipoprotein E is a protein that is involved in 
lipid transport and metabolism. It is produced and secreted in the brain and plays a role 
in neuronal regeneration (Hankey & Wardlaw, 2008). The apolipoprotein E phenotype 
is coded by a gene that has three common allelic variants: є2, є3, є4 (Geda et al., 2006; 
Podewils et al., 2005).
1
 Corder and colleagues (Corder et al., 1993) studied 42 late-
onset AD families in which all individuals were over the age of 60 years. They found 
that individuals with two є4 alleles had an increased risk for AD, and an earlier age of 
onset, compared to individuals with one inherited є4 allele. Furthermore, in a study of 
218 AD patients, Martins, Oulhaj, de Jager, and Williams (2005) found that APOE 
genotype strongly predicted rate of cognitive decline; they reported a dose-response 
relation with the APOE-є4 allele. In North America and Europe, approximately 40-50% 
of AD patients are APOE-є4 carriers. These patients developed the disease earlier and 
experienced more rapid progression than AD patients with other APOE allelic variants 
(Bu, 2009).   
 Several other studies have investigated associations between APOE-є4 and 
cognitive functioning. A meta-analysis of 38 studies demonstrated that elderly 
individuals who possessed at least one APOE-є4 allele performed more poorly than 
those without an є4 allele on assessments of global cognitive functioning, executive 
                                                 
1
Interestingly, the є2 allelic variant has been proposed as having a protective effect against the 
development of dementia (Berlau, Corrada, Head, & Kawas, 2009; Farrer et al., 1997). It is beyond the 
scope of this project to investigate this particular allelic variant, however.  
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functioning, and memory (Small, Rosnick, Fratiglioni, & Backman, 2004). 
Furthermore, Tschanz et al. (2006) found that individuals with MCI had an increased 
risk of dementia at follow-up after 3 years compared to those without cognitive 
impairment, and that this risk was further elevated in individuals with the є4 allele 
compared to those without є4.  
In the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) study, 
Packard et al. (2007) found that a cohort of older APOE-є4 carriers had poorer memory 
performance and slower information processing over a mean 3.2 year follow-up, 
compared with APOE-є4 non-carriers. In addition, memory scores decreased 2.5% from 
baseline in those without є4, 4.3% in є4 heterozygotes, and 8.9-13.8% in є4 
homozygotes.  
Although most studies of APOE-є4 and ageing have focused on its negative 
impact on cognition, research studies have investigated whether the presence of this 
allele in healthy, non-demented controls maintains high cognitive function. Riley et al. 
(2000) explored this question using a group of 241 female participants with high 
cognitive functioning, aged 75-98 years, from the Nun Study. This is a longitudinal 
study of ageing and AD in Catholic nuns. Of the 241 participants who were cognitively 
intact at the first examination, 65% of those without an є4 allele remained cognitively 
intact for the duration of their involvement in the study, compared with 41% of those 
who were є4 carriers. The authors suggested that the absence of the APOE-є4 allele 
may be related to maintaining high levels of cognitive function in cognitively intact, 
very old adults. These results, however, appear to contradict previous findings, such as 
those from the PROSPER study.  
 The studies discussed above, and investigations into the effect of the APOE-є4 
allele on cognitive performance in patients with probable AD, have primarily been 
performed on populations of European descent from the global north (and the Western 
hemisphere, in particular). Hua and colleagues (2008) reported that within these groups, 
the APOE genotype frequencies of є3/є4 and є4/є4 were 21.2% and 2.8% respectively, 
in healthy controls. In AD patients from the same population group, the APOE 
genotype frequencies of є3/є4 and є4/є4 were 44.2% and 19.9%, respectively.  
The prevalence of APOE-є4 and its influence on the development of AD in 
LAMICs, and in ethnic minority populations in developed countries, remains unclear, 
with conflicting reports indicating either little or no increase in AD in the presence of 
the allele (Evans et al., 2003). Although scarce, there is some research investigating AD 
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in African populations. For example, Sepehrnia and colleagues (Sepehrnia, et al., 1989) 
reported that the APOE-є4 allelic frequency in a sample of non-demented Nigerian 
adults was 30%. Similarly, in a group of elderly Kenyan participants, Sayi et al. (1997) 
found comparable frequencies of the APOE-є4 allele (25%), with no clear difference in 
frequency between demented and non-demented subjects. Based on their preliminary 
observations, the authors suggested that elderly East Africans with no obvious clinical 
AD possessed relatively high APOE-є4 allelic frequencies compared to healthy ageing 
participants from Western countries, including African-Americans. In support of the 
notion that people of African descent possess high frequencies of APOE-є4, 
Sandholzer, Delport, Vermaak, and Utermann (1995) reported a high allelic frequency 
of APOE-є4 (0.37), in a South African Khoi San sample. This frequency is twice as 
high as that found in control populations of European descent reported in other studies 
(Farrer et al., 1997; Sando et al., 2008b).  
Focusing on individuals of African ancestry, the Indianapolis-Ibadan Dementia 
Study explored the association between APOE genotype and the risk for AD (Gureje et 
al., 2006; Hendrie et al., 1995; Sahota et al., 1997). This longitudinal, cross-cultural 
study of AD featured African-Americans residing in Indianapolis, Indiana, and Yoruba 
residing in Ibadan, Nigeria. The researchers studied these two populations because they 
are of related ethnic origin, a consequence arising from the slave trade commencing in 
the 16
th
 century, where some West Africans were forced to migrate to the Americas and 
West Indies (Bennett et al., 2003). Although the populations from Indianapolis and 
Ibadan may share genetic similarities, they have different environmental and cultural 
contexts. This situation provided a unique opportunity to study possible interactions 
between genetic and environmental factors (Hendrie et al., 1995). Results from these 
studies indicated that APOE-є4 was associated with an increased risk for AD in the 
African-American sample (Hendrie et al., 1995; Murrell et al., 2006; Sahota et al., 
1997). However, this association was not found in the Nigerian sample, despite APOE-
є4 allelic frequencies similar to those in African-Americans (Gureje et al., 2006). 
This disparity confirmed findings from an earlier study of elderly Nigerians, 
which also reported a lack of an association between APOE-є4 and AD (Osuntokun et 
al., 1995). That study reported an APOE-є4 allelic frequency of 16.7% in AD patients 
compared with 20.5% in the control subjects. Further confirming the lack of association 
between APOE-є4 and AD, (Gureje et al., 2006) a recent study conducted in older 
adults from rural Benin found no adverse effect of APOE-є4 on the risk of cognitive 
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impairment and dementia (Guerchet et al., 2009). Furthermore, the frequency of APOE-
є4 in that sample was high, at approximately 20%, and consistent with the APOE-є4 
allelic average in Africa, which is about 20.9%.  
 Given the reported high frequency of APOE-є4 in some African samples, yet the 
lack of association between APOE-є4 and AD found in some African studies, it is 
plausible to question whether, in African populations, the influence of APOE-є4 on 
cognitive functioning is mediated by other genetic or environmental factors (Reser, 
2009). One such mediating factor might be dietary lipid intake, which may play a role 
especially in increasing the effect of APOE-є4 on cognitive functioning  in the more 
industrialized urban populations, such as the Indianapolis African-Americans 
mentioned above (Petot et al., 2003; Carvalho-Wells, Jackson, Lockyer, Lovegrove, & 
Minihane 2012; Florent-Bechard et al., 2009; Hall et al., 2006). There is broad genetic 
and cultural diversity in African populations; therefore, it should not be surprising that 
the relationship between APOE-є4 and cognition varies across different African 
samples. 
 Research suggests that an interaction between psychosocial factors and APOE-
є4 may have an effect on general health and wellbeing. For instance, Hakansson et al. 
(2009) explored the association between mid-life marital status and cognitive function 
in later life, with special focus on APOE-є4. With an average follow-up of 21 years, 
they found an increased risk for AD in individuals who lost their partner before mid-life 
and were still widowed or divorced at follow-up; this risk was further increased in 
carriers of the є4 allele. Similarly, exploring the combined influence of psychosocial 
stress and genetic factors on health, Zeng and colleagues (Zeng, Hughes, Lewis, Li, & 
Zhang, 2011) reported that interactions between the APOE-є4 allele and one of four 
life-stress factors significantly increased the odds ratio of poor self-reported health. 
These life-stress factors included being a relocated mainlander (individuals who were 
forced to leave mainland China for Taiwan) in China, living in a crowded household 
with six or more persons, living in an earthquake-damaged house, and monthly 
financial difficulty. These factors had a substantially larger adverse impact on self-
reported health in APOE-є4 allele carriers than in non-carriers.  
Based on findings such as these, researchers have proposed that the pathological 
process of AD may be initiated by gene-environment interactions. Peavy et al. (2007) 
examined the interaction between an environmental factor (i.e., “real-life” stress, as 
opposed to experimentally-induced stress; for instance, hospitalization) and a genetic 
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risk factor for AD (i.e., the є4 allele) in explaining cognitive performance in a sample of 
91 non-demented older adults (mean age: 78.8 years). Low-stress participants 
demonstrated better cognitive performance than high-stress participants on tests of 
delayed recall, list learning, and immediate and delayed recall of visual designs. 
Participants without the є4 allele obtained better scores than participants with є4 on 
tests of immediate and delayed recall of visual designs. The authors also reported 
significant stress by APOE-є4 interaction effects on memory and cortisol in the high-
stress, є4-positive group. Participants in this group displayed consistently poorer 
memory performance compared to the high stress, є4-negative group, the low-stress, 
є4-positive group, and the low-stress, є4-negative group. Participants in this group also 
had higher cortisol levels than those in the low-stress, є4-positive group; cortisol levels 
did not differ in the high- and low-stress groups who were є4-negative. 
Similarly, Lee et al. (2008) investigated APOE-є4 carrier status, cortisol levels, 
and cognitive function in community-dwelling older adults. Their results showed that, 
even though a higher cortisol level was associated with lower cognitive scores, the 
slopes of the adverse relations were steeper in individuals with at least one APOE-є4 
allele. The authors suggested that cortisol’s relationship with cognitive functioning is 
modified by APOE-є4, such that the є4 allele increases the vulnerability of the ageing 
brain to the negative effects of stress.  
Beta-amyloid and the amyloid hypothesis. Although it is generally accepted 
that, in most cases, late-onset AD has a multifactorial etiology, the amyloid cascade 
hypothesis is a widely accepted mechanistic explanation for the development of AD 
pathology. It proposes that in both autosomal dominant AD, associated with APP 
mutations, PS1, and PS2, and in sporadic AD, Aβ accumulation in the brain plays a 
central role in AD pathophysiology. Furthermore, the ensuing disease process, 
including the formation of neurofibrillary tangles, results from an imbalance between 
Aβ production and Aβ clearance (Crews & Masliah, 2010; Hardy & Selkoe, 2002; 
Holtzman, Herz, & Bu, 2012). 
Much of what we know about Aβ in AD comes from transgenic mouse models. 
In these studies, the mutant human APP genes that cause familial AD have been 
inserted into mice so that they exhibit some of the pathological features of AD. These 
mice can then be studied with respect to the accumulation of insoluble Aβ, alpha-
synuclein, and neuronal deficits (see, e.g., Gallardo, Schlüter, Südhof, 2008; Masliah et 
al., 2001).  
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The presence and accumulation of Aβ-containing neuritic plaques in 
conjunction with neurofibrillary tangles are the pathological hallmarks of Alzheimer’s 
disease (Verbeek, Eikelenboom, & de Waal, 1997). Aβ plaques develop in the 
extracellular spaces and neurofibrillary tangles form inside nerve cells. The formation 
of these amyloid plaques and neurofibrillary tangles appear to contribute to the 
degeneration of brain neurones and the ensuing symptoms of AD (Caughey & 
Lansbury, 2003). Both the Aβ plaques and NFTs are accompanied by brain 
inflammation and neuronal loss (Iqbal & Grundke-Iqbal, 2006). 
Neuritic plaques are predominantly composed of collections of 42/43 amino 
acid β-amyloid peptides (Takahashi, Nam, Edgar, & Gouras, 2002). Beta-amyloid, a 
peptide of 39-43 amino acids, is formed after cleavage of the APP; the latter is a long 
trans-membrane protein consisting of 771 amino acids. The proteolytic action of two 
enzymes (beta-secretase and gamma-secretase) cleaves APP to produce Aβ (Haass, 
Kaether, Thinakaran, & Sisodia, 2012). The predominant lengths of the Aβ peptide are 
β1-40 (Aβ1-40) and β1-42 (Aβ1-42). Where the role of beta-secretase is altered, there is 
increased production of Aβ42 (Holtzman, 2009). The 42-length amino acid is 
chemically “stickier” than the other lengths, thus increasing its likelihood of clumping 
together to form plaques. Aβ42 is highly concentrated in neuritic plaques, and its 
accumulation is proposed as a common mechanism underlying all types of AD (Roher 
et al., 1993). Within this theoretical framework, Aβ activates the resident inflammatory 
macrophages of the brain, the microglial cells. These activated microglia secrete 
neurotoxic inflammatory mediators, which then damage the neurones. Recent murine 
work has shown that a microglia-mediated inflammatory process in the hypothalamus 
drives ageing, leading to shortened lifespan and impaired cognition (Zhang et al., 2013). 
The neuronal loss in humans that occurs in AD may therefore largely be the result of 
secondary inflammatory responses to Aβ deposition (Sondag, Dhawan, & Combs, 
2009).  
Stress has been investigated in murine studies in relation to Aβ. In a recent 
review, Dong and Csernansky (2009) summarized the effects of stress and stress 
hormones on Aβ and on plaque deposition. Specifically, they examined the 
relationships between chronic stressors, on the one hand, and HPA-axis activity, Aβ 
protein, and Aβ plaque deposition, on the other, in mouse models of AD. They 
suggested that physical and psychosocial stressors acting on the HPA axis influenced 
the pathogenesis of AD. Stress increased levels of brain corticotrophin-releasing factor 
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(CRF). In turn, the increased presence of CRF led to increased neuronal activity, Aβ 
release, and finally, amyloid aggregation into plaques. 
As an empirical demonstration of this process, Carroll et al. (2011) studied 
restraint/isolation-induced stress in a model of chronic stress that exacerbated Aβ 
accumulation in transgenic (Tg) mice with an APP mutation (Tg2576). They then 
extended this stress paradigm to a tau transgenic mouse model with the P301S mutation 
(PS19). In the Tg2576 mice, one month of restraint/isolation stress increased Aβ levels, 
suppressed microglial activation, and impaired spatial and fear memory, compared with 
non-stressed mice. One month of restraint/isolation stress in the PS19 mice increased 
tau hyperphosphorylation, insoluble tau aggression, neurodegeneration, and fear-
memory impairments. The combination of these results suggests that prolonged stress, 
through dysregulation of the HPA axis, increases Aβ production and deposition, as well 
as tau phosphorylation. Thus, prolonged stress may contribute to the neuropathogenesis 
of AD. 
In further support of this idea, Green, Billings, Roozendaal, McGaugh, & 
LaFerla (2006), using in vitro and in vivo murine experiments, found that stress-level 
glucocorticoid administration increased Aβ formation by increasing steady-state levels 
of APP and beta-site APP cleaving enzyme 1 (BACE1). These authors also found that 
glucocorticoids enhanced tau accumulation, implying that these hormones played a role 
in accelerating the development of neurofibrillary tangles. These findings suggest that 
high levels of glucocorticoids, associated with AD, may not only be a consequence of 
the disease process but may also play a central role in its development and progression. 
To date, most investigations of Aβ in humans have mostly involved measuring 
Aβ levels in CSF samples. Recently, however, positron emission tomography (PET), 
using Pittsburgh Compound-B-C11 as a radiotracer that binds to Aβ plaques, has been 
used to measure plaque burden in the brain (Wolk et al., 2012). Both of these methods, 
however, are invasive (in the case of CSF sampling) and costly (in the case of PET 
imaging). Hence, there is a need to identify biomarkers in measurable samples that are 
easier and cheaper to obtain (e.g., blood samples). One such blood-based biomarker that 
has received increasing attention as a potential diagnostic marker is plasma Aβ.  
Aβ is a solute that is thought to be cleared from the brain via the CSF-brain 
barrier into the CSF and then into the venous drainage system of the brain (Toledo, 
Shaw, & Trojanowski, 2013). However, plasma Aβ measurements are more prone to 
variability than CSF, and attempts to relate plasma Aβ levels to the diagnosis of AD 
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have produced contradictory results (Rissman, Trojanowski, Shaw, & Aisen, 2012). 
Some of the difficulties may arise through inter-assay variation. Recent work by 
Figurski et al. (2012), however, using improved standardized protocols for the 
measurement of plasma Aβ, has found significant correlations between plasma Aβ and 
CSF biomarkers. For example, they reported that plasma Aβ1-42 was negatively 
correlated to the following: CSF phosphorylated tau 181 (p-tau), CSF p-tau 181/Aβ1-42 
ratio, CSF tau/Aβ1-42 ratio, CSF tau, and CSF Aβ1-42. These authors noted, though, 
that the observed correlations were not strong enough to support the use of plasma Aβ 
as diagnostic tool, but that Aβ1-42 could be used as a pharmacodynamic marker for 
drug trials of amyloid-modifying therapies.   
Studies have explored the independent roles of the Aβ1-40 and Aβ1-42 
peptides, and the role of the relative proportions of these two peptides (i.e. the Aβ1-
42/Aβ1-40 ratio), in sporadic AD. Koyama et al. (2012) conducted a systematic review 
and meta-analysis of studies investigating whether plasma Aβ levels predicted the 
development of dementia, AD, and cognitive decline. They concluded that lower ratios 
of plasma Aβ1-42/Aβ1-40, in general, predict the development of AD, but that Aβ1-42 
and Aβ1-40 alone were not strong predictors of AD risk. In concordance with this 
review, a prospective case-cohort study with a mean follow-up of 8.6 years examined 
plasma Aβ1-40 and Aβ1-42 and the risk of dementia, including AD (van Oijen, 
Hofman, Soares, Koudstaal, & Breteler, 2006). High concentrations of plasma Aβ1-40, 
but not Aβ1-42, at baseline were associated with an increased risk of dementia. An 
increased plasma Aβ1-42/Aβ1-40 ratio was associated with reduced risk of dementia. In 
contrast to these findings, a later prospective population-based study of elderly men 
found that low plasma Aβ1-40 levels predicted incident AD (Sundelof et al., 2008). The 
latter finding, that plasma Aβ1-42 was not significantly associated with AD incidence, 
was consistent with that of the van Oijen study mentioned above. 
Although there may be disagreement about the role of Aβ1-42 and Aβ1-40 in 
predicting AD risk, they may have a more clearly defined role in established disease. 
For example, Mehta et al. (2000) reported that mean plasma levels of Aβ1-40 were 
higher in their sample of patients with sporadic AD than in controls. Similarly, Mayeux 
et al. (2003) reported that levels of plasma Aβ1-40 and Aβ1-42 are elevated in the early 
stages of AD, but that they subsequently declined. The finding regarding the lower 
Aβ1-42/Aβ1-40 ratio also appears to be borne out in longitudinal research of disease 
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progression. A recently published study of AD patients reported a decrease in the 
plasma Aβ1-42/Aβ1-40 ratio over a period of 18 months (Rembach et al., 2013). 
The current state of the literature suggests that plasma Aβ levels or ratios may 
have different risks for development of AD as opposed to their role in and with disease 
progression. Clearly, further investigations are required to confirm plasma Aβ levels or 
ratios as preclinical biomarkers for AD.  
Hippocampal volume. The hippocampus plays a critical role in memory 
formation. Activation of hippocampal structures is crucial for new learning and 
declarative memory, especially episodic memory processes (Eichenbaum, 2003; 
Cipolotti et al., 2001). The brain pathology present in AD affects the hippocampus and 
other nearby regions at even early stages of the disease (Braak & Braak, 1991). These 
effects (for example, medial temporal lobe atrophy) can be seen on MRI.  
Structural imaging has become increasingly useful in aiding the differential 
diagnosis of various kinds of dementia (Ramani, Jensen, & Helpern, 2006). Regions of 
brain tissue loss, as demonstrated by structural MRI, correlate with observed cognitive 
deficits (Frisoni et al., 2010; Vemuri et al., 2009). Furthermore, rates of total brain and 
hippocampal atrophy are sensitive markers of AD (McEvoy & Brewer, 2010). 
Additionally, a number of structural MRI studies have indicated that estimates of tissue 
damage or loss in characteristically vulnerable brain areas, namely the entorhinal cortex 
and hippocampus, are predictive of progression from MCI to AD. 
Schuff et al. (2009) performed an MRI multicentre study that included 112 
cognitively healthy older adults, 226 older adults with MCI, and 96 patients with AD. 
MCI and AD patients showed significant loss of hippocampal volume over 6 months, 
and accelerated loss over 1 year. Additionally, increased rates of hippocampal volume 
loss were associated with the presence of the є4 allele in AD patients, and with lower 
CSF Aβ1-42 in MCI participants. The authors concluded that hippocampal volume 
change over time, as measured by structural MRI, has potential as a marker for AD.  
The hippocampus was also one of the first brain regions to be identified as a 
target for stress hormones such as cortisol (McEwen, Weiss, & Schwartz, 1968). 
Subsequent studies have confirmed that the hippocampus is one of the regions primarily 
affected by the acute release of excess glucocorticoids and by chronic exposure to those 
hormones (Backman, Jones, Berger, Laukka, & Small, 2005b; McDonald, 2002). The 
hippocampus lies at the intersection of limbic, cognitive, and neuroendocrine regulatory 
circuits and may, therefore, be especially vulnerable to glucocorticoids/stress. 
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Alteration or damage to the hippocampus may set the stage for deleterious feedback 
that arises via neuroendocrine dysregulation. Ensuing hippocampal atrophy could cause 
further neuroendocrine dysfunction, possibly involving failure to down-regulate 
glucocorticoid receptors, where failure of the normal negative feedback to the HPA axis 
leads to the release of even more glucocorticoids. This release is, in turn, associated 
with further damage to the hippocampus, and so the destructive cycle continues 
(Maletic et al., 2007). 
These cortisol elevations and consequent changes in hippocampal structure 
resulting from stress are linked with deficits in learning and memory function. Research 
conducted in rats indicates that a mild increase in glucocorticoid levels may enhance 
memory performance, but that large deficiencies or elevations disrupt memory 
performance (de Quervain et al., 2003; McEwen & Sapolsky, 1995; Roozendaal, 2000; 
Wolf et al., 2001). Similarly, in humans, Abercrombie, Kalin, Thurow, Rosenkranz, and 
Davidson (2003) reported enhanced memory performance following mild 
glucocorticoid elevations, but impaired performance following higher elevations. This 
result confirmed findings from an earlier study: Lupien et al. (1994) examined a group 
of 19 healthy elderly participants previously shown to differ in regard to their cortisol 
levels over a 4-year period. Those participants with increasing/high basal cortisol levels 
had significant impairments in hippocampal-dependent forms of memory compared to 
participants with decreasing/low basal cortisol levels. In a follow-up of the same cohort 
over a period of 5-6 years, Lupien et al. (1998) measured basal plasma cortisol levels 
annually over a 24-hour period in 51 healthy volunteer older adults. The authors found 
that total hippocampal volume and performance on hippocampal-dependent memory 
tasks in the increasing/high cortisol group was significantly reduced in comparison to 
that of the decreasing/moderate cortisol group. Taken together these findings provide 
support for the idea that exposure to progressively elevated glucocorticoid levels 
eventually compromises hippocampal integrity and therefore affects performance on 
hippocampal-dependent cognitive tasks (Squire, 1992).  
Decades of research into the relationships between stress and cognition confirm 
that glucocorticoids play a vital role in the regulation of memory. A review performed 
by de Quervain and colleagues (de Quervain, Aerni, Schelling, & Roozendaal, 2009) 
concluded that there was evidence for the role of glucocorticoids in impairment of 
memory retrieval based on evidence from both animal and human studies.  
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The presence of APOE є4 has also been associated with hippocampal atrophy. 
O’Dwyer et al. (2012) examined the volumes of deep grey matter structures in 22 
healthy APOE-є4 carriers and 22 non-carriers (20-38 years old). Their results indicated 
that, even in healthy young adults, the presence of є4 was associated with hippocampal 
volume reduction. They suggested that the hippocampus might be particularly 
vulnerable to further degeneration in APOE-є4 carriers as they enter middle- and old-
age. In a sample of older adults (age range: 58-91 years), individuals with cognitive 
decline who were APOE-є4 carriers had a faster rate of regional gray matter atrophy 
(affecting the hippocampi, temporal and parietal lobes, right caudate nucleus, and 
insulae) than non-carriers (Spampinato, Rumboldt, Hosker, & Mintzer, 2011). 
Of contrasting note, however, is a recent study (Walsh, Slater, Nair, & Attia, 
2013) that found no association between APOE-є4 carrier status and hippocampal 
volume in a cohort of community-dwelling individuals with mild AD. These results 
imply that the presence of є4 is, in itself, not sufficient to estimate pathological disease 
in early AD. This finding, then, confirms work by Henderson et al. (1995), who 
demonstrated that the APOE-є4 allele is a risk factor for dementia but that 
homozygosity for the є4 allele was not sufficient for the development of cognitive 
impairment and AD.  
Psychosocial factors. Several psychosocial factors have been linked to risk for 
AD. The psychosocial factors of interest in this study include psychosocial stress and 
resilience, both of which are discussed below.  
Psychosocial stress. The experience of stress, i.e., the encounter with a stressor, 
can alter brain circuitry to such an extent that it can have lasting effects on cognition 
(Arnsten, 2009; McEwen, 2007; Vasterling et al., 2012). In community-based studies, 
Neupert, Almeida, Mroczek, and Spiro III (2006) found an association between daily 
stressors and everyday memory failures, even after controlling for the effects of 
neuroticism, life-event stressors, and physical health. They also established that the 
number of life-event stressors correlated positively with the number of everyday 
memory failures (see also Stawski et al., 2006). Similarly, Caswell et al. (2003) found a 
negative association between chronic stress and information processing, episodic 
memory, and general cognitive function in older-adult caregivers of dementia patients.  
Laboratory-based studies have shown that acute stressors also have negative 
effects on cognition in elderly persons. For instance, Lupien et al. ( 1997a) found that 
acute psychosocial stress manipulations, such as public-speaking tasks, reversibly 
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impaired memory performance in elderly adults (see also Luine, Villegas, Martinez, & 
McEwen, 1994). Wilson et al. (2003) reported that elderly people who were prone to 
experience psychological distress were also more likely to develop AD than were age-
equivalent non-stressed individuals.  
Johansson et al. (2010) published a 35-year longitudinal population study that 
investigated associations between midlife psychological stress and the risk of dementia. 
Participants in this sample (1462 females aged 36-60 years) were examined in 1968-69 
and re-examined in 1974-75, 1980-81, 1992-93, and 2000-03. At the 35-year follow-up, 
161 participants had developed dementia; 105 were diagnosed with probable AD. 
Frequent/constant stress, as reported in 1968 and 1974, was associated with this 
eventual development of AD. Reports of stress at one, two, or three examinations were 
related to a sequentially increased risk of developing dementia. 
Although not explored in the current study but relevant to note in the context of 
stress and AD is post-traumatic stress disorder (PTSD), because severe psychological 
stress is associated with cognitive impairment and risk for AD. Furthermore, 
neuroimaging has demonstrated similarities between PTSD and AD on structural MRI 
(Tsolaki, Eleftheriou, & Karavida 2009). PTSD is stress-related psychopathology that 
can occur after an extreme emotional trauma that involved the threat of serious injury or 
death and resulted in intrusions, avoidance, negative alterations in cognitive functioning 
and mood, and changes in arousal and reactivity (American Psychiatric Association, 
2013). PTSD has been linked to impaired cognition, predominantly in the domain of 
memory (Samuelson, 2011). A recent study investigated neuropsychological outcomes 
and PTSD in Iraq-deployed US Army soldiers (Vasterling et al., 2012). The study 
reported that PTSD was associated with enduring effects on cognitive functioning. 
Furthermore, research has shown a greater prevalence and increased risk of dementia 
(including AD) among US combat veterans (for more information, see Yaffe et al., 
2010, and Qureshi et al., 2010).  
At this point, it also seems pertinent to make brief mention of depression, a 
psychiatric condition known to be associated with psychosocial stress (Gilman et al., 
2013; Stromberg, Backlund, & Lofvander, 2011; Siegrist, Lunau, Wahrendorf, & 
Dragano, 2012; Morris, Rao, & Garber, 2012) and cognitive impairment (Airaksinen, 
Larsson, Lundberg, & Forsell  2004; Papazacharias,& Nardini,  2012; Austin, Mitchell, 
& Goodwin, 2001; Steffens et al., 2006; Ganguli, Du, Dodge, Ratcliff, & Chang, 2006). 
Given these associations and therefore the possible confound of depression in 
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measurements of psychosocial stress and cognitive functioning, the presence of 
depressive symptoms was an exclusion criterion in this study and will therefore not be 
discussed further in this literature review. I shall discuss the specific details related to 
the exclusion of depression in the Methods section.  
Resilience. There is no general consensus regarding a definition of resilience. 
However, some researchers regard it as an individual’s ability to overcome adversity 
(Connor & Davidson, 2003; Schoon, 2006), and it is this conceptualisation that I will 
adopt here. 
Given that resilience is a multidimensional characteristic, it is not surprising that 
it is affected by numerous factors, including age (Gooding, Hurst, Johnson, & Tarrier, 
2012), sex (Samplin, Ikuta, Malhotra, Szeszko, & Derosse, 2013), education 
(Frankenberg, Sikoki, Sumantri, & Thomas, 2013), personality (Kim, Lee, & Lee, 
2013), good psychological health (Petros, Opacka-Juffry, & Huber, 2013), adaptive 
social behaviour (Charney, 2004), social support (Wilks & Croom, 2008), and 
psychosocial stress (Taylor et al., 2010). 
In a recently published longitudinal study, Terracciano et al. (2013) investigated 
whether personality traits are associated with resistance to clinical dementia, given that 
approximately 30% of cognitively normal older adults have, on autopsy, AD 
neuropathology.  
The aforementioned studies indicate that there is a link between resilience and 
ageing, as well as a link between resilience and stress. Furthermore, both stress and 
resilience appear to play a role in the cognitive functioning of older adults, and in AD. 
These links, however, have been established relatively recently and further research is 
required, both for more nuanced exploration of these relationships and in different 
populations.  
Sociodemographic factors. The sociodemographic factors of interest in this 
study are age, sex, and education. Each is discussed in turn below.  
Age. Increased age confers the greatest risk for AD (Lindsay et al., 2002). AD is 
a disease predominantly of older adults, usually affecting people over the age of 65 
years. Its prevalence doubles approximately every 5 years through to the 90s (Corrada, 
Brookmeyer, Paganini-Hill, Berlau, & Kawas, 2010; Jorm & Jolley, 1998).  
Several factors may influence the rate at which individuals age. One such factor 
is stress. A sizeable body of literature suggests that stress plays a role in both biological 
ageing and age-related diseases. Empirical studies investigating indicators of biological 
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ageing have shown that one of the ways in which it is manifested is shortened 
telomeres. Telomeres are an area of repetitive nucleotide sequences that cap the ends of 
eukaryotic chromosomes (Capper, et al., 2007; Blackburn, 2000). These nucleotide 
sequences protect the ends of chromosomes from deterioration and help to prevent cell 
senescence. Telomeres are considered an index of cell age, where a shortened telomere 
indicates shortening of the cell’s lifespan (Bekaert et al., 2007; Blackburn, 2000). 
The experience of psychosocial stress has also been linked with ageing. 
Individuals who have had more lifetime experiences of psychosocial stress tend to 
display biomarkers of ageing such as higher oxidative stress, lower telomerase activity, 
and shorter telomere length. For example, Epel et al. (2004) demonstrated that women 
with the highest levels of perceived stress had shorter telomere lengths than those with 
the lowest such levels. Such findings have consequences for our understanding of how, 
on a cellular level, psychosocial stress may be linked with biological ageing. Factors, 
such as stress, shown to be associated with biological ageing may also then be 
associated with diseases arising from such biological ageing.  
There are, however, age-related differences regarding exposure to, and reactions 
to, psychosocial stress. Birditt, Fingerman, and Almeida (2005) found that physically 
and cognitively healthy older people reported fewer interpersonal tensions, and 
experienced fewer stressful events, than did younger controls. Additionally, when they 
did encounter stressors, they were less reactive in their responses to them than were 
younger people. Similarly, Cohen & Janicki-Deverts (2012) found that, in adults, the 
experience of stress decreased with increasing age. In other words, older adults 
perceived their lives to be less stressful than younger adults did. 
In direct contrast to the studies, reviewed above, reporting that, with increasing 
age, adults experience less stressful events and also perceive their lives to be less 
stressful, Krause (1999) reported that older adults are more likely than young adults to 
experience ongoing and chronic stressors, particularly relating to financial and medical 
concerns. The experience of these stressors, he argued, leads to negative side-effects, 
including detrimental impacts on cognition. Krause (2005) later proposed two 
explanations for why age-related variations in the stress response may occur. Firstly, he 
suggested that the developmental changes that arise during advanced old age may affect 
the nature and functioning of social networks. Secondly, he commented that older 
adults, particularly the old-old (75-84 years) and the oldest-old (85+ years), may be 
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more vulnerable to stress as a result of the physical and cognitive changes that can 
occur in later life.  
While older adults may be more vulnerable to stress than younger adults, 
stressful experiences occur across the lifespan. Literature from both animal and human 
studies suggests that both lifetime and current experiences of stressors are associated 
with the acceleration of age-related cognitive decline. For instance, Bodnoff et al. 
(1995) found, using a spatial learning task, that middle-aged rats were more susceptible 
to the negative effects of chronic glucocorticoid exposure than were young adult rats. 
Similarly, in humans, Lupien et al. (1994) found that elderly participants with chronic 
glucocorticoid elevations showed significantly impaired explicit memory functioning 
relative to elderly participants with either decreasing cortisol over time or moderate 
current basal cortisol. McDonald (2002) suggested that good versus poor cognitive 
ageing might be the result of a combination of factors, one of which was exposure to 
chronic stressors and consequent elevated glucocorticoid levels. MacLullich et al. 
(2005) demonstrated that higher plasma cortisol levels in healthy older men were 
associated with more age-related cognitive decline (but not age-related brain atrophy). 
In summary, although ageing is associated with increased risk for cognitive 
impairment and for the development of AD, chronological age is not a sufficient 
predictor of cognitive impairment either within or outside dementia. To elaborate, all 
individuals of the same age will not show the same degree of cognitive decline. Stress is 
one of the moderating factors in this relationship, as is the occurrence of age-related 
diseases such as AD. 
Sex. Sex differences in the development of AD have been reported in studies 
from around the world. Dementia prevalence studies in Europe and North America, 
among others, report a higher risk of AD in women than in men (Brookmeyer, Gray, & 
Kawas, 1998; Di et al., 2002). A meta-analysis (Gao, Hendrie, Hall, & Hui, 1998) of 10 
studies from 5 countries, covering the period 1966-1997, also reported that women are 
at higher risk of developing AD than men. 
Age is thought to contribute to sex differences in the risk of developing AD. 
Andersen et al. (1999) found significant gender differences in incidence of AD after age 
85 years, where women were at increased risk. Another theory for the observed sex 
difference in the risk of AD, supported by recent evidence, proposes that men have 
greater cognitive reserve than women (Schmidt et al., 2008). The concept of cognitive 
reserve (Manly, Jacobs, Touradji, Small, & Stern, 2002) arose from repeated 
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observations demonstrating that there did not seem to be a direct relationship between 
degree of brain pathology and clinical expression of such damage (Katzman, 1989). 
Cognitive reserve explains why individuals with age-related or AD pathology but with 
higher IQ (Pavlik, Doody, Massman, & Chan, 2006), years of education (Kemppainen 
et al., 2008), occupational attainment (Richards & Sacker, 2003), or participation in 
leisure activities (Fritsch, Smyth, Debanne, Petot, & Friedland, 2005) demonstrate less 
severe clinical or cognitive changes. 
Sex differences in physiological and emotional responses to stress have also 
been reported (Chaplin, Hong, Bergquist, & Sinha, 2008; Wang et al., 2007). The 
direction of these differences suggest that women may experience a greater response to 
stress than men. Combined findings from three national surveys assessing 
psychological stress at three time points (1983, 2006, and 2009) showed that stress was 
higher in women than in men at all points (Cohen & Janicki-Deverts, 2012). Similarly, 
in a sample of 2816 people, (Matud, 2004) found that women scored significantly 
higher than men on measures of chronic stress and minor daily stressors, even after 
adjusting for sociodemographic variables. 
 Investigations of sex differences in functional brain responses to stress have 
also been performed. For instance, a functional MRI study of healthy young adults 
found that, in men, increased activity in the right prefrontal cortex was associated with 
the response to psychosocial stress. In women, however, increased activity in brain 
regions involved with emotion (including the limbic system) was associated with the 
stress response; additionally, these changes in blood-flow lasted longer in women than 
in men (Wang et al., 2007). Similarly, Kudielka and Kirschbaum’s (2005) review 
concluded that adult men respond to laboratory-induced psychological stress with 
greater cortisol increases than women. The direction of this sex difference regarding the 
response to stress is in contrast to that discussed in the previous paragraph. Kudielka 
and Kirschbaum also proposed that sex differences in the structure of brain regions such 
as the limbic system, and in cognitive processing of a stressor, may be responsible for 
sexually dimorphic HPA-axis stress responses.  
Education. Even in healthy older adults, there is a strong and well-established 
association between number of completed years of formal education (often termed 
‘level of education’ in the literature) and cognitive test performance (Alley, Suthers, & 
Crimmins, 2007; Ganguli et al., 2010; van Hooren et al., 2007; Wilson et al., 2009). 
Furthermore, a lower level of education has been identified as a risk factor for AD 
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(Callahan et al., 1996; Evans et al., 1997; Qiu, Backman, Winblad, Aguero-Torres, & 
Fratiglioni, 2001; Stern et al., 1994b). In a sample of 373 AD patients and 559 healthy 
control participants, Sando et al. (2008a) found that education had a consistently 
protective effect on the risk of developing AD in a dose-dependent manner in both men 
and women, even after adjusting for the number of APOE-є4 alleles. They reported that 
the odds ratio for developing AD was reduced significantly in individuals with 8-9 
years of education compared to those with 6-7 years, and was further reduced for those 
with 10-18 years of education.  
The protective role of higher levels of education is understood in the context of 
cognitive reserve because education is considered a proxy measure of cognitive reserve 
(Meng & D'Arcy, 2012). As noted earlier, there is wide individual variation in the 
likelihood of dementia with several possible contributory factors; cognitive reserve, 
with its link to education, adds to this variation. Part of the cognitive reserve hypothesis 
postulates that education plays a role in delaying the manifestation of dementia 
symptoms by enabling compensatory techniques that allow individuals to cope more 
effectively with pathological brain changes (Stern, 2009).  
The cognitive reserve hypothesis is further supported by Roe and colleagues 
(Roe, Xiong, Miller, & Morris, 2007), who found that older adults (age 65+ years) with 
more education were less likely to have a diagnosis of dementia. Their higher levels of 
education may have enabled them to cope with AD brain pathology for a longer period 
of time therefore delaying the manifestation of clinical symptoms. They concluded that 
education is predictive of dementia status in individuals with neuropathologic AD.  
Studies have investigated links between education and psychosocial stress. 
Research carried out in 1031 adults demonstrated that better-educated adults had fewer 
physical symptoms and less psychological distress (Grzywacz, Almeida, Neupert, & 
Ettner, 2004). Although the better-educated individuals in the sample reported more 
daily stressors, those stressors were less severe than those reported by those with less 
education. Furthermore, the authors reported that the subjective experience of stressors 
seemed to promote more negative changes in daily health in those who had not 
completed high school compared to those who had completed high school or who had at 
least some college education. Similarly, in adults aged 18 years and older (mean age 
44.6 years), Cohen and Janicki-Deverts (2012) found that stress increased with 
decreasing levels of education.  
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Alzheimer’s Disease Research in Africa 
To my knowledge, there has been no African research examining the 
combination of questions investigated in this dissertation. Indeed, studies relating to AD 
in general in African populations are scarce (see Figure 2), and those that have been 
conducted have been predominantly of a (limited) epidemiological nature.  
An African study has reported an AD prevalence rate of 1.41% in Ibadan, 
Nigeria (Hendrie et al., 1995). Overall dementia prevalence rates have been reported as 
10.1% in South-West Nigeria (Gureje et al., 2006); 6.4% in Jos, Nigeria (Ochayi & 
Thacher, 2006); 2.79% in Zaria, Nigeria (Yusuf, Baiyewu, Sheikh, & Shehu, 2011), 
4.5% in Assuit, Egypt (Farrag, Farwiz, Khedr, Mahfouz, & Omran, 1998); 2.2% in 
Ibadan, Nigeria (Hendrie et al., 1995); 2.6% in rural Benin, West Africa (Guerchet et 
al., 2009); 8.1% in the Bangui, Central African Republic and 6.7% in Brazzaville, 
Congo (Guerchet et al., 2010). The latter two studies suggest that the prevalence of 
dementia in urban areas of central Africa is similar to that observed in HICs. 
Many of the studies cited above were conducted in Nigeria. Some of this work 
was performed in Ibadan, where one particular study, the Indianapolis-Ibadan Dementia 
Study that I discussed previously as regards APOE-є4, compared the prevalence of AD 
in two community-dwelling samples. As mentioned, one of the samples was drawn 
from Ibadan, Nigeria, and the other from an African-American population in 
Indianapolis, United States. This study reported that in adults over 65 years old in the 
Ibadan sample, age-adjusted prevalence rates of dementia and AD were 2.29% and 
1.41%  respectively (Hendrie et al., 1995). These rates were markedly lower than those 
for the Indianapolis sample where prevalence rates for dementia and AD in a combined 
sample of individuals from nursing homes and in the community was 8.24% and 6.24% 
respectively. 
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Figure 2. Global research evidence on the prevalence of dementia (Ferri et al., 2005). 
Those regions coloured in red (North America, Europe, Japan, and Australia) boast 
several studies of good methodological quality. The pink regions consist of some 
epidemiological studies but they are insufficient in quality or quantity to provide 
estimates that are representative of the regional dementia prevalence. The white regions 
lack completely, or almost completely, epidemiological studies, and those with a red 
dot represent region sites of single studies. 
 
Given the relatively limited scope of the studies described above, the prevalence 
of AD in Africa remains largely unknown. It is only recently that systematic hospital 
surveys or community-based studies of AD have been initiated in Africa. In 2005, 
Alzheimer’s Disease International reviewed epidemiological data on dementia to reach 
a consensus estimate of prevalence in each world region. Their findings supported the 
trend for a somewhat lower prevalence of dementia in LAMICs as opposed to that in 
HICs (Ferri et al., 2005).  
Estimations of the prevalence rates for dementia in sub-Saharan Africa have 
been approximately 2.4% (Ferri et al., 2005). This low rate derives from one good-
quality study, discussed previously, which was conducted in Ibadan, Nigeria (Hendrie 
et al., 1995).  
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A recent systematic review was performed to estimate the prevalence of 
dementia in Africa in persons over the age of 50 years (George-Carey et al., 2012). This 
review, modelled on 10 studies, included community-based studies conducted in 
LAMICs in Africa that reported dementia prevalence. Based on this collection of 
studies, the authors reported an overall dementia prevalence of 2.4% and that dementia 
prevalence was highest among females aged 80 years and over. AD was the most 
prevalent cause of dementia, and the main risk factors were increasing age, female sex, 
and cardiovascular disease. These risk factors correspond with those reported in 
previous studies African studies; the latter showed the major risk factors for AD to be 
age, female gender, BMI less than 18.5, illiteracy, and vascular disease (Farrag et al., 
1998; Kalaria et al., 2008; Ochayi & Thacher, 2006; Yusuf et al., 2011).  
In South Africa, a study on prevalence rates of dementia in the urban black 
population is currently being conducted at the University of the Free State in 
Bloemfontein (University of the Free State, 2010). The pilot study involved a test group 
of older adults (age ≥ 65 years) from 250 households in the township of Mangaung. In 
this sample, 6% were identified with possible age-related dementia. The latter are to be 
followed up with more extensive confirmatory diagnostic assessment. This finding of a 
prevalence rate over 5%, albeit in a small sample drawn from a restricted geographic 
region, goes some way in dispelling the myth that AD is linked to European ethnicity 
and that it is not prevalent in black communities (Steyn, 2010). These data also suggest 
that prevalence rates of dementia in urban Black African communities in South Africa 
are higher than initially estimated.  
Possible reasons for earlier studies providing relatively low estimated rates of 
dementia prevalence in African populations include a low life expectancy at birth and 
differential survival rates. Currently, the average life expectancy at birth in sub-Saharan 
Africa is 53 years; this is largely a result of the high rates of HIV infection (Lawn, 
Harries, Anglaret, Myer, & Wood, 2008). The low life expectancy in sub-Saharan 
Africa will therefore reduce the total number of cases of AD, which, as noted earlier, is 
a disease predominantly of older adults and which generally presents 65 years of age. 
However, for those individuals who do not contract HIV in their youth, life expectancy 
is likely to increase. For example, Statistics South Africa (Statistics South Africa, 2013) 
estimated that the Western Cape province of South Africa has the highest life 
expectancy for males and females. Males were estimated to have a life expectancy of 
64.2 years and females approximately 70 years. Thus, an age-associated increase in 
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prevalence of AD is still likely to be seen, particularly in places such as the Western 
Cape.  
Despite a relatively low life expectancy in sub-Saharan Africa, projections from 
the United Nations indicated that the number of adults aged 60 years and over will 
increase exponentially from 5% to 8% of the population by the year 2050 (United 
Nations Population Division, 2006). In South Africa, the population of older adults is 
expected to increase from 3.3 million to 6.4 million. This equates to an increase from 
7% to 13% of South Africa’s population (Kalula et al., 2010). Thus, the prevalence of 
dementia and AD in this country is expected to increase exponentially over the next 
several decades.  
Currently, there are no studies examining whether prevalence rates for AD are 
similar in South Africa and Western populations. If there is a real trend for lower 
prevalence rates of AD in African populations, then there may exist unique, culture-
based, dietary, or environmental factors, or possibly protective factors, for cognitive 
impairment in African populations. This doctoral dissertation is not a prevalence study, 
however; its main aim is to identify factors associated with cognitive functioning in 
older adults across a continuum from healthy to impaired cognition. The identification 
of such factors in different African populations is necessary, at least as an initial step, in 
order to identify possible explanations for Africa’s (lower?) prevalence rates of AD.  
  
Cross-Cultural Issues in Neuropsychological Testing 
 As mentioned in the General Introduction, neuropsychological testing 
contributes pivotally to the diagnostic assessment of older adults. However, 
performance on cognitive tests represents, to a certain extent, culturally learned 
abilities. Variations in cultural and environmental settings (e.g., differences in the types 
of learning materials that are available; whether students have the opportunity to work 
independently as well as in groups) may give rise to the development of different 
patterns of cognitive abilities (Ardila, 1995). Although performance on verbal tests is 
obviously influenced heavily by cultural variation, the impact of culture is also present 
for performance on visuospatial and non-verbal tests; clinical neuropsychologists no 
longer consider these kinds of tests as being, by default, culture-fair (Rosselli & Ardila, 
2003). Many definitions exist for the word “culture” but broadly defined, it refers to the 
set of characteristics of a particular group of people that incorporates their language, 
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religion, social habits, and ways of thinking and behaving within a social group 
(Hofstede & Hofstede 2005). It is developed though interaction among individuals in a 
community and it has a large influence on human nature (Parrish & Linder-vanBerschot 
2010).  
Some cross-cultural factors that may influence neuropsychological performance 
include the effects of culture itself (Manly et al., 1998), home language (MacIntyre & 
Gardner, 1994), socioeconomic status (SES) (Rabbitt, Donlan, Watson, McInnes, & 
Bent, 1995), and level and quality of education (Lezak, Howieson, & Loring, 2004; 
Manly et al., 2002; Ostrosky-Solis, Ramirez, & Ardila, 2004; Shuttleworth-Edwards et 
al., 2004). 
Most neuropsychological instruments have been developed and validated in 
HICs, and most are therefore normed on populations that, generally, have higher levels 
and quality of education than do those in LAMICs. Thus, the reliability, validity, 
specificity, and sensitivity of existing cognitive measures can be compromised when 
administered to individuals from LAMICs. Differences in cognitive performance 
among different cultural groups may increase the possibility of overdiagnosing 
cognitive impairment (Potter et al., 2009). Hence, there is general agreement among 
clinicians that most neuropsychological measures do not have adequate diagnostic 
accuracy when administered to individuals who are not middle- to upper-class, of 
European descent, well-educated, first-language English speakers (Boone, Victor, Wen, 
Razani, & Ponton, 2007; Manly, 2005).  
To place this problem in the South African context, under apartheid rule, the 
type and quality of education was determined by a system of “racial” classification 
resulting in varying quality of education across different ethnic groups. For instance, 
Shuttleworth-Edwards and colleagues (2004) showed that black South Africans, 
especially those with a low quality of education, performed more poorly on 
neuropsychological tests than white South Africans. However, such effects on cognitive 
performance have been accounted for more by socio-cultural factors that typify a 
particular ethnic group, than the ethnic traits themselves (Shuttleworth-Edwards et al., 
2004). These results showed that quality of education was a stronger predictor of 
cognitive performance than race or ethnicity. This does not mean, however, that factors 
relating to ethnicity should not be considered in the context of cognitive performance. 
Indeed, assessing cognitive performance across different ethnic groups without suitable 
methods of standardization is cause for concern, especially in the context of a 
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diagnostic process (Manly et al., 1998; Okazaki & Sue, 2000; Stricks, Pittman, Jacobs, 
Sano, & Stern, 1998). Individuals from particular ethnic groups who were afforded a 
higher quality of education are more likely to have been exposed to formal cognitive 
testing procedures. Nell (2000) emphasized the role of ‘test wiseness’: the concept that 
individuals with higher quality and level of education perform better in test-taking 
environments at least in part because of greater familiarity with the actual test-taking 
process. 
Data such as these reaffirm the notion that “race”, being a socially constructed 
concept, is not in itself responsible for performance on neuropsychological measures. 
Rather, it is the factors that are linked with race that are more likely to be responsible; 
these factors include quality of education, language, and SES (Shuttleworth-Edwards et 
al., 2004; Shuttleworth-Jordan, 1996; Ardila, 1995). 
Regarding the influence of language on cognitive test performance, it stands to 
reason that individuals who are assessed in a language that is not their primary language 
may be disadvantaged; their scores may not reflect their true cognitive abilities 
accurately. For example, Boone et al. (2007) examined the relationship between 
neuropsychological scores and ethnicity, language, and acculturation variables in a 
large patient population. The authors found that cognitive scores on several measures 
were significantly higher in patients for whom English was a first language compared to 
patients for whom English was a second language.  
Regarding the influence of SES on cognitive test performance, it appears that 
lower SES is associated with poorer performance (Kyle, Fox, & Whalley 2010; Sarsour 
et al., 2011; Brooks-Gunn, & Duncan 1997; Currie, 2005; Malecki, & Demaray 2006). 
This association was confirmed in a recent study of older adults with cirrhosis from 
centers in three cities, namely, Virginia, Ohio, and Rome (Bajaj et al., 2013). Analyses 
revealed a strong positive association between SES (estimated from employment level 
and personal income) and cognitive performance, irrespective of age, education, and 
location. 
  As discussed in the paragraphs above, there are several cross-cultural issues 
which arise in neuropsychological assessment. It is evident that addressing cultural 
diversity in cognitive assessment and performance is a critical part of 
neuropsychological research and practice (Manly, 2008). This cultural diversity should 
be taken into consideration especially when diagnoses are informed by such 
assessments. Compared with resources available in HICs, poor access to resources in 
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populations from LAMICs increases the likelihood of fewer years and a lower quality 
of education. The latter increases the probability of a poorer performance on cognitive 
tests which may lead to an incorrect diagnosis being made, if the diagnosis relies 
heavily on cognitive performance. Thus, it is perhaps more difficult to diagnose 
cognitive impairment and AD accurately in LAMICs because of problems surrounding 
the psychometric properties of the tests that are currently used. This means that 
adequate consideration should be given to non-organic factors, such as those listed 
above, that might affect assessment and diagnostic decisions.  
 Consideration  of cross-cultural factors is relevant in the context of the current 
study because the group of South African older adults assessed here comprises 
individuals from heterogeneous cultural, educational, and SES backgrounds. 
Furthermore, the neuropsychological measures used in this study were developed in 
Europe and North America, and were standardised on samples from HICs. To 
accommodate for this some of the test items needed to be altered in order to be 
appropriate for this South African sample. I shall discuss these changes in more details 
in the Methods section. Additionally, the cognitive performance of the AD participants 
in this study was not compared to norms from HICs; rather, cognitive performance was 
compared to the control participants in this sample. This had the benefit of reducing 
errors that might otherwise have been present if the cognitive performance in my 
sample had been compared to norms for HICs. 
 
Summary 
A multi-factorial aetiology suggests there is no specifically defined pattern of 
factors associated with the development of cognitive impairment in older adults. 
Furthermore, such factors may vary in different environments, in different family 
settings, or with different genetic dispositions. The literature review above has 
discussed several factors associated with age-related cognitive impairment and AD, 
including a range of physiological, genetic, psychosocial, and sociodemographic 
factors. This is not an exhaustive list of factors related to the development of cognitive 
impairment, however, but it is a list of factors known to be associated with both stress 
and cognitive impairment in AD. 
All of these factors have been investigated previously within HIC populations. 
Some have been explored in terms of their relationships with each other; for example, 
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psychosocial stress and APOE-є4, cortisol and hippocampal atrophy, stress and Aβ. To 
my knowledge, however, there is no study that explores the inter-relationships of all of 
these factors, together, in one sample. 
Furthermore, there are few LAMIC studies investigating these variables in older 
adults, both cognitively healthy and demented. Certainly, no research of this kind has 
been performed in a South African population. Thus, my research focuses on 
psychosocial stress, cortisol, the APOE-є4 allele, Aβ, and hippocampal volume in a 
sample population of older South African adults from the Western Cape region with 
and without cognitive impairment. I aimed to examine the independent relationships of 
these factors with cognitive functioning in healthy older adults and in patients with 
early-to-moderate AD (i.e., to examine whether the relationships changed across a 
spectrum of cognitive functioning in these two groups), and to examine the associations 
of these factors with one another. 
 
Study Aims and Hypotheses 
The general aim of this study was to explore, in a South African population 
sample, the relationships between psychosocial stress, cortisol, APOE-є4, Aβ, 
hippocampal volume, and cognitive functioning in cognitively healthy older controls 
and in participants with Alzheimer’s disease. I aimed to investigate not only the 
relationships between these psychosocial, physiological, and genetic variables and 
cognitive impairment, but also the relationships of those variables amongst each other. 
Figure 3 depicts, in sketch form, the study’s aims; it is a schematic representation of the 
separate (boxed) research areas of interest here. This diagram speaks to the central 
theme of this thesis: that there are numerous factors associated with the development of 
cognitive impairment, and that one such factor is stress, as both a psychosocial and 
physiological construct. Furthermore, some of these factors are inherent, and some are 
modifiable in early life but less so later in life. The figure also shows that stress 
(psychosocial and physiological) is proposed to have lasting effects on cognitive 
function and brain structure, probably via its instigation of biochemical changes in the 
brain. These possible effects are measurable by neuropsychological testing, 
neuroradiological imaging, and biochemical tests of blood samples. 
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Figure 3. Schematic representation of research areas of interest. APOE-є4 = apolipoprotein- є4; Aβ = beta-amyloid;  
CAMCOG-R = Cambridge Cognitive Examination-Revised; LTE-Q = List of Threatening Life Events Questionnaire;  
MMSE = Mini-Mental State Examination; MRI = magnetic resonance imaging; PSS = Perceived Stress Scale. 
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In addition to the aims outlined above, I also sought to explore the role of 
demographic factors, such as age and education, and levels of resilience, in determining 
their relationship to cognitive functioning in this sample of South African older adults. 
The variables listed earlier (psychosocial stress, cortisol, APOE- є4) are associated with 
cognitive functioning, and with the sociodemographic variables listed above, and are 
thus explored in one large model. 
Because this is not an experimental study, and because the predictor variables 
do not influence cognition in isolation from each other, I used a hierarchical regression 
model to explore all of their relationships together. However, I also wished to establish 
the initial direction of bivariate associations as well as between-group differences, and 
so tested the hypotheses listed below.  
The first set of hypotheses related to the putative risk factors of psychosocial 
stress, physiological stress (cortisol), and cognition in cognitively healthy older adults 
and in participants with AD. Hypothesis 1a stated that AD patients would have higher 
levels of current psychosocial stress, more lifetime experiences of traumatic life events 
(recent and remote stress), and higher baseline cortisol levels than controls. Hypothesis 
1b stated there would be a larger positive association between psychosocial stress and 
cortisol levels among AD patients than among controls. Hypothesis 1c stated that levels 
of psychosocial stress and cortisol would be negatively correlated with cognitive 
performance within each group separately and across the entire sample. 
The second set of hypotheses related to resilience, psychosocial stress, and 
education, and how they are associated with each other in controls and AD patients. 
Hypothesis 2a stated there would be an inverse association between resilience and 
psychosocial stress in both groups. Hypothesis 2b stated there would be a positive 
association between education and resilience in both groups. 
The third set of hypotheses related to APOE-є4 and its association with both 
psychosocial and physiological stress. Hypothesis 3a stated AD patients would have a 
higher allelic frequency of APOE-є4 than controls, and Hypothesis 3b stated those AD 
patients carrying the є4 allele would perform more poorly on a measure of overall 
cognitive function than those who did not carry it. Finally in this set of hypotheses, 
Hypothesis 3c stated AD patients with higher baseline cortisol levels and presence of 
the є4 allele would perform more poorly on a measure of overall cognitive function 
than would AD patients with lower baseline levels of cortisol and an absence of APOE-
є4. 
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The fourth set of hypotheses related to plasma Aβ and its association with 
psychosocial and physiological stress. Hypothesis 4a stated AD patients would have a 
lower ratio of Aβ1-42/Aβ1-40 than controls, and Hypothesis 4b stated AD patients with 
high levels of psychosocial stress and cortisol would have a lower plasma Aβ1-42/Aβ1-
40 ratio than AD patients with low levels of psychosocial stress and cortisol.  
The fifth set of hypotheses related to the neuroimaging component of this study. 
They aimed to investigate hippocampal volumes in both groups and their association 
with psychosocial stress, as measured by the PSS, and physiological stress, as measured 
by baseline levels of circulating cortisol. Hypothesis 5a stated AD patients would have 
smaller hippocampal volumes than controls, and Hypothesis 5b stated that AD patients 
with higher baseline cortisol levels and the APOE-є4 allele would have smaller adjusted 
total hippocampal volume than patients with low baseline cortisol levels and no APOE-
є4. 
As mentioned previously, after exploring these initial relationships I then used 
each of these factors (age, education, APOE-є4, psychosocial stress, and cortisol) as 
predictor variables in a large regression model that aimed to determine their 
independent and interactive effects on cognition. This modelling step was an 
exploratory analysis as I did not have a specific hypothesis regarding which factors, 
other than age, would be significant and/or unique predictors of cognitive functioning.
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Methods 
Participants 
Alzheimer’s disease patients (nAD = 65) were recruited from a variety of 
sources: a nursing home located near Cape Town, Groote Schuur Hospital’s Memory 
Clinic and geriatric outpatient clinics, and general practitioner (GP) referrals. Most of 
these patients had been diagnosed, prior to entering the study, as having mild to 
moderate AD, or possible or probable AD, in terms of NINCDS/ADRDA criteria 
(McKhann et al., 1984). Some were referred directly to the study by the Groote Schuur 
Hospital (GSH) Memory Clinic. Those participants who had not yet been diagnosed 
were assessed by a senior neurologist and were identified as cognitively healthy 
controls, or as mild to moderate stage possible or probable AD based on a detailed 
medical history, physical exam, bedside cognitive tests, and a brain CT scan in some 
cases. We selected patients who were in the mild to moderate stages of possible or 
probable AD so that they would be able to consent to procedures and to complete the 
questionnaires and cognitive tests. Patients in the severe stage of the disease were 
therefore excluded from participation.  
Control participants (nHC = 69) were healthy, community-dwelling, independent 
volunteers. They were recruited from communities in and around Cape Town via word-
of-mouth advertising. I obtained general health information from all participants using a 
clinical interview. 
All participants were over the age of 60 years. Other inclusion criteria included 
literacy and a good command of either English or Afrikaans, which was established 
based on comprehension and answering of questions during the screening procedure. 
Participants who scored above the cut-off score for depression were excluded. Figure 4 
illustrates the participant enrolment process.  
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Figure 4. Diagram illustrating the number of participants (healthy controls and AD 
patients) enrolled in Study 1 (the cross-sectional study), as well as details relating to 
exclusion. 
  
Individuals screened and 
enrolled for participation 
as per protocol 
N = 152 
Individuals who decided against 
participation and therefore 
excluded prior to the Baseline visit 
n = 4 
Participants enrolled 
for the 
Baseline visit 
(July 2008 – Oct 2012) 
N = 148 
Participants excluded 
post-diagnosis 
(total n = 14): 
Depression n = 4 
Parkinson’s disease n =2 
Psychiatric symptoms n = 2 
Dementia not Alzheimer’s type n = 3 
Epilepsy n = 1 
Decided against participation n = 2 
 
Study 1 
 
Controls 
n = 69 
 
 
Study 1 
 
AD Patients 
n = 65 
Total participants in Study 1 
N = 134 
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Table 1 provides a detailed breakdown of the inclusion and exclusion criteria for 
participation in this study.  
Only a subset of these participants (N = 40) was selected for the Aβ analyses. 
Participants’ plasma samples for the Aβ analyses were selected based on their age (to 
ensure the groups were age-matched) and how recently their samples had been obtained 
(Controls n = 10, AD patients n = 30). More AD patients than controls were selected for 
this subset of participants because I was primarily interested in investigating levels of 
Aβ in patients with AD, as this is where most of the variation might occur.  
Similarly, only a subset of participants (N = 40) was selected for the MRI 
component of this study. For the MRI scans, participants who were willing to have an 
MRI scan were selected according to age, as I wanted to match the groups as closely as 
possible in this regard. Five of the selected participants (4 patients and 1 control) did 
not complete the scan, and so the final sample size for this component of the study was 
N = 35 (Controls n = 14, AD patients n = 21). 
The reason for performing the Aβ and MRI assessments in only a subset of 
participants was due to resource constraints; study funding only allowed for 40 MRI 
scans and one 96-well assay, including standards and controls, for the Aβ (i.e., 40 
participants’ samples in duplicate). 
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Table 1 
Inclusion and Exclusion Criteria for Participation in the Study 1 
  
Inclusion criteria Exclusion criteria 
Age Medical health history 
≥ 60 years  Diagnosis of: 
  HIV/AIDS 
   Uncontrolled hypertension 
Literacy  Uncontrolled diabetes mellitus 
Basic ability to speak, read, 
and write 
 
Language 
 Fluent in English 
 Any other medical condition 
that, in the opinion of the 
investigator should preclude 
the patient from participation 
 Oral steroid treatment 
 
Cognition (controls)  
    Normal for age range 
Cognition (patients) 
Mild to moderate or 
possible/probable AD 
 
Psychiatric history  
 Presence of any major 
disorder (e.g. depression; 
Geriatric Depression Scale 
score > 7) 
Informant Neurological history 
Availability of close relative 
or similar who could 
provide information about 
changes in cognitive 
function 
 Presence of any major 
disorder  
(e.g., Parkinson’s disease,    
Huntington’s disease) 
  Recent (past 6 months) stroke 
  
 Substance use 
  Any history of alcohol or drug 
abuse 
 Heavy smoking (> 20 
cigarettes per day) 
  
 Mini-Mental State Examination < 12 
  
 No access to a freezer at home 
 (for storage of saliva samples) 
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Research Design and Setting 
Most study procedures were conducted in the Division of Neurology at Groote 
Schuur Hospital, at a nursing home, or at the participant’s residence. Irrespective of the 
venue, all participants were tested in an isolated, quiet room at similar times of day, 
between the hours of 09h00 and 11h30. MRI scans were performed at the Cape 
Universities Brain Imaging Centre (CUBIC) on the University of Stellenbosch Health 
Sciences Campus. 
 
Materials  
This study formed part of a larger research programme that employed numerous 
instruments to measure physiological and biochemical markers of stress, genetic risk 
factors, brain volume, lifetime exposure to traumatic events, current stress levels, and 
cognitive, behavioural, affective, interpersonal, and adaptive functioning measures. 
Only a subset of those instruments was used in the current study, and only those are 
described here. The instruments selected for this study were chosen because they relate 
directly to its aims and hypotheses. Some of these instruments had been used with some 
success in previous studies in South Africa (e.g., Heckmann et al., 2004; Lenger, de 
Villiers, & Louw, 1996). Only the non-copyrighted materials used in this study have 
been reproduced as appendices.  
Sociodemographic questionnaire. Participants completed a questionnaire, 
created specially for this study, which asked for information on their age, sex, race, 
home language, education, and health (see Appendix A). Where necessary, the 
participant’s caregiver/spouse/guardian/family member (hereafter referred to as the 
informant) was asked to corroborate this information. 
Psychosocial stress measures. I used the List of Threatening Life Events 
Questionnaire (LTE-Q; Brugha & Cragg, 1990) to identify lifetime stress and whether 
participants had ever experienced certain traumatic life events, such as losing a loved 
one or being fired from a job. This instrument consists of 11 statements. It required 
participants to indicate whether or not they had experienced any of the events described 
by those statements, and, if so, whether the event occurred within the past 6 months 
(recent stress) or earlier in their life (remote stress). Participants were then required to 
rate the impact a particular event had on their life at the time of its occurrence (none = 
1, some = 2, significant = 3). If a participant had not experienced any of these events, 
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then s/he would have obtained a minimum score of 0. If a participant had experienced 
every event both in the last 6 months and more than 6 months ago and had rated each 
event as having a significant effect on his/her life, then his/her total score on this 
measure would have been the maximum, 66 points. Hence, higher scores on this 
instrument indicate more experiences of traumatic life events that have had some or a 
significant impact on one’s life. 
The questions asked in this measure refer to significant life events that I 
expected would remain well-remembered by patients in the mild to moderate stages of 
AD. The developers of this instrument have shown that the LTE-Q has high test-retest 
reliability and good agreement with informant information relating to life events 
(Brugha & Cragg, 1990). To my knowledge, this instrument has not been used in a 
previously published South African research study. 
I administered the Perceived Stress Scale (PSS; Cohen, Kamark, & 
Mermelstein, 1983). This 14-item scale assesses the degree to which situations in one’s 
life over the past month are appraised as stressful. The items are designed to detect how 
unpredictable, uncontrollable, and encumbered participants find their lives. To score 
this instrument, scores on the seven positive items are reversed (e.g., 0 = 4, 1 = 3, 2 = 
2, and 4 = 0), and then scores for all 14 items are summed; the minimum score is 0 and 
the maximum score is 56 points. Higher scores indicate that the individual perceives 
him or herself as having experienced a stressful life over the last month. 
The developers have reported that the PSS shows adequate reliability and 
validity (Cohen, Kamarck, & Mermelstein, 1983). This instrument has been used 
previously in South African research investigating depressive symptoms and perceived 
stress in adults (Hamad, Fernald, Karlan, & Zinman 2008). 
In this study, the PSS was used as the primary indicator of ‘psychosocial stress’. 
In contrast to major life events (such as those measured by the LTE-Q) which are 
relatively rare, daily stressors occur frequently and analysis of such can provide a more 
accurate picture of how stressful one’s life currently is (Stawski, Sliwinski, Almeida, & 
Smyth, 2008). Furthermore, the PSS is the most widely used measure of stress 
appraisal, it correlates well with life-event scores, and it has been found to be a stronger 
predictor of several health outcomes relative to life-event measures (Cohen et al., 1983; 
Cohen, Kessler, & Gordon, 1995).  
Affective, behavioural, and adaptive functioning questionnaires. I used the 
Deterioration Cognitive Observee (DECO; Ritchie & Fuhrer, 1996) to provide 
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collateral information regarding the participant’s level of cognitive and functioning 
abilities. The DECO is a 19-item Likert-type scale that measures aspects of behaviour 
and cognition (activity level, semantic and visual memory, memory for places, events, 
and procedures, visuospatial performance, and new skill learning). In accordance with 
standard procedure, it was completed by an individual, nominated by the participant, 
who had had at least monthly contact with the participant over a period of 3 years. 
This questionnaire required the informant to rate the participant’s level of 
functioning, relating to a number of everyday situations, compared to 1 year previously. 
The informant needed to indicate for each statement whether the participant’s 
functioning or ability to perform a particular task was either better or about the same (a 
score of 2), not as well (a score of 1), or much worse (a score of 0). Hence, the 
minimum score is 0 (decline in functioning across all areas) and the maximum score is 
38 (intact functioning). Scores lower than 30 have been established by Receiver 
Operating Characteristics analysis as indicating a high probability of dementia within a 
general population sample (Ritchie & Fuhrer, 1996). 
Psychometric studies of the DECO have shown that it has good face validity as 
well as high test-retest and inter-rater reliability, and that it does not show bias with 
regards to education or social class (Ritchie & Führer, 1996). The Xhosa translation of 
the DECO has been used previously in South African research studies of early-onset 
AD and it has been recommended as a possible screening measure for dementia in older 
adults in South Africa (Heckmann et al., 2004; Lenger et al., 1996). 
The Bristol Activities of Daily Living Scale (BADLS; Bucks, Ashworth, 
Wilcock, & Siegfried, 1996) provided a short assessment of the functional ability of 
participants, focusing on tasks such as handling finances, dressing, and eating. The 
same informant who completed the DECO completed this 20-item scale. The informant 
rated the participant’s ability to perform tasks on a scale of: 0 = able to perform task 
independently/unobservable; 1 = able to perform task with some instructions/prompts; 2 
= able to perform task with assistance; 3 = unable to perform task independently and 
requires full assistance. The minimum score for this measure is 0 (totally independent) 
and the maximum score is 60 (totally dependent). 
The BADLS has good test-retest reliability and validity (Lezak et al., 2004). In 
terms of relevant cross-cultural use, it was administered to an elderly South African 
sample in a study investigating the reliability and validity of a Xhosa version of a 
health-related quality of life measure (Jelsma, Mkoka, Amosun, & Nieuwveldt. 2004). 
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I used the Connor-Davidson Resilience Scale (CD-RISC; Connor & Davidson, 
2003) to obtain a self-rated assessment of resilience. Each of the 25 items on this 
instrument is rated on a 5-point scale (0 = not true at all; 1 = rarely true; 2 = sometimes 
true; 3 = often true; 4 = true nearly all the time), where higher ratings indicate greater 
resilience (total score out of 100). This instrument required participants to think about 
how they felt over the last month when answering each statement. The developers note 
that the scale has been tested in both the general population and in clinical samples, 
where it has displayed good psychometric properties, including good internal 
consistency, test-retest reliability, and convergent validity with other measures of stress 
and endurance. This instrument has been used previously in South African research 
focusing on perceived social support in youth (Bruwer, Emsley, Kidd, Lochner, & 
Seedat, 2008).  
I administered the Geriatric Depression Scale (GDS; Yesavage et al., 1982) as a 
screening measure to detect the presence of symptoms of depression. Hence, 
individuals who scored above 7/15 (i.e., who self-reported the presence of at least 
moderate depression) were excluded from participation. The GDS, in its original form, 
is a self-report 30-item scale that was developed as a basic screening measure for 
depression in older adults. Higher scores indicate a greater number of symptoms of 
depression. For this study, participants were required to answer a 15-item version of the 
scale. Both the original and shortened versions of the GDS display high internal 
consistency, test-retest reliability, and validity (Yesavage et al., 1982). The 15-item 
version has been established as an instrument suitable for diagnosing depression in 
elderly populations (de Craen, Heeren, & Gussekloo, 2003). This measure has been 
used previously in a South African study examining depression and social support in 
elderly people (Rodriguez, Brathwaite, & Dorsey, 2002). 
Neuropsychological test battery. The Cambridge Cognitive Examination for 
Mental Disorders of the Elderly-Revised (CAMCOG-R; Huppert, Brayne, Gill, Paykel, 
& Beardsall, 1995) provided a baseline measure of general cognitive functioning. This 
instrument is the revised version of a cognitive examination section that forms part of 
the Cambridge Mental Disorders of the Elderly Examination-Revised. The CAMCOG-
R was originally devised as a screening tool for dementia in older adults (Leeds, Meara, 
Woods, & Hobson, 2001). It consists of 67 items divided into eight cognitive domains: 
Orientation, Language, Memory, Attention, Praxis, Calculation, Abstract Thinking, and 
Perception. The CAMCOG-R has a maximum attainable score of 105, and it requires 
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approximately 25 minutes for administration. It has high test-retest and inter-rater 
reliability, and it is sensitive in the detection of dementia and to changes in cognition 
over time (Hobson & Meara, 1999; Leeds et al., 2001). 
Some of the CAMCOG-R items were altered, however, because they were not 
suitable for use with South African participants. The altered items included those 
related to geographical places and to historical figures and events; the changes ensured 
that those items were more appropriate for use with a South African sample. The 
booklet that accompanies the CAMCOG-R (which contains pictures relating to some of 
the test items) was reprinted with more culturally appropriate images. (For details on 
specific changes, see Appendix B.) 
Included in the CAMCOG-R are the 19 questions that comprise the Mini-Mental 
State Examination (MMSE; Folstein et al., 1975). The MMSE was used as a screening 
tool for dementia and for the detection of late-stage dementia, in accordance with the 
exclusion criterion of an MMSE score < 12. This instrument is the most commonly 
used and studied screening test for dementia. Despite controversies about its specificity 
and sensitivity, the MMSE has good test-retest and inter-rater reliability, and high 
construct validity (Strauss, Sherman, & Spreen, 2006). This measure has been used 
previously in a South African study investigating early-onset AD (Heckmann et al., 
2004), and is used regularly as a screening tool for dementia in South African clinical 
practice.  
The Placing Test (TPT; Anderson, de Jager, & Iversen, 2006) is a measure of 
implicit visual learning and memory. This instrument was developed as a tool for use in 
the early detection of AD. It assesses whether the testee can form associations between 
commonly-seen objects (for example, faces and shoes) and their location on the page of 
a stimulus booklet. 
I showed participants two sets of five pages, with each page divided into four 
quadrants. On each page were two pictures; the first set of five pages featured two 
pictures of faces on each page, and the second set of five pages featured two pictures of 
shoes on each page. The location of the pictures on each page varied randomly. To 
control for encoding, participants were asked to judge whether the faces looked young 
or old, and whether the shoes would be worn by a man or a woman. After presentation 
of the pictures in each category, I showed participants the presented pictures one at a 
time and asked them to indicate where on the page (in one of the four quadrants 
numbered 1-4) they recalled seeing the picture. 
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Administration time for this test is 5-10 minutes, and performance is scored by 
the number of items placed correctly; hence, the maximum attainable score is 20. The 
fact that this is a non-verbal test renders it suitable for individuals whose first language 
is not English or who have a limited educational background. The test has been 
demonstrated to be free from the influence of education (de Jager, Hogervorst, 
Combrinck, & Budge, 2003), and has good discriminative capacity between controls 
and other groups with cognitive impairment (Anderson, de Jager, & Iversen, 2006). To 
my knowledge, test-retest reliability for this measure has not yet been formally 
established. Prior to this study, the TPT had not yet been administered to a South 
African sample in a published research study.  
The Trail Making Test (TMT; Reitan & Wolfson, 1985) is a measure of motor 
speed, visuomotor tracking, visual attention, and switching ability (Lezak et al., 2004). 
This measure often forms part of neuropsychological screening batteries. The first part 
of the test (TMT-A) requires the testee to connect circled numbers in ascending 
numerical order. The second part of the test (TMT-B) requires the participant to connect 
numbers and letters in alternating order (i.e., 1-A-2-B-3-C, etc.). 
Here, time taken to complete the task served as the performance measure. If the 
participant did not complete either TMT-A or TMT-B within 5 minutes, or if s/he was 
simply unable to meet the demands of the test, s/he was assigned a score of 300 
seconds. 
The TMT is sensitive to cognitive decline consistent with dementia (Kowalczyk, 
McDonald, Cranney, & McMahon, 2001), and is used often as a measure of how much 
an older adult might struggle with complex daily activities, such as driving (Stutts, 
Stewart, & Martell, 1998). This test has fairly good psychometric properties (Lezak et 
al., 2004), and is used frequently in South African clinical settings. 
The Executive Clock Drawing Task (CLOX; Royall, Cordes, & Polk, 1998) 
provided an indicator of participants’ executive and visuospatial performance. The first 
part of this task (CLOX 1) requires the participant to draw a clock with no help or cues 
from the examiner other than the following instructions: “Draw me a clock that says 
1:45pm. Set the hands and numbers on the face so that a child could read them.” CLOX 
1 measures an individual’s ability to perform in a novel situation; the focus is on 
executive (planning, executing, judging) and constructional abilities. The second part of 
the task (CLOX 2) requires the participant to copy a clock drawn by the examiner, and 
demonstrates visuospatial ability (Royall, Cordes, & Polk, 1998; Shon et al., 2013). 
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Scores for each part of the test range from 0-15. Each is scored separately, and 
an additional score can be calculated by subtracting scores for CLOX 1 from scores for 
CLOX 2. This latter score allows one to examine the contribution of executive control 
versus visuospatial praxis (Royall et al., 1998). The CLOX has good internal 
consistency and high inter-rater reliability (Strauss et al., 2006). This test has been used 
in studies focusing on the early detection of AD (e.g., Toepper, Beblo, Thomas, & 
Driessen, 2008), and is used for this purpose at the GSH Memory Clinic. 
Physiological measures. I used Sarstedt Salivette® Cortisol devices to collect 
saliva samples for the determination of cortisol levels. These devices are composed of a 
cylindrical cotton sponge in a plastic holder fitted inside a centrifuge tube.  
A research nurse drew blood samples from all participants after informed 
consent for this procedure (see Appendix C) had been obtained. These samples were 
used to perform APOE genotyping, and to determine plasma Aβ concentrations.  
Structural MRI acquisition. All scans were performed by a radiographer using 
a 3-Tesla Siemens Allegra head scanner (Siemens Medical Systems, Erlangen, 
Germany). The individual imaging sequence that was relevant to the analysis was a T1-
weighted MRI anatomical scan using a sagittal volumetric magnetization-prepared 
rapid gradient-echo. The acquisition parameters were as follows: slices = 160 
contiguous slices; slice thickness = 1.3 millimetres (mm); resolution = 1.3x1.0x1.3 mm; 
recovery time (TR) = 2530 ms; field of view read = 256 mm; flip angle = 7 degrees; 
echo spacing = 8.9 ms; base resolution = 256; phase resolution = 75%; and bandwidth = 
651 Hz/pixel. For the purposes of this study, I was especially interested in acquiring 
hippocampal volumes from the structural MRI datasets.  
 
Procedures  
Figure 5 shows a general outline of the entire study procedure. Members of the 
research team contacted participants either telephonically or via the care homes in 
which the participants resided. After initial contact, a member of the research team 
screened the participant telephonically to determine if s/he met the study’s inclusion 
criteria. Those who were eligible were asked to give their initial verbal consent for 
participation. In the case of the possible or probable AD patients, the researcher also 
obtained consent from family members or legal guardians. Full details regarding ethical 
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considerations will be discussed later in this section under the heading Ethical and 
Safety Considerations.   
During the same telephone call, the researcher arranged an appointment for the 
participant and an informant to attend a test session and a clinical visit in the Division 
of Neurology. The day before the test session, the researcher contacted the participant 
and/or the informant to remind them of their GSH visit.  
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Figure 5. Flow chart of the procedures followed, including baseline collection of 
cognitive and physiological data and neuroimaging. 
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Clinical interview and neuropsychological testing. When the participant and 
informant arrived at GSH, they were met by the researcher and escorted to the testing 
venue in the Division of Neurology. The participant was provided with an information 
and consent document that provided full details of the study (Appendix C). Participants 
were provided with time to read through document, to ask questions, and to withdraw 
from participation if they so wished, without any prejudice for their future medical 
treatment. Participants who chose to continue were asked to sign the informed consent 
document before commencing testing procedures.  
The first part of the test session involved the participant and informant 
completing the questionnaires described above (i.e., the sociodemographic 
questionnaire, the LTE-Q, PSS, DECO, BADLS, CD-RISC, and GDS). If an informant 
was not present, the relevant questionnaires were completed telephonically or 
electronically. Where the participant was not able to complete the self-report 
questionnaires by him/herself, the researcher assisted by reading the questions and 
filling in the participant’s responses. After completion of the questionnaires, the 
researcher administered the neuropsychological test battery (i.e., CAMCOG-R, TPT, 
TMT, and CLOX). The interview and neuropsychological test session usually lasted 
between 1.25 and 2 hours. Participants were offered short breaks during this time.  
At the end of the interview and testing session, the researcher provided the 
participant and/or the informant with two sets of salivettes and instructions for using 
them (see Appendix D). For those participants with memory problems, the instructions 
and salivettes were given to the informant, who was also instructed to assist the 
participant in obtaining the saliva sample. Participants were required to collect their 
saliva samples at 09h00 on two mornings in succession, within approximately one week 
of their cognitive assessment. Once both samples had been taken, the participant, or the 
informant, called the research team to let us know that the samples were ready for 
collection. After the researcher collected the salivettes, they were stored in a freezer at -
20°C at GSH.   
Immediately after the testing session, the research doctor performed the clinical 
exam and the research nurse took blood samples (maximum 36ml of blood taken), time 
permitting. Where there was insufficient time for all the assessments to be conducted on 
the same day, the clinical exam was performed at a subsequent visit a few days later. 
Either way, the clinical exam lasted between 1 and 2 hours.  
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Analytical procedures for saliva and blood samples. Once a batch of 
salivettes had been collected and stored in a freezer at -20°C, the researcher took them 
to the hospital’s Chemical Pathology Laboratory, where a standard assay was 
performed to determine salivary cortisol levels. 
Baseline blood samples taken at either the first cognitive testing session or at the 
subsequent clinical examination visit were sent immediately to a diagnostic chemical 
pathology laboratory for routine dementia screening blood tests, including renal, 
hepatic, thyroid function, vitamin B12, and syphilis serology tests. Samples for specific 
research tests were transported immediately and on ice to the research laboratory, where 
serum, plasma, and buffy coat were collected using a benchtop laboratory centrifuge 
machine. 
The serum and plasma supernatants were aliquotted into individual 
polypropylene tubes to avoid the effects of repeated freeze/thaw cycles on potential 
assay parameters. The aliquotted samples were then stored in a -80°C freezer before 
being sent in batches to a pathology lab. Laboratory technicians extracted genomic 
DNA from the stored buffy coat layers. APOE genotype was determined using a 
standard method involving the polymerase chain reactions technique, as described by 
Hixson and Vernier (1990). The laboratory scientists who performed the APOE 
genotyping had no knowledge of the participants’ demographic characteristics or of 
their clinical diagnoses. Furthermore, the researchers and clinicians were unaware of 
the genotype results when the diagnosis of possible or probable AD was given and 
when the neuropsychological exam was performed. 
Regarding plasma Aβ determinations, 40 samples of 200µl undiluted human 
plasma samples, prepared from whole blood samples collected in EDTA-containing 
tubes, were stored at -80°C prior to analysis. Laboratory technicians used the Bio-
Plex® 200 technology, based at a specialist laboratory at UCT’s Faculty of Health 
Sciences, to determine the different forms of the plasma Aβ concentrations (Aβ1-42 and 
Aβ1-40) from these samples, using a commercially available fluorimetric bead-based 
immunoassay from INNOGENETICS (Ghent, Belgium). This was a 96-well assay kit 
called the Inno BIA Plasma Aβ Forms 96 Test. This assay allows for the simultaneous 
quantification of human Aβ forms in plasma. Calculations can then be performed of the 
ratios of the amounts of the different Aβ forms that are present in the sample, for 
example, Aβ1-42/1-40. The numbers 1-40 and 1-42 correspond to the length of the 
sequence of the Aβ peptide. The specialist laboratory performed the assay according to 
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the manufacturer’s instructions. This kit required the use of 50µl of plasma, in duplicate 
for each participant, which was then diluted and run through the Bio-Plex system. For 
the test results, the laboratory technicians calculated the means of the median 
fluorescence intensity signal for the standards and unknown samples and constructed a 
standard curve. Using the mean signal value of each unknown plasma sample, they 
determined the corresponding concentration of each Aβ form from the relevant standard 
curve and then provided us with the detailed results.  
Neuroimaging. A radiographer at the imaging centre performed the MRI scans. 
The latter provided the raw data for the determinations of brain hippocampal volumes. 
The methods used in the neuroimaging protocol were as follows: Only those 
participants who provided consent to have a brain scan, who were within the required 
age range (60-90 years), and/or where it was justified for diagnostic purposes, were 
included in this part of the study. Members of the research team (Katharine James and 
Laurian Grace, a fellow PhD researcher in the Faculty of Health Sciences at the 
University of Cape Town), in consultation with the radiographer, formally screened 
participants telephonically to determine whether or not they were suitable for scanning. 
This screening involved using a questionnaire (see Appendix E) that confirmed that the 
participant had not previously been a welder/metal grinder, and that s/he did not have 
any of the following: cardiac pacemaker, neurostimulator, eye trauma/foreign body, 
previous neurosurgery, previous surgery, cochlear implant, or claustrophobia.  
Eligible participants were collected from either their place of residence or from 
GSH and taken to the imaging centre by a driver (an employee of the research team). 
On arrival, participants were asked to sign a consent form. This is the same form as that 
used for their screening; in other words the form that was used to assess their suitability 
for having an MRI scan. The radiographer confirmed that the participant did not have 
any contraindications for having a brain MRI scan. Following this, but prior to the scan 
itself, a researcher administered the MMSE and Learning subscale of the CAMCOG-R 
to the participants. These cognitive tests were performed so that the cognitive data 
would correspond in terms of time with the neuroimaging data. These specific tests 
were selected because (a) the MMSE has frequently been used as a measure of 
cognition in neuroimaging studies of the hippocampus (Slavin, Sandstrom, Tran, 
Doraiswamy, & Petrella, 2007; Steffens, McQuoid, Payne, & Potter, 2011; 
Vijayakumar & Vijayakumar, 2012), and (b) the Learning subscale provides an 
approximate measure of new learning and memory which are key features of 
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hippocampal functioning (Eichenbaum, 2003; Cipolotti et al., 2001). The research nurse 
drew blood samples (these blood samples were taken as part of a co-researcher’s 
project). Participants then changed into a hospital gown.  
The radiographer then took each participant into the scanner room and asked 
him/her to lie down on the scanning table. The radiographer provided the participant 
with an emergency button, and she explained how and when to use it. She gave each 
participant earplugs (to reduce the noise of the scanner) as well as MRI-compatible 
headphones (to enable communication between the participant and the radiographer and 
for music to be played to the participant). Lastly, the radiographer placed foam padding 
around the participant’s head within the head cradle for head stabilization, and she 
instructed participants to lie as still as possible and to avoid head movements during the 
scanning procedure.  
The table on which the participant was lying was then moved into the scanning 
machine for the 28-min duration of the scan. The scanning procedure included the 
acquisition of magnetic resonance spectroscopy data, which were collected for another 
study. The duration of the scan specifically for the acquisition of the localization and 
structural MRI data was 8:06 min.  
MRI automated analyses. I performed automated analyses of the MRI data 
using the Freesurfer image analysis suite (version 4.5; see 
http://surfer.nmr.mgh.harvard.edu/). This software provided reliable automated 
measurements of total intracranial volume (ICV), which would be too time-consuming 
to determine manually, but which corresponds well with manual measurements 
(Buckner et al., 2004). The Freesurfer software was also used for the automated 
parcelation and segmentation of all brain regions. Reconstructions of these images were 
run on an Intel Nehalem cluster at the Centre for High Performance Computing in Cape 
Town (http://www.chpc.ac.za). 
The automated image processing for cortical reconstruction and volumetric 
segmentation used in this study included the automated Talairach transformation, 
segmentation of the subcortical deep grey matter volumetric structures such as the 
hippocampi (Fischl et al., 2002; Fischl et al., 2004a), intensity normalization (Sled, 
Zijdenbos, & Evans, 1998), tessellation of the grey matter white matter boundary, and 
automated topology correction (Fischl, Liu, & Dale, 2001; Segonne, Pacheco, & Fischl, 
2007). More extensive details relating to the Freesurfer technical procedures can be 
found elsewhere (Dale, Fischl, & Sereno, 1999; Fischl & Dale, 2000; Fischl, et al., 
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2001; Fischl, 2002; Fischl et al., 2004a; Han et al., 2006; Segonne et al., 2004; Fischl, 
2012). 
Within the Freesurfer software program, I used TKMedit which allowed me to 
review the image data with a display of anatomical volumes in different orientations. 
This review enabled me to verify all reconstructions individually and across different 
slices and planes. Where necessary, I manually corrected the Talairach transformation, 
the skull stripping, and the white matter and pial edits within Freesurfer. The corrected 
images were then submitted to the Intel Nehalem cluster for reconstruction. Inspection 
and reconstruction of the images was supervised by an independent consultant from 
CUBIC who has specialist knowledge and expertise in neuroimaging and in use of the 
Freesurfer software. The consultant was blind to group status of the images and had no 
knowledge of the study hypotheses.  
MRI manual analyses. This study employed a manual technique for the 
structural MRI analysis of hippocampal volume. To prepare the MRI images for manual 
analysis, I used Brain Voyager QX, version 2.0 (Brain Innovation B.V., Maastricht, 
Netherlands). I first checked that the images were iso-voxeled, then rotated them into 
the anterior-commissure–posterior-commissure plane, and normalised them to the 
standard Talairach anatomical brain template for the purpose of between-group 
analyses. After taking those steps, I exported the images to the Analyze format for 
manual tracing.  
I performed the manual tracing using MultiTracer, version 1.0 (Woods, 2003) 
from the Laboratory of Neuro Imaging, University of California, Los Angeles. I 
magnified the images 6 times and traced them on a laptop tablet with an LED screen, 
using a stylus pen. 
I traced the hippocampal volumes manually, with the assistance of an 
experienced neuroanatomist, using the same type of tablet at the same level of 
magnification. This method provided accurate volumetric measurements of the 
hippocampus, specifically. As mentioned above, I also used Freesurfer software to 
determine total ICV, from which I then adjusted the hippocampal volumes.  
I traced the hippocampal structures in both the sagittal and coronal planes to 
enhance viewing accuracy; only the coronal tracings were used to calculate 
hippocampal volumes, however (see Figure 6). I defined and traced the hippocampus 
including the head, body, and tail, the dentate gyrus, and part of the subiculum. I used 
the alveus as a marker between the hippocampus and the amygdala. I drew within the 
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inner boundary of the alveus to exclude it, and, where visible, I used the CSF and lateral 
ventricle as supplementary landmarks. I excluded the fimbria and the fornix from the 
tracings. I also used the superior medial edge of the temporal lobe white matter as the 
medial boundary, drawing a line at 90° to the cortical surface, to demarcate the junction 
of the hippocampal formation with the parahippocampal gyrus. 
 
A 
 
B 
 
Figure 6. Coronal view of the anatomic borders of the left hippocampus, outlined in 
red, on MRI. Selected images from (A) a 69-year-old male control participant, and (B) 
a 69-year-old male AD patient. 
 
Blind to participant group status and demographic variables, I traced the 
hippocampi of all the participants and captured their frust volume measurements. (The 
frust volume is the volume calculated by assuming that the structure extends from the 
centre of the first plane on which it was drawn to the centre of the last plane on which it 
was drawn, with the square root of areas varying linearly when moving from the centre 
of one plane to the centre of the next; (Woods, 2005)).  
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One month later, I retraced the hippocampi of 10 brains. To assess my self-
consistency, I calculated intra-rater reliability using a two-way ANOVA (N = 10), 
mixed-effects model Intraclass Correlation Coefficient (ICC) test to evaluate the degree 
of agreement between my first and second tracings. The ICC demonstrated that I had 
good intra-rater reliability, with an average measure’s ICC value of .993, p < .001 and a 
single measure’s ICC of .986, p < .001 for the left hippocampi, and an average 
measure’s ICC value of .987, p < .001 and a single measure’s ICC of .974, p < .001 for 
the right hippocampi. The single measure ICC indicates the reliability of the individual 
raters, while the average measure ICC relates to the reliability of the mean of the 
ratings. Also blinded to participant group status and demographic variables, the 
neuroanatomist traced hippocampi from 10 scans to determine the reliability of my 
tracings (i.e., to measure how similar my hippocampal volumetric measurements were 
with his). We achieved strong inter-rater reliability, with an average measure’s ICC 
value of .965, p < .001, and a single measure’s ICC of .932, p < .001 for the right 
hippocampi. 
 
Ethical and Safety Considerations 
All study procedures were approved by the Research Ethics Committees of the 
University of Cape Town’s Department of Psychology and the Faculty of Health 
Sciences (REC REF 346/2008). This study was conducted according to the ethical 
guidelines and principles stated in the International Declaration of Helsinki, the South 
African Guidelines for Good Clinical Practice, and the South African Medical Research 
Council (MRC) Ethical Guidelines for Research.  
All participants were provided with thorough and detailed written and verbal 
information about the study (Appendix D); their anonymity was assured and they were 
informed of their right to withdraw from the study at any given point. Participants were 
informed about all the relevant study procedures and what their role in the study would 
entail.  
Ethical approval for the neuroimaging study was granted in a protocol 
amendment document (REC REF 346/2008, Amendment 2012). Regarding 
participation in the neuroimaging component of the study, these participants were 
provided with a separate consent form and were informed about any possible risks. The 
facility where the scanning procedure took place is a well-equipped centre with highly 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
84 
 
qualified staff members who ensured that all the necessary MR safety protocols were 
adhered to strictly. 
Prior to commencement of the scanning procedure, participants were provided 
with hospital robes to wear in the scanner. During the scan itself, participants were able 
to close their eyes, listen to music, or rest. If necessary, participants were able to talk to 
the study doctor/assistant/radiographer at any time. We bore in mind that, because the 
scan was done in a relatively confined space, some people might have become 
claustrophobic. This did not occur often, however, and where any of the participants did 
feel anxious, a study representative gave them time to get used to the surroundings 
before scanning began. In a small number of cases, the participants became very 
anxious and elected not to proceed with the scan. In those cases (n = 5), the scan was 
terminated prematurely. The participants who withdrew thus were four female AD 
patients (67, 70, 79, and 83 years old respectively), and one female control (74 years 
old). 
 
Statistical Analyses 
I sorted and cleaned the data and checked for any missing items. I performed all 
analyses using Statistica 10 or SPSS version 19.0. I performed descriptive statistical 
analyses for all the data and calculated measures of central tendency (mean and median) 
and dispersion (range, standard deviation, and variance) for all variables. I also 
constructed boxplots for all the continuous independent variables in order to detect 
outliers that may have influenced the measures of central tendency. For all of these 
analyses, the alpha level was set at .05. I used Cohen’s d or partial eta squared (ηp
2
) as 
estimates of the effect sizes for parametric data. To calculate effect sizes for non-
parametric data, I used Cohen’s r. Cohen defines the effect size ranges as 0.2 = small 
effect, 0.5 = medium effect, 0.8 = large effect (Cohen, 1988).  
For some of the factors of interest, I performed exploratory analyses that were 
not a direct part of any of the a priori hypotheses, but which the literature indicated 
might be worthwhile. I present the results of those exploratory analyses at the end of 
each relevant section, after presentation of the hypothesis-driven results.  
Demographic, neuropsychological, affective, and behavioural data. To 
examine between-group differences in sociodemographic variables and in measures of 
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current neuropsychological, affective, and behavioural functioning, I used independent-
samples t-tests or Mann-Whitney U-tests. 
Current psychosocial stress, lifetime trauma, and current cortisol levels. As 
noted above, the PSS is a measure of current perceived stress, and was used here as a 
measure of psychosocial stress because it relates to everyday stressors. I decided to use 
only the PSS, which looks at recent acute stressors likely to occur in daily life, as a 
measure of psychosocial stress, rather than using a composite of the PSS and LTE-Q. I 
made this decision because research suggests that daily life stressors, rather than major 
life events which are relatively rare, have a cumulative and perhaps more severe effect 
on well-being (Zautra, Affleck, Tennen, Reich, & Davis, 2005; Almeida, Neupert, 
Banks, & Serido, 2005) Scores on the PSS and LTE-Q were weakly correlated with 
each other, r(132) = .29, p < .001, but the instruments do not measure the same 
construct(s); thus, creating a composite variable might have conflated constructs. 
As noted above, the LTE-Q provides scores for recent stress (traumatic events 
experienced < 6 months ago) and remote stress (traumatic events experienced > 6 
months ago). Hence, from here onwards, the variable names recent stress and remote 
stress refer to those separate LTE-Q scores. The sum of those separate LTE-Q scores 
produced a total LTE-Q score (i.e., the lifetime stress variable). To test hypotheses 
related to psychosocial stress and lifetime traumatic events (Hypothesis 1a, as listed 
above), I examined between-group differences using either independent samples t-tests 
or Mann Whitney U-tests.  
Pearson product-moment correlation analyses assessed the associations between 
psychosocial stress and current cortisol levels (Hypothesis 1b), between psychosocial 
stress and cognition, and between cortisol and cognition (Hypothesis 1c). I derived a 
single measure of circulating cortisol for each participant by averaging the two morning 
salivary cortisol readings from each. The cortisol measurements are in nanomoles per 
litre (nmol/L). These baseline raw scores for cortisol levels were not normally 
distributed, and so the appropriate nonparametric tests were used in analyses of this 
variable. Regarding the measure of cognition used in the abovementioned correlations, 
there were three: CAMCOG-R Total score, MMSE score, and CAMCOG-R Learning 
subscale score. Furthermore, I performed a correlational analysis to determine if 
cortisol was related to age, in which case I would need to control for age in the cortisol 
analyses. I also performed a t-test to examine between-group differences for cortisol 
levels.   
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Resilience. Correlational analyses assessed the associations between levels of 
resilience and psychosocial stress (Hypothesis 2a), and between levels of resilience and 
years of education (Hypothesis 2b). 
Apolipoprotein є4. After calculating descriptive statistics to determine the 
frequency of APOE-є4 in each group, I conducted a chi-square (χ2) test of contingency 
to assess between-group differences in terms of APOE-є4 frequency (Hypothesis 3a). 
Due to the limited number of APOE-є4 homozygotes (nHC = 2, nAD = 9) in this sample, 
I divided participants into two groups for APOE-є4: those with the є4 allele, є4 carriers 
(є4+), and those without the є4 allele, є4 non-carriers (є4-). I then conducted t-tests to 
determine differences in cognition (CAMCOG-R score) within each group (Hypothesis 
3b). I also ran t-tests to determine if levels of psychosocial stress and cortisol were 
higher in controls and AD patients with APOE-є4 than in those without APOE-є4. To 
assess whether AD patients with higher levels of psychosocial stress and the presence 
of the є4 allele performed more poorly on the CAMCOG-R than AD patients with 
lower levels of psychosocial stress and an absence of APOE-є4 (Hypothesis 3c), I 
performed a univariate ANOVA. For this analysis, the total CAMCOG-R score was the 
dependent variable and psychosocial stress, defined by a median split (high:low) and 
APOE-є4 (with:without) were entered as fixed factors. Finally, to examine whether AD 
patients with higher baseline cortisol levels and the presence of the є4 allele performed 
more poorly on the CAMCOG-R than AD patients with lower baseline levels of cortisol 
and an absence of APOE-є4 (Hypothesis 3d), I performed a univariate ANOVA. For 
this analysis, the total CAMCOG-R score was the dependent variable and cortisol, 
defined by a median split (high:low) and APOE-є4 (with:without) were entered as fixed 
factors. 
Beta-amyloid. I used t-tests to determine whether there were between-group 
differences in plasma Aβ levels (Aβ1-42, Aβ1-40, and Aβ1-42/Aβ1-40 ratio; 
Hypothesis 4a). To determine whether AD patients with high levels of psychosocial 
stress had lower levels of plasma Aβ than AD patients with low levels of psychosocial 
stress (Hypothesis 4b), I created a median split for psychosocial stress and performed a 
t-test. To determine whether AD patients with high levels of cortisol had lower levels of 
plasma Aβ than AD patients with low levels of cortisol, I created a median split for 
cortisol and performed a t-test.  
Hippocampal volume. I determined left and right hippocampal volumes in each 
participant using the manual tracing method described above. Hippocampal volumes 
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are presented in cubic millimetres (mm
3
). I then summed and divided the hippocampal 
volumes by each participant’s total ICV to control for intersubject variation in brain 
size, in accordance with previous volumetric analyses (Basso et al., 2006; Knoops, 
Gerritsen, van der Graaf, Mali, & Geerlings, 2012). The size of hippocampi can vary 
proportionally to ICV, and structural analysis of brain regions is challenged by the fact 
that brain size can vary markedly among individuals (Buckner et al., 2004). 
Measurements of ICV are independent of atrophy and can be used safely to adjust for 
premorbid brain and head size in studies of cerebral structures in AD (Jenkins, Fox, 
Rossor, Harvey, & Rossor, 2000).  
I conducted Pearson product-moment correlations to examine associations 
between age and ICV, between disease status (as measured by MMSE scores in the AD 
patient group) and ICV, between adjusted hippocampal volume (right, left, and total) 
and cortisol levels, and between hippocampal volume (right, left, and total) and 
cognitive performance. I performed t-tests to examine whether AD patients had smaller 
hippocampal volumes than controls (Hypothesis 5a). 
To test whether AD patients with high baseline cortisol levels (defined by a 
median split) and the presence of the APOE-є4 allele had smaller hippocampal volumes 
than patients with low baseline cortisol levels and without APOE-є4 (Hypothesis 5b), I 
performed a univariate ANOVA with total adjusted hippocampal volume as the 
dependent variable and cortisol defined by a median split (high:low) and APOE-є4 
(with:without) as the fixed factors. 
Multiple regression model. Initially, I intended to explore my data using a 
structural equation model (SEM) which would have allowed for the simultaneous 
investigation of the relationships between age, education, resilience, APOE-є4, cortisol, 
psychosocial stress, and cognition. Unfortunately, preliminary analyses indicated that 
the SEM was not going to be a feasible technique for analyzing these data. For instance, 
some of the variables that should not have been correlated with each other, for the 
purposes of the SEM, were highly correlated (see Table F1 in Appendix F for details of 
these preliminary results). 
As a reasonable alternative to using a SEM, I performed a hierarchical multiple 
regression to investigate which factors were significant predictors of cognition. The 
following independent variables (selected based on the literature) were entered into the 
model one by one, in this order: age, education, APOE-є4, cortisol, and psychosocial 
stress. Resilience was not entered as a variable in this model because of its high 
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collinearity with psychosocial stress. The outcome variable (i.e., the measure of 
cognitive functioning) was CAMCOG-R Total Score. 
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Results 
Results for Study 1 are grouped and presented in order of their related 
hypotheses. Results for the five sets of hypotheses are presented first, followed by the 
results for the regression model. For some variables (viz., psychosocial stress, lifetime 
trauma, current cortisol levels, APOE-є4, and Aβ), I performed exploratory analyses. 
These analyses were not related directly to the hypotheses, but I report them here 
because they might be of interest in that they relate to data reported in previously 
published studies. Therefore, in the exploratory analyses sections, I refer briefly to 
relevant studies to place those analyses in the context of the literature.   
 
Demographic, Neuropsychological, and Behavioural Data 
Table 2 presents the sample’s demographic data. On average, controls were 
significantly younger than AD patients and had more years of education. Most 
participants in both groups were female. Although AD patients had, on average, a 
slightly lower body mass index (BMI) than controls, there were no significant between-
group differences in this regard; hence, this variable should not have influenced 
between-group differences in cortisol levels. In terms of SES status, most controls had a 
monthly household income of more than ZAR2500 (approximately US$250, at the time 
of this study), whereas most AD patients had a monthly household income of less than 
that. 
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Table 2 
Sample Demographic Data at Baseline (N = 134) 
 Group    
 Controls AD Patients    
Variable (n = 69) (n = 65) df t / χ2 p ESE 
Age 71.03 (8.72) 76.49(7.92) 133 -.3.79
a
 < .001*** 0.66 
Sex (M:F) 16:53 22:43 1 1.87
b
 .17 -0.12 
Race (W:B:C:I) 43:1:25:0 13:1:49:2 3 25.76
b
 .001*** 0.44 
Education (years) 13.81 (4.68) 9.32 (3.13) 133 6.49
a
 .001*** 1.11 
Handedness (Right:Left) 62:7 61:4 1 0.71
b
 .40 0.07 
Body Mass Index 27.40 (6.05) 25.57 (5.11) 107 1.69
a
 .09 0.33 
Income        
< ZAR2500:≥ ZAR2500 13:56 50:15 1 45.33 < .001*** 0.58 
Note. For the variables Age, Education, and Body Mass Index, means are presented with standard deviations  
in parentheses. For the variable Race, W = White, B = Black African, C = Coloured, I = Indian. (This  
classification of race groups is in line with historical classification of the dominant population groups in South  
Africa, and with current census classification practice; it is eported here purely as a means to characterize the  
sample). The variable Income refers to monthly household income; all units of currency in this study are  
ZAR = South African Rand. 
a
Test statistic for t-test. 
b
Test statistic for Mann-Whitney U test. ESE = effect  
size estimate; in this case, either Cohen’s d (for t-tests) or phi (φ) (for χ2 tests). 
*p < .05. **p < .01. ***p < .001. 
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Table 3 presents descriptive statistics for the cognitive and behavioural 
measures at baseline. AD patients had significantly poorer affective, behavioural, and 
adaptive functioning compared to the controls. Although the analyses presented in the 
Table did not control for the significant between-group differences in terms of age and 
education (see Table 2), the influence of education and age on cognitive functioning are 
examined in the regression models presented later. Of note here, though, is that, across 
the entire sample, age was significantly correlated with CAMCOG-R total score; with 
increasing age, CAMCOG-R scores decreased, r(133) = -0.38, p < .001. Similarly, 
across the entire sample, education was significantly correlated with CAMCOG-R total 
score; with increasing education, r(133) = -.57, p < .001. There was no significant sex 
difference in CAMCOG-R Total Score (men: M = 80.71, SD = 14.00; women: M = 
79.05, SD = 18.13), t(131) = 0.51, p = .61. 
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Table 3 
Descriptive Statistics for Cognitive and Behavioural Measures at Baseline (N = 134) 
 Group  
 Controls AD Patients  
  (n = 69) (n = 65)    
Variable 
Max. Attainable 
Score 
M (SD) Median (IQR) M (SD) Median (IQR) t / Z p ESE 
CAMCOG-R 105 92.52 (5.21) 94.00 (7.00) 65.38 (13.78) 68.00 (20.00) 15.36
a
 < .001*** 2.61 
 Memory 27 21.36 (2.12) 21.00 (3.00) 10.94 (5.22) 10.00 (8.00) 9.47
b
 < .001*** 0.82 
 Orientation 10 9.77 (0.55) 10.00 (0.00) 6.89 (2.44) 7.00 (4.00) 7.25
b
 < .001*** 0.63 
 Language 30 27.13 (1.55) 27.00 (1.00) 23. 35 (3.08) 24.00 (5.00) 7.81
b
 < .001*** 0.67 
 Attention 7 6.28 (0.55) 7.00 (1.00) 4.17 (2.24) 4.00 (4.00) 5.81
b
 < .001*** 0.50 
 Calculation 2 1.20 (0.35) 2.00 (0.00) 1.42 (0.66) 2.00 (1.00) 4.05
b
 < .001*** 0.35 
 Praxis 12 11.22 (0.89) 11.00 (1.00) 9.07 (2.24) 9.00 (3.00) 6.14
b
 < .001*** 0.53 
 Abstract Thinking 8 6.91 (1.09) 7.00 (2.00) 4.12(2.34) 5.00 (4.00) 7.52
b
 < .001*** 0.65 
 Perception 9 7.87 (1.24) 8.00 (2.00) 5.45 (1.72) 5.00 (2.00) 9.43
a
 < .001*** 1.61 
MMSE 30 28.14 (2.36) 29.00 (2.00) 20.80 (5.10) 22.00 (6.00) 8.95
b
 < .001*** 0.77 
Learning 17 14.00 (2.40) 14.00 (2.00) 7.51 (3.85) 8.00 (6.00) 8.88
b
 < .001*** 0.77 
GDS 15 1.70 (2.32) 1.00 (2.00) 2.60 (2.22) 2.00 (3.00) -2.99
b
 0.002** -0.26 
BADLS 60 0.33 (1.30) 0.00 (0.00) 8.02 (6.80) 7.00 (11.00) -7.82
b
 < .001*** -0.67 
DECO 38 35.90 (3.48) 38.00 (4.00) 23. 50 (8.67) 23.50 (12.50) 7.72
b
 < .001*** 0.66 
CD-RISC 100 80.26 (12.71) 82.00 (17.00) 66.58 (12.67) 67.00 (16.00) 6.26
a
 < .001*** 1.08 
Note. Means (M) are presented with standard deviations (SD) in parentheses. Raw score medians are presented with interquartile ranges (IQR) in 
parentheses. CAMCOG-R = Cambridge Cognitive Examination-Revised; MMSE = Mini-Mental State Examination; GDS = Geriatric 
Depression Scale; BADLS = Bristol Activities of Daily Living; DECO = Deterioration Cognitive Observee. For each between-group 
comparison, degrees of freedom = 133, except for BADLS (120) and DECO (118). 
a
Test statistic for t-test. 
b
Test statistic for Mann-Whitney U 
test. ESE = effect size estimate; in this case, Cohen’s d (for parametric data) or Cohen’s r (for non-parametric data).  
*p < .05. **p < .01. ***p < .001. 
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Table 4 presents between-group comparisons of neuropsychological test scores 
at baseline. AD patients performed more poorly than controls across measures of 
visuoconstructional ability (CLOX 2), planning and organization in addition to 
visuoconstructional ability (CLOX 1), visual attention and processing speed (TMT-A), 
cognitive switching in addition to visual attention and processing speed (TMT-B), and 
visual associative memory (TPT). 
 
Table 4 
Between-Group Comparisons: Neuropsychological test scores at baseline (N =134) 
Test variable 
Group  
Controls AD Patients 
(n = 69) (n = 65)    
Median (IQR) Median (IQR) Z p ESE 
TPT (total score) 16.00 (5.00) 7.00 (5.00) 7.52 < .001*** 0.65 
TMT-A 43.50 (19.00) 88.00 (66.00) -7.34 < .001*** -0.63 
TMT-B 100.00 (45.00) 300.00 (124.00) -8.10 < .001*** -0.70 
CLOX 1 13.00 (2.00) 11.00 (4.00) 6.56 < .001*** 0.57 
CLOX 2 14.00 (2.000 13.00 (3.00) 5.60 < .001*** 0.48 
Note. Medians are presented with interquartile ranges in parentheses. TPT = The 
Placing Test; TMT-A = Trail Making Test (Part A); TMT-B = Trail Making Test (Part 
B); CLOX 1 = Executive Clock Drawing Task (Part 1); CLOX 2 = Executive Clock 
Drawing Task (Part 2). For both TMT trials, the outcome variable is time, in seconds. 
For each between-group comparison, degrees of freedom = 132. 
*p < .05. **p < .01. ***p < .001. 
 
 
Hypotheses Set 1: Psychosocial Stress, Lifetime Trauma, and Current Cortisol 
Levels 
This group of results relates to this study’s first set of hypotheses (viz., 
Hypotheses 1a, 1b, and 1c). Table 5 presents results of the between-group comparisons 
regarding perceived current psychosocial stress, lifetime experiences of stress (recent 
and remote stress), and baseline cortisol levels. 
Partially confirming Hypothesis 1a, mean PSS scores for patients (n = 65) were 
significantly higher than those for controls (n = 69); on the PSS, higher scores indicate 
greater perceived stress. PSS scores, however, were not influenced by disease severity, 
as measured by the AD patients’ scores on the MMSE, r(63) = -.02, p = .89. 
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Partially disconfirming Hypothesis 1a, there were no significant between-group 
differences in terms of total LTE-Q scores (in fact, controls had, on average, slightly 
higher levels of total stress, as well as slightly higher levels of remote stress). Also 
partially disconfirming Hypothesis 1a, controlling for age, there were no significant 
between-group differences in terms of mean salivary cortisol levels (on average, AD 
patients had only slightly higher mean cortisol levels than controls).  
The analyses did not confirm Hypothesis 1b (viz., that there would be a larger 
positive association between psychosocial stress and cortisol levels among AD patients 
than among controls): For patients, r(63) = -.09, p = .45, whereas for controls r(67) = 
.03, p = .81. 
Similarly, the analyses did not confirm Hypothesis 1c (viz., that levels of 
psychosocial stress and cortisol would be negatively correlated with cognitive 
performance); see Table 6 for the results of these analyses within each group separately. 
The relationships between psychosocial stress and cortisol with cognition across the 
entire sample are explored in the multiple regression model discussed later in this 
section. 
Exploratory analyses. There were no significant between-group differences in 
terms of LTE-Q measures of recent, remote, or total stress (Table 5). Furthermore, none 
of the three LTE-Q outcome variables correlated significantly with scores on any of the 
cognitive measures (CAMCOG-R, MMSE, or Learning score).  
Regarding sex differences on the in psychosocial stress, previous studies suggest 
that healthy women experience their lives to be more stressful than healthy men do and 
that women achieve higher scores on the PSS than men (Cohen & Janicki-Deverts, 
2012; Matud, 2004). This sex difference was confirmed in the current sample of healthy 
controls: Women (n = 53, M = 19.00, SD = 8.48) had significantly higher PSS scores 
than men (n = 16, M = 13.06, SD = 6.72), t(67) = -2.56, p = .01, d = 1.01. In the AD 
patient group, however, men (n = 22, M = 24.27, SD = 7.12) had significantly higher 
PSS scores than women (n = 43, M = 19.93, SD = 7.67), t (63) = 2.21, p = .03, d = .59.  
An association between education and psychosocial stress has also been 
reported: Better-educated adults have been found to have less psychological stress 
(Grzywacz, Almeida, Neupert, & Ettner, 2004). In the current sample, there was a trend 
for higher levels of education to be associated with lower levels of psychosocial stress, 
as measured by the PSS, r(133) = -.15, p = .08.  
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Cortisol levels are known to increase with age, particularly in older adults (Zhao 
et al., 2003). In this sample, however, morning cortisol levels were not associated 
significantly with age in the AD patient group, r(63) = .18, p = .16. However, cortisol 
was associated with age in the control group, r(67) = .36, p = .003. Sex differences in 
salivary cortisol have also been reported previously (Larsson, Gullberg, Rastam, & 
Lindblad, 2009). In this sample, however, there was no statistically significant between-
sex difference in cortisol levels (men, n = 38, M = 9.11, SD = 15.39; women, n = 96, M 
= 10.96, SD = 19.68), t(144) = 0.55, p = .58, d = 0.11.  
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Table 5 
Between-Group Comparisons: Psychosocial and physiological stress at baseline (N = 134) 
 
Group 
 
Controls AD Patients 
 (n = 69) (n = 65)  
Type of Stress M (SD) Median (IQR) M (SD) Median (IQR) t / Z p ESE 
LTE-Q        
 Total stress 12.64 (6.60) 12.00 (9.00) 11.89 (7.60) 10.50 (7.00) 0.61
a
 .55 0.11 
 Remote stress 10.42 (5.50) 10.00 (8.00) 9.57 (5.29) 9.00 (7.00) 0.91
a
 .36 0.16 
 Recent stress 2.21 (2.79) 2.00 (3.00) 2.32 (4.52) 0.00 (3.00) 1.10
b
 .27 0.03 
PSS 17.63 (8.45) 17.00 (10.00) 21.40 (7.71) 21.00 (10.00) -2.70
a
 .01
*
 0.47 
Cortisol 0.80 (0.31) 0.79 (0.35) 0.82 (0.33) 0.85 (0.52) -0.31
a
 .76 0.06 
Note. LTE-Q = List of Threatening Life Events Questionnaire. PSS = Perceived Stress Scale. Cortisol is measured in nmol/L. 
a
Test statistic for  
t-test. 
b
Test statistic for Mann-Whitney U test. ESE = effect size estimate (in this case, Cohen’s d for parametric data and Cohen’s r for non-
parametric data). For each between-group comparison, degrees of freedom = 132, except for cortisol (115). 
*p < .05. 
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Table 6 
Correlations: Cognition, psychosocial stress, and cortisol at baseline (N = 134)  
 
Group 
Controls AD Patients 
(n = 69) (n = 65) 
PSS Cortisol PSS Cortisol 
CAMCOG-R .05 -.18 .04 .06 
Note. Values presented are for Pearson’s r. PSS = Perceived Stress Scale –  
measure of psychosocial stress. Cortisol = log transformed salivary cortisol levels. 
CAMCOG-R = Cambridge Cognitive Examination-Revised. 
 
Hypotheses Set 2: Resilience  
Hypotheses 2a and 2b related to resilience and education and how they are 
associated with each other in both controls and AD patients. Confirming Hypothesis 2a, 
there was a statistically significant inverse relationship between resilience, as measured 
by the CD-RISC, and psychosocial stress, as measured by the PSS, in controls, r(67) =  
-.46, p < .001, in AD patients, r(64) = -.28, p = .02, and in the entire sample, r(133) =    
-.43, p < .001. 
The analyses did not confirm Hypothesis 2b, however. There was no significant 
association between resilience, as measured by the CD-RISC, and number of years of 
formal education in either controls, r(67) = .18, p = .15, or AD patients, r(64) = .04, p = 
.76. In the entire sample, however, there was a significant positive association between 
resilience and education, r(133) = .31, p < .001. 
 
Hypotheses Set 3: Apolipoprotein є4 
Confirming Hypothesis 3a, AD patients (n = 64) had a significantly higher є4 
allelic frequency than controls (n = 65), χ2(127) = 9.25, p = .002. The є4 allelic 
frequency in the control group was 0.20, in the AD patient group it was 0.35, and in the 
entire sample it was 0.28. The є3 allelic frequency in the control group was 0.70, in the 
AD patient group it was 0.56, and in the entire sample it was 0.63. The є2 allelic 
frequency in the control group was 0.10, in the AD patient group it was 0.08, and in the 
entire sample it was 0.09.  
Previous work has suggested that the presence of APOE-є4 may modify the 
association between salivary cortisol levels and cognitive function (Gerritsen, Comijs, 
Deeg, Penninx, & Geerlings, 2010). Similar findings have been reported for 
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psychological stress (Peavy et al., 2007). In light of these findings, Hypotheses 3b and 
3c involved the relationship of APOE-є4 to psychosocial stress, physiological stress, 
and cognition. Hypothesis 3b was not confirmed: Performance on the CAMCOG-R in 
AD patients with APOE-є4 (n = 37, M = 65.24, SD = 14.16) did not differ significantly 
from performance on the CAMCOG-R in AD patients without є4 (n = 27, M = 66.43, 
SD = 13.81), t(63) = 0.34, p = .74, d = 0.09.  
In terms of Hypothesis 3c, the mean scores appeared to indicate that AD patients 
with high levels of psychosocial stress (as defined by a median split) and presence of 
the є4 allele performed more poorly on the CAMCOG-R (n = 33, M = 61.38, SD = 
13.73) than did AD patients with lower levels of psychosocial stress and absence of the 
є4 allele (n = 32, M = 66.45, SD = 13.99). However, a univariate ANOVA found no 
main effect for APOE-є4, F(3, 60) = .00, p = .99, ηp
2
 < .001; no main effect for 
psychosocial stress, F(3, 60) = 1.33, p = .25, ηp
2
 = .02; and no significant interaction 
between APOE-є4 and psychosocial stress, F(3, 60) = 2.76, p = .10, ηp
2
 = .04.  
In terms of Hypothesis 3d, the mean scores depicted in Figure 7 appear to 
indicate that AD patients with high baseline cortisol levels (as defined by a median 
split) and presence of the є4 allele (є4+) performed more poorly on the CAMCOG-R (n 
= 30, M = 61.38, SD = 13.73) than did AD patients with low baseline cortisol levels and 
absence of the є4 allele (є4-; n = 10, M = 66.45, SD = 13.99). However, a univariate 
ANOVA found no main effect for APOE-є4, F(3, 61) = 0.02, p = .88, ηp
2
 = .00; no 
main effect for cortisol, F(3, 61) = 1.49, p = .23, ηp
2
 = .02; and no significant interaction 
between APOE-є4 and cortisol, F(3, 61) = 1.44, p = .24, ηp
2
 = .02.  
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Figure 7. CAMCOG-R total scores in AD patients, grouped by cortisol levels and 
APOE-є4 status. Cortisol: High or Low as defined by a median split. APOE-є4 status: 
є4+ = participants with the є4 allele; є4- = participants without the є4 allele. 
 
Exploratory analyses. In light of previously established links between cortisol 
and APOE-є4 (Lee et al., 2008; Peavy et al., 2007), I wished to explore whether those 
participants who were є4+ had higher levels of psychosocial stress and salivary cortisol 
than those who were є4-. Exploring these data, I found that, among controls, those who 
were є4+ had higher mean levels of psychosocial stress and cortisol than those who 
were є4-, but these differences did not reach statistical significance (see Table 7). In the 
AD patient group, those who were є4+ had higher means levels of psychosocial stress 
and cortisol than those who were є4-; here, the differences for psychosocial stress also 
did not reach statistical significance, but those for cortisol were significant (see Table 
8). 
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Table 7 
Psychosocial Stress and Cortisol as a Function of Group and Apolipoprotein E Status 
in Controls (N = 65) 
 Group    
 є4+ є4-    
 (n =  24) (n = 41)    
Variable M (SD) M (SD) t  p ESE 
Psychosocial stress  19.13 (8.26) 16.90 (8.76) 1.01 .32 0.26 
Cortisol 0.85 (0.25) 0.76 (0.33) 1.05 .30 0.31 
Note. Values are means (and standard deviations). є4+ = participants with the 
apolipoprotein є4 allele; є4- = participants without the apolipoprotein є4 allele.  
Cortisol values are the log transformed cortisol value. ESE = effect size estimate,  
Cohen’s d. For each between-group comparison, degrees of freedom = 63. 
 
 
Table 8 
Psychosocial Stress and Cortisol as a Function of Group and Apolipoprotein E Status 
in AD Patients (N = 64) 
 Group    
 є4+ є4-    
 (n =  37) (n = 27)    
Variable M (SD) M (SD) t  p ESE 
Psychosocial stress  22.30 (7.43) 20.33 (8.18) 1.00 .32 0.25 
Cortisol 0.89 (0.34) 0.70 (0.28) 2.20 .03* 0.61 
Note. Values are means (and standard deviations). є4+ = participants with the 
apolipoprotein є4 allele; є4- = participants without the apolipoprotein є4 allele.  
Cortisol values are the log transformed cortisol value. ESE = effect size estimate,  
Cohen’s d. For each between-group comparison, degrees of freedom = 62. 
*p < .05.  
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Hypotheses Set 4: Beta-Amyloid 
To investigate the fourth set of hypotheses, the research team analysed levels of 
plasma Aβ in 10 controls and 30 AD patients. In 3 controls and 4 patients, the 
immunoassay kit could not detect levels of plasma Aβ. As this could have been due to a 
technical problem related to an interfering substance, I had to exclude these data from 
the analyses. 
Table 9 presents demographic characteristics for the participants whose blood 
samples were analysed for levels of Aβ. Although group sample sizes were unequal, the 
data were normally distributed and the variances were similar; hence, I conducted t-
tests to compare group levels of Aβ. These data indicate that the groups were similar in 
age, sex, and for cortisol levels, however, the AD patients had higher PSS scores.  
 
Table 9 
Demographic Data for Participants whose Aβ Samples were Analysed (N = 33) 
                  Group  
  Controls AD Patients 
Variable (n = 7) (n = 26) df t / χ2 p ESE 
Age 77.57 (4.65) 75.15 (5.45) 31 1.07
a
 .29 0.48 
Sex (M:F) 2:5 9:17 1 .09
b
 .76 -0.05 
PSS Score 14.71 (4.72) 22.15 (8.16) 31 -2.29
a
 .03* 1.12 
Cortisol 0.83 (0.36) 0.93 (0.32) 
) 
28 -0.67
a
 .51 0.29 
Note. For the variables Age, PSS Score, and Cortisol, means are presented with  
standard deviations in parentheses. PSS = Perceived Stress Scale – measure of 
psychosocial stress. Cortisol values are the log transformed values. 
a
Test statistic  
for t-test. 
b
Test statistic for χ2. ESE = effect size estimate (in this case, Cohen’s d 
 for t-tests, and φ for χ2). 
*p < .05. 
 
Although the data presented in Table 10 suggest that AD patients had a slightly 
lower Aβ1-42/Aβ1-40 ratio than controls, the between-group difference was not 
statistically significant, thus disconfirming Hypothesis 4a. AD patients had slightly 
lower levels of plasma Aβ1-42 and slightly higher levels of Aβ1-40 than age-matched 
controls.  
Hypothesis 4b was not confirmed. The analyses showed that the plasma Aβ1-
42/Aβ1-40 ratio (n = 14, M = .24, SD = .05) in AD patients with high psychosocial 
stress (as defined by a median split) was not lower than the ratio (n = 12, M = .21, SD = 
.06) in AD patients with low psychosocial stress, t(24) = -1.30, p = .21, d = 0.13. The 
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analyses also showed that the plasma Aβ1-42/Aβ1-40 ratio (n = 13, M = .22, SD = .06) 
in AD patients with high cortisol (as defined by a median split) was not lower than the 
ratio (n = 13, M = .23, SD = .05) in AD patients with low cortisol, t(24) = -0.48, p = .64, 
d = 0.18.  
 
Table 10 
Levels of Aβ in Controls and AD Patients (N = 33) 
                  Group  
  Controls AD Patients 
Beta-amyloid (n = 7) (n = 26) df t p ESE 
Aβ1-42 42.57 (22.47) 40.19 (13.23) 31 0.36 .72 0.13 
Aβ1-40 165.29 (82.48) 181.81 (53.97) 31 -0.64 .53 0.24 
Aβ1-42/Aβ1-40 Ratio 0.26 (0.02) 0.22 (0.05) 31 1.51 .14 1.05 
Note. Values are means (and standard deviations). Aβ = beta-amyloid. ESE = effect size 
estimate (in this case, Cohen’s d).  
 
Exploratory analyses. A low plasma Aβ1-42/Aβ1-40 ratio has been associated 
with the development and progression of AD patients over a period of 18 months 
(Koyama et al., 2012; Rembach et al., 2013). To explore this I chose to examine the 
relationship between the plasma Aβ1-42/Aβ1-40 ratio and cognitive scores across the 
entire sample. Figure 8 demonstrates a positive and significant relationship between the 
plasma Aβ1-42/Aβ1-40 ratio and cognitive scores as measured by the CAMCOG-R 
total score, r(31) = .63, p < .001. When analysed separately in each group, there was no 
relationship in the controls, r(5) = .08, p < .87. In the AD patient group there was a 
significant positive relationship, r(24) = .64, p < .001 
 Elevated levels of glucocorticoids have been associated with increased Aβ 
formation and deposition in animal models (Dong & Csernansky, 2009; Green, et al., 
2006; Kulstad et al., 2005) and in humans (Toledo et al., 2012). Similarly, in rats, 
psychosocial stress has been found to exacerbate Aβ-induced short-term memory 
deficits (Srivareerat, Tran, Alzoubi, & Alkadhi, 2009), and to intensify levels of beta-
site APP-cleaving enzyme (Alkadhi, Alzoubi, Srivareerat, & Tran, 2012). Based on 
these findings, I performed exploratory correlational analyses examining relationships 
between beta-amyloid, cortisol, and stress in the current sample. Across the entire 
sample, there were no significant correlations between Aβ1-42 and psychosocial stress 
(as measured by the PSS), r(31) = .22, p = .23, or between Aβ1-42 and morning cortisol 
levels, r(31) = -14, p = .44. Similarly, there were no significant correlations between 
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Aβ1-40 and psychosocial stress, r(31) = .10, p = .58, or between Aβ1-40 and cortisol, 
r(31) = .08, p = .66, or between psychosocial stress and the Aβ1-42/Aβ1-40 ratio, r(31) 
= .23, p = .21. There was, however, a significantly negative relationship between 
cortisol and the Aβ1-42/Aβ1-40 ratio, r(31) = -0.37, p = .03.  
 
 
Figure 8. The relationship between the plasma Aβ1-42/Aβ1-40 ratio and cognitive 
scores as measured by the CAMCOG-R total score across the sample (N = 33). 
 
 
Hypotheses Set 5: Hippocampal Volume 
This set of hypotheses relates to hippocampal volumes, as determined from the 
structural MRI scans. Five of the selected participants for the MRI scan did not 
complete the scan (4 patients and 1 control; these participants were all females and were 
aged 67, 83, 70, 79, and 74 respectively), and so the final sample size for this 
component of the study was N = 35 (Controls n = 14, AD patients n = 21).  
Hypotheses 5a and 5b related to hippocampal volume, stating that (5a) AD 
patients will have smaller ICV-adjusted hippocampal volumes than controls, and that 
(5b) AD patients with higher baseline cortisol levels and the APOE-є4 allele will have 
smaller ICV-adjusted total hippocampal volumes than patients with low baseline 
cortisol levels and no є4. Table 11 presents demographic data for the subset of 
participants who had MRI scans and for whom hippocampal volumes were recorded. 
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The control and AD patient groups were well matched for age, sex, and handedness. 
AD patients tended to have higher PSS scores than controls but the cortisol levels 
between the groups were similar. AD patients had significantly fewer years of 
education and performed significantly worse on the MMSE and Learning subscale. 
Before testing Hypotheses 5a and 5b, I adjusted the absolute hippocampal 
volumes for total ICV by dividing hippocampal volume by total ICV for each 
participant.  Overall, male participants (n = 15, M = 1.52E-6, SD = 1.89E-5) had larger 
ICVs (mm
3
) than female participants (n = 20, M = 1.25E-6, SD = 1.27E-5), t(33) = 
5.00, p < .001, d = 0.17. There were no significant associations between ICV and age, 
or between ICV and cognitive functioning (as measured by MMSE score).  
 
Table 11 
Demographic Data for Participants with MRI Scans (N = 35) 
 
Group  
 Controls AD Patients 
Variable (n = 14) (n = 21) df t / χ2 p ESE 
Age 72.43 (6.24) 75.57 (7.86) 33 -1.25
a
 .22 0.44 
Sex (M:F) 5:9 10:11 1 0.49
b
 .49 -0.12 
Education (years) 13.29 (3.10) 10.00 (2.74) 33 3.30
a
 .002** 1.12 
Handedness (R:L) 13:1 18:3 1 0.42
b
 .52 -0.11 
PSS score 16.43 (5.02) 20.62 (6.75) 33 -1.98
a
 .06 0.70 
Cortisol 6.19 (4.28) 5.29 (4.42) 33 0.61
a
 .55 0.21 
MMSE 28.57 (1.22) 20.00 (4.62) 33 6.76
a
 < .001*** 2.54 
Learning Score 14.93 (1.27) 6.52 (3.92) 33 7.72
a
 < .001*** 2.88 
Note. For the variables Age, Education, PSS Score, Cortisol, MMSE, and Learning 
Score, means are presented with standard deviations in parentheses. PSS = Perceived 
Stress Scale. MMSE = Mini-Mental State Examination. 
a
Test statistic for t-test. 
b
Test 
statistic for χ2. ESE = effect size estimate (in this case, Cohen’s d for t-tests and φ for χ2 
tests). 
**p < .01. ***p < .001. 
 
Table 12 presents the relationships between key demographic variables and 
ICV-adjusted hippocampal volumes in controls and AD patients. In controls, age was 
negatively correlated with right, left, and total hippocampal volumes, and sex was 
positively correlated with left and total hippocampal volume. In AD patients, there were 
no significant associations with age or sex. There were significant associations in this 
group between education and right, left, and total hippocampal volumes. In both the 
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controls and AD patients, there were no associations between ICV-hippocampal 
volumes and MMSE or Learning subscale scores.  
Correlations performed across the entire sample between ICV-adjusted 
hippocampal volumes (right, left, and total) and cognitive performance (as measured by 
the MMSE) showed significant associations: right HV, r(33) = .40, p = .02; left HV, 
r(33) = .37, p = .03; total HV, r(33) = .39, p = .02. Correlations performed across the 
entire sample between adjusted hippocampal volumes (right, left, and total) and 
Learning subscale score performance showed significant associations: right HV, r(33) = 
.48, p < .001; left HV, r(33) = .54, p < .001; total HV, r(33) = .57, p < .001. 
 
Table 12 
Correlations: Sociodemographic variables and ICV-adjusted hippocampal volume  
(N = 35) 
 Group 
Controls AD Patients 
(n = 14) (n = 21) 
Variable Left HV Right HV Total HV Left HV Right HV Total HV 
Age -.67** -.63* -.65* .07 -.01 .03 
Sex .60* .53 .57* -.02 .03 .01 
Education -.17 -.16 -.17 -.50* -.49* -.50* 
MMSE -.15 .08 -.12 .03 .11 .07 
Learning .41 .40 .41 .22 .33 .28 
Note. HV = hippocampal volume. MMSE = Mini-Mental State Examination. Learning 
= Learning subscale score. For most correlations, the test statistic was Pearson’s r 
correlation coefficient. For the categorical variable Sex, I used the point-biserial 
correlation coefficient. 
*p < .05. **p < .01. 
 
Confirming Hypothesis 5a, analysis of the absolute (unadjusted) and ICV-
adjusted hippocampal volumes (see Table 13) indicated that AD patients had 
statistically significantly smaller hippocampal volumes than controls. This finding was 
true for right, left, and total hippocampal volumes.  
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Table 13 
Between-Group Comparisons: Absolute and ICV-adjusted hippocampal volume  
(N = 35) 
 Group  
Controls AD Patients 
(n = 14) (n = 21) 
Hippocampal  
volume 
M (SD) M (SD) t p ESE 
Absolute      
 Left 1574.68 (231.99) 1055.74 (341.25) 4.96 < .001*** 1.78 
 Right 1627.623 (229.82) 1151.85 (308.56) 4.92 < .001*** 1.75 
 Total 3202.30 (442.28) 2207.59 (639.27) 5.06 < .001*** 1.81 
Adjusted      
 Left 1.19E-3 (3.09E-4) 7.90E-4 (2.97E-4) 3.85 < .001*** 1.39 
 Right 1.23E-3 (2.99E-4) 8.60E-4 (2.84E-4) 3.65 < .001*** 1.26 
 Total 2.42E-3 (6.02E-4) 1.650E-3 (5.74E-3) 3.80 < .001*** 1.30 
Note. Absolute hippocampal volumes are presented in cubic millimetres. The ICV-
adjusted hippocampal volumes are presented in scientific notation. ESE = effect size 
estimate (in this case, Cohen’s d). For each between-group comparison, degrees of 
freedom = 33. 
***p < .001. 
 
 
Hypothesis 5b was not confirmed. A univariate ANOVA detected no significant 
main effect of cortisol, F(3, 12) = 0.18, p = .68, ηp
2
 = .02, and no significant cortisol x 
APOE-є4 interaction effect, F(3, 12) = 2.73, p = .12, ηp
2
 = .19 on hippocampal volumes 
(see Figure 9). The analysis did, however, detect a significant main effect of APOE-є4, 
where AD patients with APOE-є4 had smaller ICV-adjusted total hippocampal volumes 
(n = 10, M = 1.32E-3, SD = 2.01E-4) than AD patients without APOE-є4 (n = 9, M = 
1.95E-3, SD = 6.43E-4), F(3, 12) = 5.14, p = .04, d = 0.30.  
Exploratory analyses. Previous studies have indicated associations between 
cortisol and hippocampal volumes (Lupien et al., 1998; Tessner, Walker, Dhruv, 
Hochman, & Hamann, 2007), and between psychosocial stress and hippocampal 
volumes (Childress et al., 2013; Szeszko et al., 2006). In my study, across the entire 
sample, Pearson product-moment correlations between adjusted hippocampal volumes 
(right, left, and total) and cortisol levels, controlling for age and sex, showed no 
associations: right HV, r(31) = .09, p = .63; left HV, r(31) = .04, p = .81; total HV, 
r(31) = .07, p = .72. Across the entire sample, Pearson product-moment correlations 
between adjusted hippocampal volumes (right, left, and total) and psychosocial stress 
(as measured by the PSS), controlling for age and sex, showed no associations: right 
HV, r(33) = -.07 , p = .67; left HV, r(33) = -.09, p = .60; total HV, r(33) = -.08, p = .63. 
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Figure 9. Intracranial volume-adjusted total hippocampal volumes (mm
3
) in AD 
patients, grouped by cortisol levels and APOE-є4 status. Cortisol: High or Low as 
defined by a median split. APOE-є4 status: є4+ = participants with the є4 allele;  
є4- = participants without the є4 allele.  
 
Multiple Regression Modelling 
Given that a structural equation model could not be created based on the current 
data (see Appendix F), I performed hierarchical multiple regression modelling to 
examine which of the factors investigated above were significant predictors of cognitive 
functioning, as measured by CAMCOG-R Total Score. I entered the following 
predictors into the model, singly and separately and in this order: age (in years), sex (as 
a dichotomous variable: male:female), years of completed education, APOE-є4 (as a 
dichotomous variable, i.e., allele present or absent), morning cortisol levels (log 
transformed), and psychosocial stress (as measured by the PSS). 
Table 14 presents the results for each stage of the modelling process. Age, 
education, and APOE-є4 were significant predictors; overall, the final model accounted 
for 42% of variance in the outcome. Cortisol and psychosocial stress accounted for very 
little variance in the model and were not significant predictors of the outcome.   
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Table 14 
Hierarchical Multiple Regression Modelling of CAMCOG-R Total Score (N = 115)  
Predictors Β SE B β 
Step 1    
 (Constant) 130.41 12.91  
 Age -0.68 0.18 -.34*** 
Step 2    
 (Constant) 130.85 13.40  
 Age -0.68 .18 -.34*** 
            Sex -0.42 3.21 -.01 
Step 3    
 (Constant) 88.03 13.14  
 Age -0.41 0.16 -.21* 
            Sex 0.99 2.70 .03 
 Education  1.85 0.28 .52*** 
Step 4    
 (Constant) 94.70 12.96  
 Age -0.44 0.15 -.22** 
            Sex 0.69 2.66 .02 
 Education  1.79 0.27 .50*** 
            APOE-є4 -6.83 2.43 -.21** 
Step 5     
 (Constant) 97.51 13.28  
 Age -.44 0.15 -.22** 
            Sex 0.63 2.66 .02 
 Education  1.80 0.28 .50*** 
            APOE-є4 -6.32 2.48 -.19* 
            Cortisol -3.83 3.93 -.07 
Step 6    
 (Constant) 108.01 15.37  
 Age -0.51 0.16 -.26** 
            Sex 0.38 2.66 .01 
 Education  1.70 0.28 .47*** 
            APOE-є4 -5.70 2.52 -.17** 
            Cortisol -4.33 3.94 -.08 
            PSS -0.21 0.16 -.11 
Note. CAMCOG-R = Cambridge Cognitive Examination-Revised. The predictor 
variable Education refers to number of years of completed education. The predictor 
variable APOE-є4 refers to apolipoprotein є4. The predictor variable Cortisol refers to 
the log transformed values of the salivary cortisol measure. The predictor variable PSS 
refers to the Perceived Stress Scale – measure of psychosocial stress. Β = 
unstandardized coefficients for beta. SE B = standard error of B.  
β = standardized coefficients for beta. R2 = multiple regression correlation coefficient.  
ΔR2 = change in multiple regression correlation coefficient.  
For Step 1: R
2 = .12, ΔR2 = .12; Step 2: R2 = .12, ΔR2 < .001;  
Step 3: R
2 = .36, ΔR2 = .25; Step 4: R2 = .41, ΔR2 = .04; Step 5: R2 = .41, ΔR2 = .01;  
Step 6: R
2 = .42, ΔR2 = .01. 
*p < .05**p < .01. ***p < .001. 
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I performed diagnostic tests on the model; Table 15 provides details of these. 
Briefly, analysis of the partial correlations confirmed that age, education, and APOE-є4 
contributed to the majority of the variance in the model. Psychosocial stress and cortisol 
did not predict much unique variance. The tolerance levels were high, suggesting that 
there were no problems with multicollinearity. Values for the Durbin-Watson statistic 
(1.29) and Variance Inflation Factor (< 1.09) also confirmed that there were no 
problems with multicollinearity. Examination of the residuals indicated that there were 
four potential outliers. I then excluded these four participants and performed the 
regression model again. Excluding these participants did not change the results of the 
initial model and thus these participants were retained in the regression model reported 
in Table 14. 
 
Table 15 
Hierarchical Multiple Regression Model: Diagnostic data 
Predictor Partial correlation Semi-partial correlation Tolerance 
Age -.34 -.34 1.00 
Education -.26 -.21 0.99 
APOE-є4 .53 .50 0.93 
Cortisol -.09 -.07 0.95 
PSS -.13 -.10 0.83 
Note. The predictor variable Education refers to number of years of completed 
education. The predictor variable APOE-є4 refers to apolipoprotein є4. The predictor 
variable PSS refers to the Perceived Stress Scale – measure of psychosocial stress. 
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Summary of Results 
This cross-sectional study investigated the relationships between 
sociodemographic variables, psychosocial stress, cortisol, APOE-є4, Aβ, and 
hippocampal volume in a sample of South African older adults with and without 
cognitive impairment. The most significant finding emerged from the multiple 
regression analysis that explored several of the abovementioned variables in relation to 
cognitive functioning. Because this was the most comprehensive model to be explored 
in this study, I will summarize these findings first. Then, I will then summarize the 
results pertaining to the relationships between stress, psychological and physiological, 
and APOE-є4, Aβ, and hippocampal volume. The purpose of that section, then, will be 
to summarize the results pertaining to the relationships between stress and the other 
factors of interest. In-depth interpretation and discussion of the results from this study 
(as well as those from Study 2) appear in the General Discussion. 
 
Integrated Model of Factors Associated with Cognitive Functioning 
The appearance, and acceleration, of cognitive decline in older adults has been 
the focus of much research over the past several decades. This research has identified 
several putative risk factors for age-related cognitive impairment (and for the 
development of AD). Several of these factors are also related to the experience of stress, 
and its neurobiological and cognitive consequences. A major aim of this research was to 
examine the roles of these common factors in cognitive functioning across a spectrum 
of healthy to impaired cognition in AD, as well as their associations with stress in older 
adults.  Regarding sociodemographic characteristics of the study sample, on average 
controls were significantly younger than AD patients and had more years of education. 
Although most participants in both groups were female, the sex distribution across 
groups was not statistically significantly different. AD patients did, however, have 
significantly lower SES status than controls; most AD patients had a monthly household 
income of less than ZAR2500.  
Because the groups differed significantly on some sociodemographic variables, 
these variables (viz., age and education) were entered first into the regression model. 
This strategy allowed examination of the effects on cognitive functioning of other 
variables of interest (psychosocial stress, cortisol, and APOE-є4) over and above the 
potentially confounding variables of age and education. Although there was no 
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significant between-group difference in sex distribution, I included the variable in the 
model because (a) there were more females than males in the sample, and (b) female 
sex has been associated with increased risk for AD (Holland, Desikan, Dale, & 
McEvoy, 2013; Vina & Lloret, 2010). 
Although there were significant between-group differences in terms of both SES 
status and level of education, only the latter featured as a predictor in the regression 
model. In this way, I sought to limit redundancy, and possible multicollinearity, because 
of the strong positive association between education and SES status, r(128) = .57, p < 
.001. Even in South Africa, where race and SES status were so closely entwined for so 
many years, educational attainment is (as in other countries) a key marker of SES status 
in terms of its influence on job opportunities and earning potential (Adler & Newman, 
2002; Miech & Hauser, 2001).  
In summary, I entered the following predictor variables, in this order, in the 
hierarchical regression model: age (in years), sex (male or female), education (in years), 
APOE-є4 (as a dichotomous variable, i.e. allele present or absent), morning cortisol 
levels (log transformed values), and self-perceived psychosocial stress (as measured by 
the PSS). The outcome variable was cognitive functioning, as measured by CAMCOG-
R Total score. In the final model, age, education, and APOE-є4 were the only 
significant predictors of cognitive functioning in the current sample; that model 
accounted for 42% of the variance in the outcome variable. 
Based on previous findings reported in the literature, I performed a number of 
analyses to examine the relationships between cognitive functioning, resilience, APOE-
є4, Aβ, and hippocampal volumes, on the one hand, and psychosocial and physiological 
stress, on the other. This section will provide a summary of those findings which are 
summarized in order of the hypothesis-driven analyses and then the exploratory 
analyses; the General Discussion chapter offers further interpretation and discussion of 
these findings.  
 
Hypothesis-Driven Analyses 
Hypotheses Set 1. Hypothesis 1a was partially confirmed: Compared with 
controls, AD patients had higher levels of psychosocial stress, but they did not have 
more lifetime experiences of traumatic life events or higher cortisol levels. Hypothesis 
1b was not confirmed: AD patients did not demonstrate a larger positive association 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
112 
 
between psychosocial stress and cortisol levels than controls. Hypothesis 1c was not 
confirmed: levels of psychosocial stress and cortisol were not negatively correlated with 
cognitive performance when examined separately in each group, or when examined 
across the entire sample in the regression model.  
Hypotheses Set 2. Hypothesis 2a was confirmed: In controls, AD patients, and 
across the entire sample, there was a significant negative correlation between levels of 
resilience and psychosocial stress. Hypothesis 2b was not confirmed: No association 
was found between resilience and education in either group or across the entire sample.  
Hypotheses Set 3. Hypothesis 3a was confirmed: AD patients had a higher 
APOE-є4 allelic frequency than controls. Hypothesis 3b was not confirmed: AD 
patients who were є4 carriers did not perform more poorly on a measure of cognition 
than non-carriers. Hypothesis 3c was not confirmed: AD patients with high levels of 
cortisol and the presence of the є4 allele did not perform more poorly on a measure of 
cognition than those AD patients with low levels of cortisol and an absence of the є4 
allele. 
Hypotheses Set 4. Hypothesis 4a was not confirmed: AD patients did not have a 
significantly lower plasma Aβ1-42/Aβ1-40 ratio than controls. Hypothesis 4b was not 
confirmed: AD patients with high levels o  psychosocial stress and cortisol did not have 
a lower plasma Aβ1-42/Aβ1-40 ratio than AD patients with low levels of psychosocial 
stress and cortisol.  
Hypotheses Set 5. Hypothesis 5a was confirmed: AD patients had smaller ICV-
adjusted hippocampal volumes than controls. Hypothesis 5b was not confirmed: AD 
patients with high cortisol levels and APOE-є4 did not have smaller ICV-adjusted 
hippocampal volumes than AD patients with low cortisol levels and without APOE-є4. 
 
Exploratory Analyses 
Exploratory analyses were performed for several variables based on previous 
findings in the literature. Below, I discuss the results from the exploratory analyses in 
the order in which they were performed, namely, for psychosocial stress, cortisol, 
APOE-є4, Aβ, and hippocampal volumes. 
Exploratory analyses were performed for the measures of psychosocial and 
physiological stress in relation to demographic variables. Psychosocial stress was found 
to decrease with age in both groups. In controls, females had significantly higher levels 
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of psychosocial stress than males. In AD patients, males were found to have 
significantly higher levels of psychosocial stress than females. There were no sex 
differences for lifetime experiences of stress. There were no significant between-group 
differences in terms of mean morning salivary cortisol levels. There were also no age- 
or sex-related effects for cortisol. 
Exploratory analyses for APOE-є4, in both control and AD patient groups, did 
not find that participants who were APOE-є4 carriers had higher levels of psychosocial 
stress. In controls, APOE-є4 carriers also did not have higher levels of salivary cortisol 
than those who were not carriers; however in the AD patient group APOE-є4 carriers 
had higher salivary cortisol level than those who were not carriers. Investigating the 
combination of psychosocial stress and APOE-є4 on cognitive performance (as 
measured by CAMCOG-R Total score), there was no significant main effect of either 
psychosocial stress or APOE-є4 carrier status on cognitive function; there was also no 
significant interaction effect.  
 Exploratory analyses performed for the plasma Aβ1-42 or Aβ1-40 
concentrations across the entire sample found no significant correlations between Aβ1-
42 or Aβ1-40 and psychosocial stress. There were no significant correlations between 
Aβ1-42 or Aβ1-40 and cortisol.  
Exploratory analyses for hippocampal volume and stress, indicated that across 
the entire sample there were no significant correlations between ICV-adjusted 
hippocampal volumes (right, left, or total) and psychosocial stress or cortisol.  
In summary, the regression analyses demonstrated that age, level of education, 
and APOE-є4 carrier status were significant predictors of cognitive function in this 
sample of South African older adults. Psychosocial and physiological stress was largely 
unrelated to cognitive function and to the other variables in this study. In general, my 
hypotheses for this cross-sectional study were not confirmed. The hypotheses that were 
confirmed related to APOE-є4 and hippocampal volume.  
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CHAPTER THREE: STUDY 2 – A LONGITUDINAL STUDY 
 
Introduction 
 
Longitudinal Studies of AD 
Although there is a wealth of cross-sectional research on AD, there is a 
comparative paucity of longitudinal studies. Cross-sectional studies have their 
advantages, in that they can examine various outcome variables at one time point 
(Mann, 2003). Also, cross-sectional studies allow for a single point estimate to be used 
as the dependent measure; in the context of predictable variables, this can be useful for 
estimating the likelihood of future disease course and progression (Fotenos, Snyder, 
Girton, Morris, & Buckner, 2005). Although cross-sectional research design has the 
benefit of measuring several variables at once, it cannot provide distinct information 
pertaining to cause-and-effect relationships. Furthermore, it is likely that differences 
found in cross-sectional research represent entrenched differences that were established 
prior to old age; these factors may, therefore, not be the same as those that influence 
decline (Alley et al., 2007). Longitudinal research allows for the observations of 
developments over time at an individual and group level. Furthermore, it has the 
capacity for establishing sequences of events, and thus causal relationships, provided 
the study is started prior to the onset of disease. Repeated measurement of cognitive 
decline at several time points provides a more reliable estimation of long-term cognitive 
change. Based on the progressive cognitive decline that is a defining feature of AD, the 
ability to monitor such cognitive change over time and to assess the contribution of 
different factors to this change confirms the utility and relevance of longitudinal 
research of AD.  
The history of AD research is dominated by cross-sectional studies. This is 
surprising given that declining cognition over time is the principal clinical 
manifestation of AD. There is evidence for a preclinical period in which the 
pathophysiological process of AD in the brain may have commenced, but in which the 
clinical symptoms of AD such as cognitive impairment are too mild to be detected 
(Morris & Price, 2001; Price et al., 2009). These undetected changes pose problems for 
investigating possible preceding risk factors for AD and the causal role of such factors 
in cognitive impairment. Longitudinal studies, especially in the case of AD given the 
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progressive nature of the disease, are therefore useful because they can track changes 
over time and allow for the predictive value of certain factors to be explored. While 
some factors have been identified as risk factors for developing the disease, it is less 
clear what influence these factors have in the course of neurodegeneration as the 
disease progresses.  
Cognitive decline represents a continuum of cognitive changes from normal 
ageing, to MCI, to dementia (Plassman, Williams, Burke, Holsinger, & Benjamin, 
2010). Therefore it makes sense to perform longitudinal studies that include a range of 
adults along this continuum. Longitudinal studies that include older adults who are 
cognitively healthy at baseline are particularly useful for detecting cognitive changes 
that may not have warranted a clinical diagnosis of cognitive impairment at cross-
sectional assessment (Johnson, Storandt, Morris, & Galvin, 2009). Early identification 
of cognitive changes over time might denote that a process of cognitive decline has 
commenced and may be an indicator of Alzheimer’s disease in its early stages. For 
example, Sliwinski, Lipton, Buschke, and Stewart (1996) reported that mild AD may be 
present in some older people who appear clinically ‘normal’, and that memory loss may 
be apparent approximately 5-7 years prior to the clinical diagnosis of dementia. This 
report suggests that estimates of cognitive change in healthy samples may be negatively 
biased in cross-sectional studies; one of the limitations of cross-sectional studies of AD 
is that they can only provide a snapshot of cognitive functioning.  
Cognitive decline in ageing is not restricted to one domain of cognition, such as 
memory; other cognitive domains are often involved and should also be explored in 
relation to cognitive decline (Park & Reuter-Lorenz, 2009; Wilson et al., 2002). For 
instance, evidence of multi-domain cognitive decline is provided by Cullum et al. 
(2000) who investigated the change in several different domains of cognition (as 
measured by MMSE total score, CAMCOG total score, and individual scores on eight 
CAMCOG subscales) over 4 years in a sample of non-demented older adults. They 
reported an annual rate of change of -1.6 points on the CAMCOG total score, and found 
statistically significant decline on several CAMCOG subscale scores. Similarly, 
Johnson et al. (2009) performed a longitudinal study to model cognitive decline in 
preclinical AD. Results showed accelerating cognitive decline, not just in memory, but 
in multiple domains. Assessment of memory alone may not be sufficient for the 
detection of cognitive impairment if the memory deficits are mild. The above findings 
reported by Johnson et al., indicate the relevance of assessing cognition across several 
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domains, as mild changes across other domains will also indicate incipient cognitive 
impairment. Studies such as these confirm the presence across time of cognitive 
changes in multiple domains in older adults. 
Of the longitudinal studies performed in ageing, one particularly notable 
example of successful longitudinal research in older adults is The Nun Study (e.g. 
Butler & Snowdon, 1996; Mortimer, 2012; Greiner, Snowdon, & Greiner, 1996). This 
project is a collaborative effort between the University of Minnesota and the School 
Sisters of Notre Dame congregation. Its participants are 678 American members of the 
School Sisters of Notre Dame religious congregation who are between the ages of 75 
and 106 years, representing a broad distribution of function and health. In one of the 
studies that examined data from within this large project, Butler, Ashford, and Snowdon 
(1996) investigated age, education, and change in MMSE scores in a population sample 
of older nuns. Their results indicated that cognitive function as measured by the MMSE 
decreased over an average of 1.6 years within individuals, and the extent of the decline 
increased with age in those sisters who held a bachelor’s degree. These data raise the 
question about the role that demographic factors, such as education, may play in 
cognitive decline in the elderly. 
Another prospective longitudinal study of the antecedents of ageing is the 
Baltimore Longitudinal Study of Aging (Kawas, Gray, Brookmeyer, Fozard, & 
Zonderman, 2000). One set of findings from this study demonstrated age-specific 
incidence rates of AD and showed a trend for increased incidence in women and in 
individuals with fewer years of education.   
Longitudinal studies of cognitive change have also been performed in 
individuals who are already cognitively impaired. For example, Suh, Ju, Yeon, and 
Shah (2004) investigated rates of cognitive decline in a 1-year longitudinal 
observational study of AD patients. The sample consisted of 107 AD patients who were 
assessed at three time points, namely, at 0, 6, and 12 months. Using mixed-model 
analyses, Suh et al. found that the average annual rate of cognitive decline in AD 
patients was 2.3 MMSE points.  
Unfortunately, many studies investigating cognitive decline using longitudinal 
designs have been fraught with methodological problems. One such problem is the use 
of a single measurement follow-up (i.e. two observations in total). If only a single 
measurement follow up is used, it is difficult to reliably discern chance variability from 
person-specific patterns of change (Wilson et al., 2002). 
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In addition to the methodological problems that afflict its investigation, 
cognitive decline is difficult to pin down because (a) it is not linear, and (b) it is 
affected by numerous factors that can vary in, and between, individuals (Daviglus et al., 
2010).  
What is evident, though, is that cognitive decline is worse in those individuals 
who are already cognitively impaired at baseline measurement than in those who are 
cognitively healthy at that time (Butler, Ashford, & Snowdon, 1996). Although it is not 
entirely clear which factors contribute to the speed of cognitive decline, different 
factors may vary in their effect on cognitive change among people with healthy 
cognition and those with pre-existing cognitive impairment. There is evidence for the 
wide variability, on an individual level, in age-related cognitive decline pertaining to 
initial level of cognitive function and rate of decline (Wilson, Beckett, Bennett, Albert, 
& Evans, 1999). AD, a clinically heterogeneous disease characterized by progressive 
incapacitating cognitive impairment, is prone to such individual variability in its course 
and progression. Wilkosz et al. (2010) explored this variability by identifying 
trajectories of cognitive decline in AD. Their results showed that six trajectories 
represented patterns of change in MMSE score, with significantly different courses and 
rates of cognitive decline for the majority of the AD participants. These trajectories 
included initial MMSE, age, gender, education, APOE-є4, and psychosis. The 
trajectories were best defined by the participants’ initial MMSE score and age; older 
participants with higher initial MMSE score tended to follow trajectories of slower 
cognitive decline. In light of the variability found in cognitive decline, the following 
section discusses the role of various factors that might affect rate of cognitive decline in 
both healthy older adults and AD patients.  
 
Factors Associated with Cognitive Change and Decline in Older Adults 
A recent systematic review suggests there is insufficient evidence to support an 
association between cognitive decline and many of its proposed risk factors, i.e., risk 
factors for cognitive decline in the first case (Plassman et al., 2010). Their review 
summarizes evidence about putative risk and protective factors for cognitive decline in 
older adults. The factors that were considered included nutritional factors, medical 
factors and medications, social, economic, behavioural factors, toxic environmental 
exposure, and genetic factors. They reported that only a handful of the factors showed 
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adequate evidence to favour an association with cognitive decline; these factors were 
current tobacco use, the APOE-є4 genotype, and certain medical co-morbidities such as 
diabetes mellitus and the metabolic syndrome. Stern et al. (1994) investigated the 
annual rate of cognitive change in patients with AD over a period of up to 90 months; 
they also explored the effects of dementia severity, gender, age at onset, family history 
of dementia, and prior rate of cognitive decline, on that rate. They found that none of 
these variables predicted the rate of cognitive deterioration, other than the degree of 
cognitive impairment and previous rate of decline based on scores from the Alzheimer’s 
Disease Assessment Scale-cognitive subscale (ADAS-cog). Similarly, Suh et al. (2004) 
found, in a longitudinal study using a sample of AD patients, that cognitive decline was 
not predicted by years of education or duration of AD since onset.  
Recent observational studies, though, have identified several factors associated 
with increased rate of cognitive decline. These factors included higher age and lower 
initial MMSE score (Wilkosz et al., 2010); presence of Type 2 diabetes, higher systolic 
blood pressure, higher serum triglycerides (Umegaki et al., 2012); smoking (Peters et 
al., 2008); and elevated cardiovascular risk (Dregan, Stewart, & Gulliford, 2013). 
Likewise, some studies have identified factors that may protect against cognitive 
decline. These protective factors included statin use (Szwast et al., 2007); physical 
fitness (Sattler, Erickson, Toro, & Schroder, 2011); and cognitive reserve (Tucker & 
Stern, 2011). 
It is beyond the scope and purpose of this dissertation to review all of the above-
mentioned factors in detail. Rather, the following sections of this literature review will 
focus on some specific factors that have been associated with increased rate of 
cognitive decline. The reason for choosing these is that they are central to the main 
focus of this thesis, namely,  psychosocial and physiological stress, and that some of 
them - age, education, and APOE-є4 - were identified in Study 1 as being significant 
predictors of cognitive function in older adults across a spectrum of cognitive 
functioning. I shall review the literature in the order of physiological factors, 
psychosocial factors, and then sociodemographic factors. 
Physiological factors. The physiological factors discussed below include 
changes in the hypothalamic-pituitary-adrenal axis and APOE-є4. 
Changes in the hypothalamic-pituitary-adrenal axis. Associations have been 
established between increases in HPA-axis activity and impairment in cognitive 
functioning (O'Brien, Ames, Schweitzer, Mastwyk, & Colman, 1996; Sandstrom et al., 
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2011). The focus of these studies has been especially on the glucocorticoid, cortisol, 
which is a marker of physiological stress and HPA axis activity. The glucocorticoid 
cascade hypothesis of the pathophysiology of AD states that excessive quantities of 
circulating glucocorticoids can lead to neuronal cell death in the hippocampus 
(Backman et al., 2005; Sapolsky, Krey, & McEwen, 1986). This damage to the 
hippocampus may then result in further HPA-axis dysfunction. The latter, in turn, 
causes more hypercortisolism and this further contributes to hippocampal 
dysfunctioning (Weaver et al., 2004). 
Swanwick et al. (1998) investigated HPA-axis dysfunction in AD in a cross-
sectional and longitudinal study using the dexamethasone suppression test. This test 
measures the response of the adrenal glands to ACTH after the administration of 
dexamethasone, a synthetic version of cortisol (Miller, Chen, & Zhou, 2007). 
Participants included 30 patients with probable AD and 17 healthy older adults. The 
researchers measured participants’ cortisol levels before and after administration of 
1mg of dexamethasone. The dexamethasone administration and cortisol measurements 
were repeated at two 9-month follow-up periods. The results of the cross-sectional 
study were not consistent with the longitudinal study: HPA-axis dysfunction was 
associated with severity of dementia at baseline, but it did not persist at follow-up and 
cortisol levels did not increase over time. In summary, these data did not support the 
glucocorticoid-cascade hypothesis of AD progression. 
In another longitudinal study of  cortisol levels over time, Weiner, Vobach, 
Svetlik, and Risser (1997) determined plasma cortisol concentrations in 19 probable AD 
patients. Cortisol concentrations were measured at 12 noon and then several times 
between 13:00 and 16:00 hours for the Afternoon Cortisol Test, which established 
average 24 hour cortisol levels. These cortisol measurements were performed at the 
initial assessment and at 12 monthly intervals over a period of two to three years. They 
found that none of the cortisol measures increased over the study period, and the 
Afternoon Cortisol Test, used to estimate the average 24 hour cortisol reading, was not 
associated with more rapid cognitive decline. However, they did find that the baseline 
12 noon cortisol measurement was associated with more rapid cognitive decline. 
An association between cortisol and cognitive decline has been reported in other 
studies. For instance, Lupien et al. (1994) explored the relationship between basal 
cortisol levels and cognitive decline in a small sample (N = 19) of healthy older adults 
over a four-year period. These adults had previously been shown to differ in their 
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cortisol levels. The researchers found that the combination of increased plasma cortisol 
over time and a high final level of cortisol predicted worse memory performance over 
time. Csernansky and colleagues (2006) explored whether raised plasma cortisol levels 
were associated with clinical and cognitive measures of the rate of disease progression 
in participants with AD. Their study included 33 participants with very mild and mild 
AD and 21 cognitively normal participants; each had a cognitive assessment annually 
for up to 4 years. Results from growth curve models supported the researchers’ 
hypothesis that elevated morning plasma glucocorticoid hormone levels were associated 
with the rate of change of both clinical and cognitive measures of dementia severity in 
participants with AD. The association between plasma cortisol and memory function 
was particularly prominent, as it lent support to the idea that elevated glucocorticoid 
levels affect progression of AD, especially with regard to the amnesia associated with 
hippocampal degeneration (Serrano-Pozo et al., 2011). 
Clearly, the findings reported by Lupien et al. (1994), Weiner et al. (1997), and 
Csernansky et al. (2006) stand in contrast to those reported by Swanwick and 
colleagues (Swanwick et al., 1998; Weiner, Vobach, Svetlik, & Risser, 1993). A 
possible explanation for this difference relates to the different stages of AD. Swanwick 
et al. (1998) included a mixture of very mild, mild, and moderate probable AD patients, 
while the other studies included either cognitively healthy controls (Lupien et al., 1994) 
or very mild and mild AD patients (Csernansky et al., 2006; Weiner et al., 1997). There 
is evidence that the rate of cognitive decline may vary at different points during the 
disease (Stern et al., 1994). Furthermore, Bunce et al. (Bunce, Fratiglioni, Small, 
Winblad, & Backman, 2004) found that cognitive decline was most prominent 
approximately 3 years prior to a clinical diagnosis of AD, with an abrupt decline shortly 
before diagnosis. Thus the mixture of AD patients in Swanwick’s study, particularly the 
inclusion of patients with mild and moderate AD, may have diluted the effects of 
cortisol on cognition. Swanwick and colleagues acknowledge that the glucocorticoid 
hypothesis may only be relevant in the early stages of AD. In support of this, 
Csernansky and colleagues (2006) reported significant correlations between plasma 
cortisol concentrations and measures of disease progression in participants with very 
mild dementia but not in those with mild dementia.  
Drawing on the combined evidence from the studies discussed above, it is clear 
that there is marked variability in the effects of cortisol on cognitive decline. What 
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seems to be evident, however, is that the stage and severity of AD should be taken into 
account when exploring the association between cortisol and cognitive decline.  
Apolipopoprotein є4. Individuals who carry the APOE-є4 allele have an 
increased risk of developing AD. The evidence suggests that APOE-є4 may play a role 
prior to the clinical (symptomatic) phase of the disease. However, once clinical disease 
is established, the contribution of APOE-є4 to cognitive decline within the disease 
remains unclear.  
The majority of studies investigating APOE-є4 and cognition have included 
population samples that were followed up over several years, thus providing data for 
cognitively healthy participants, incident AD, and AD progression. One such study 
investigated the association between APOE-є4 and rate of cognitive decline in 
community-dwelling older adults with and without dementia (Jonker, Schmand, 
Lindeboom, Havekes, & Launer, 1998). Included in this 4-year longitudinal study were 
participants identified at baseline as having normal cognition, minimal dementia, or 
dementia. The presence of the APOE-є4 allele was found to be significantly associated 
with cognitive decline in those participants who were cognitively normal at baseline, 
but was not associated with decline in participants with mild dementia and dementia. 
More recently, however, Schiepers et al. (2012) found that in cognitively healthy older 
adults, the presence of APOE-є4 predicted more accelerated cognitive decline over 8 
years (between 79 and 87 years) in the domains of verbal memory and abstract 
reasoning. This finding implicates APOE-є4 as a contributing risk factor for non-
pathological cognitive decline. 
Contrary to the findings that APOE-є4 is associated with decline in cognitively 
normal participants, Dik et al. (2000) found that the presence of APOE-є4 presence was 
not associated with memory decline in cognitively normal participants. Confirming this, 
Bunce and colleagues (Bunce et al., 2004) found that presence of APOE-є4 did not 
affect the rate of cognitive decline in pre-demented or non-demented individuals, or in 
pre-demented individuals relative to cognitively normal adults. Furthermore, Bunce et 
al. (2013) assessed eight-year cognitive change in a large sample of normal, community 
dwelling adults, including older adults aged 60-64 years at baseline. They reported no 
association between APOE-є4 and cognitive change in these older adults. Such findings 
suggest that the association between APOE-є4 and cognitive decline in cognitively 
normal older adults may be due to a higher probability of pre-clinical AD in APOE-є4 
carriers (Batterham, Bunce, Cherbuin, & Christensen, 2013).  
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The above studies have focused predominantly on the role of APOE-є4 in 
cognitively normal older adults and in pre-clinical AD. Other studies, however, have 
focused on the role of APOE-є4 in the progression of AD and have confirmed that the 
APOE-є4 allele is associated with a more rapid cognitive decline (Cosentino et al., 
2008; Liu, Kanekiyo, Xu, & Bu, 2013). For example, Henderson et al. (1995) found an 
association between having the APOE-є4 allele and cognitive decline in a population 
sample of adults aged 70 years and over. Similarly, Martins, et al. (2005) found that the 
APOE-є4 allele strongly predicted the rate of cognitive decline in AD, with a dose-
response relation. In other words, they found more rapid cognitive decline in patients 
with one ε4 allele, compared with those with none, and also in ε4/4 homozygotes 
compared with ε3/4 heterozygotes. 
Exploring the role of APOE-є4 in incident, prevalent, and diagnosed cases of 
AD, Consentino and colleagues demonstrated that presence of at least one є4 allele was 
associated with cognitive decline in an incident population-based AD group. They 
concluded that the association between APOE-є4 presence and cognitive decline was 
most significant in the earliest stages of AD (Cosentino et al., 2008).  
APOE-є4 has been implicated as a risk factor for cognitive decline in both 
normal cognitive ageing as well as in AD. However, findings related to its role in non-
pathological ageing are mixed. The sum of the evidence suggests that APOE-є4 may 
play a bigger role in the development of AD than in the progression of the disease; 
however, there is also evidence for its role in disease progression. The most recent 
research seems to favour the notion that APOE-є4 exerts a larger effect on individuals 
who are already cognitively compromised compared to cognitively healthy controls, 
and that this effect is most prominent in early AD.  
Psychosocial factor. The psychosocial factor described here is psychosocial 
stress. 
Psychosocial stress. The experience of psychosocial stress is generally 
associated with poorer cognitive functioning (Neupert, Almeida, Mroczek, & Spiro, III; 
Peavy et al., 2007; Stawski et al., 2006). Psychosocial stress is also a risk factor for 
developing AD (Wilson et al., 2003). However, the association between psychosocial 
stress and cognitive decline is less well documented, and there is a need for prospective 
longitudinal studies to define the relationship between psychosocial stress and cognitive 
decline. 
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Epidemiological studies have found that chronic stress and stressful life events 
tend to accelerate cognitive decline. For instance, Peavy et al. (2009) explored the 
effects of chronic stress on memory decline in cognitively normal and mildly impaired 
older adults. This longitudinal study comprised 61 cognitively normal participants and 
41 participants with MCI who completed repeated stress and cognitive assessments for 
up to 3 years. Higher event-based stress ratings were associated with faster cognitive 
decline, but only in MCI participants. In a later study, Peavy et al. (2012) examined the 
influence of chronic stress on dementia-related diagnostic change in older adults. At 
baseline, the participants were either cognitively normal or had a diagnosis of MCI. The 
researchers found that the conversion from MCI to dementia was associated with 
prolonged, highly stressful experiences. This association was not found in the 
conversion to MCI. These findings suggest that the influence of psychosocial stress 
may vary depending on the stage of cognitive impairment. The authors also propose 
that different mechanisms may exist in the conversion from normal cognition to MCI 
than in the conversion to dementia. 
Some studies exploring the association between stress and cognitive decline 
have done so specifically in older adults who, at baseline, were cognitively normal. For 
example, Wilson et al. (2007) examined chronic distress and incidence of MCI in 1,256 
older adults without cognitive impairment. During up to 12 years of follow-up, they 
found that the risk of MCI increased approximately 2% for each one unit increase on a 
distress scale. This study also found that individuals with a higher distress score were 
more likely to have a lower level of function in several cognitive domains at baseline. 
Furthermore, a higher distress score was associated with more rapid cognitive decline, 
particularly in the domain of episodic memory. Similarly, Vitaliano et al. (2005) 
investigated relationships between chronic stress and cognitive decline in cognitively 
healthy older adults to determine whether these relationships are mediated by 
psychophysiological factors. They compared 96 caregivers of spouses with AD with 95 
similar non-caregiver spouses. The researchers hypothesized that the spouse caregivers, 
exposed to chronic caregiver-related stress, would show greater cognitive decline over 
the follow-up period than demographically similar non-caregiver spouses. Their data 
analyses detected a small but significant cognitive decline after two years in the 
caregivers, while the non-caregivers’ cognitive functioning did not change.  
The relationship between psychosocial stress and cognitive decline has been 
explored in more recent work and in larger samples than some of those previously 
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reported. For instance, Tschanz et al. (2012) explored the association between stressful 
life events and cognitive decline in late life, among 2,665 non-demented participants of 
the Cache County Memory Study. Participants completed a stressful life events 
questionnaire and were administered the MMSE. The MMSE was re-administered at 
follow-up visits 4 and 7 years later. General linear models assessed the association 
between stressful life event scores and cognitive functioning, and also explored the 
effects of age. Their results indicated that years of formal education modified the effect 
of number of stressful life events on the rate of cognitive decline; a more rapid rate of 
decline occurred among those with fewer years of education experiencing more 
stressful life events. Additionally, age modified the effect of negative stressful life 
events on the rate of cognitive decline; faster decline was observed in younger 
participants who experienced more negative stressful life events. 
The findings discussed above indicate that chronic psychosocial stress is 
associated with cognitive decline in both cognitively normal and mildly cognitively 
impaired older adults. The general consensus seems to be that the effects of stress are 
greatest in those individuals who are already mildly cognitively impaired.  
Sociodemographic factors. These include age and education. 
Age. Age is a well-established risk factor for cognitive impairment (Kawas et 
al., 2000; Unverzagt et al., 2011), and has also been identified as a risk factor for 
increased rate of cognitive decline (Salthouse, 2009; Wilkosz et al., 2010). Brayne and 
colleagues (1995) examined cognitive decline in a sample of 1,111 older adults (all over 
the age of 75 years) who were administered the MMSE on two occasions separated by 
28 months. Data analyses revealed a mean decline of 1.3 points in MMSE score and an 
increase in mean decline of MMSE score with increasing age. Similarly, in their 
observational, longitudinal study of rates of cognitive and functional decline in AD, Suh 
et al. (2004) found annual rates of decline of 2.3 MMSE points in AD patients. In this 
study, age was the only factor significantly related to more rapid annual decline; 
gender, duration of formal education, and duration of AD were not significant 
predictors of cognitive decline. In general, age confers significant risk for cognitive 
decline in older adults. 
Education. The MacArthur Studies of Successful Ageing (e.g., Kubzansky, 
Berkman, Glass, & Seeman, 1998) identified an extensive group of psychological and 
physiological benefits of education in older adults. One of those benefits is better 
cognitive performance across the lifespan. In comparison, fewer years of education 
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have been associated with poorer performance on neuropsychological measures in older 
adults (Ganguli et al., 2010). Although such cross-sectional research demonstrates a 
clear relationship between education and cognitive performance, longitudinal data 
relating education to the rate of cognitive decline in older adults have been less 
convincing. 
 Alley, Suthers, and Crimmins (2007) investigated the relationship between 
education and age-associated rate of cognitive decline in a representative sample of 
community-dwelling American adults aged 70 years and older. This study consisted of 
four waves, between the years of 1993-2000; the same cognitive tests were 
administered to participants at all four waves. Their findings indicated that more years 
of education were associated with better initial cognitive performance and slower 
decline in mental status. These findings implicate the role of active cognitive reserve, 
i.e. those individuals with higher levels of education used more efficient ways to 
process cognitive tasks than those with lower levels of education. However, the results 
also demonstrated that there was greater absolute cognitive decline on the more 
complex verbal and working memory tasks among those individuals with the highest 
levels of education. These findings suggest that early-life experiences such as formal 
educational achievement play a role both in long-term cognitive functioning and in 
cognitive trajectories in old age.  
The influence of education on long-term cognitive functioning is pertinent to 
diseases of old age such as AD.  The relationship between level of education and the 
development of AD is well established (Barnes & Yaffe, 2011; Karp et al., 2004; 
Letenneur et al., 2000; O'Bryant et al., 2008; Sharp & Gatz, 2011). Fewer years of 
education are associated with an increased incidence of clinical AD, and have been 
noted as a risk factor for developing AD (Qiu et al., 2001).  
While some studies have reported associations between fewer years of education 
and the development of AD, other studies (Schneider et al., 2012) have found faster 
rates of progression in AD patients with high levels (i.e. more years) of education (Hall 
et al., 2007; Scarmeas, Albert, Manly, & Stern, 2006; Stern, Tang, Denaro, & Mayeux, 
1995; Teri, McCurry, Edland, Kukull, & Larson, 1995). In a sample of African-
Americans, Unverzagt, Hui, Farlow, Hall, & Hendrie (1998) investigated the 
relationship between education and the degree of cognitive decline in mild dementia. 
They found that participants with dementia and a high level of education had greater 
cognitive decline, from estimated premorbid levels, than participants with dementia and 
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a low level of education. Similarly, Wilson et al. (2004) found that higher educational 
attainment was associated with a slightly increased rate of cognitive decline in a sample 
of 494 older adults with clinically diagnosed AD. In further support of this association, 
Scarmeas et al. (2006) reported that AD patients with higher levels of education 
experienced a faster rate of cognitive decline, and that this association occurred mainly 
in verbal fluency and memory. This association remained significant even after 
controlling for age, sex, ethnicity, differential baseline cognitive performance, 
depression, and vascular comorbidity.  
A possible mechanism underlying this pattern of data is that AD patients with 
higher levels of education are better equipped, in terms of the cognitive reserve 
hypothesis and compensation techniques, for tolerating a heavier pathological load 
when the symptoms of clinical dementia emerge (Tucker & Stern, 2011). In other 
words, the pathological process of AD is more advanced when it first manifests, largely 
due to better compensatory mechanisms. In this instance, older persons with higher 
levels of education might make better use of their intact neuro-cognitive pathways to 
compensate for declining performance in regions that may be impaired. However, this 
compensation would only serve to slow cognitive decline temporarily; as the disease 
progresses into the later stages, more cognitive domains will become affected and start 
to deteriorate, leading to a more rapid rate of cognitive decline (Stern, 2009). 
Some studies, employing multiple observations over longer periods of time, 
have found, however, that cognitive decline might not be moderated by formal 
educational attainment. For example, Wilson and colleagues (2009) confirmed that 
education is strongly associated with level of cognitive functioning as measured at any 
single point, but they found no linear association between education and rates of 
cognitive decline in community-dwelling older adults. Furthermore, using an analysis 
that allowed for nonlinearity in education, this study showed that rates of cognitive 
decline for those with average or high levels of education was slightly increased during 
the earlier follow-up years but decreased in the later follow-up years, compared to the 
rate for those with low levels of education.  Based on longitudinal research findings, 
education seems less likely to play a role in cognitive decline than it does in cross-
sectional assessments. 
Consistent with the findings reported by Wilson et al. (2009), the Victoria 
Longitudinal Study reported that education was not related to age-associated cognitive 
decline over a 12 year study period (Zahodne et al., 2011). In a sample of 1014 
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participants aged 54-95 years and with an education range of 6-20 years, number of 
years of education was strongly related to cognitive functioning, but was unrelated to 
rates of change over time for any cognitive domain. 
In summary, the extant literature seems to suggest the conclusion that there is a 
strong association between levels or years of formal educational attainment and risk for 
developing AD, i.e. those with fewer years of formal education are more likely to be at 
risk for AD, but the association between education and cognitive decline is not as 
strong.  
 
Performing Longitudinal Studies of Ageing in LAMICs 
The longitudinal studies reported in this literature review have emerged from 
high-income, predominantly Western, countries. To the best of my knowledge, there is 
no published longitudinal research of AD in African populations, apart from the studies 
performed in Nigeria with regards to incident dementia (for e.g., see Gureje, Ogunniyi, 
Kola, & Abiona, 2011). Kalaria and colleagues (2008) reviewed AD in developing 
countries, and described the difficulties associated with the measurement of cognitive 
decline in communities in LAMICs, particularly in the rural and more resource poor 
areas. Many of these difficulties are also present in cross-sectional studies. One such 
difficulty, which has been discussed in more detail in the Introduction section of Study 
1, is the lack of standardized, culture-fair screening tools. Another obstacle to measure 
cognitive decline in developing countries is illiteracy which is reportedly high in 
developing countries such as in sub-Saharan Africa (Dowse & Ehlers, 2001; Umeora & 
Egwuatu, 2009). In addition, tracking cognitive decline in such contexts is often more 
difficult than in HICs as a result of migration (individuals from rural areas seeking 
employment often move to more urban areas) and lack of communication (frequently 
one cellular telephone is shared between several family members). Furthermore, when 
individuals are followed up, assessing changes in function may prove problematic 
because in some cultures, family members may take on the responsibilities of the older 
adults, leaving these adults with a limited range of activities to perform. It is difficult to 
assess changes in older adults’ abilities to perform certain tasks when the activities that 
they do perform have become limited to a small number of simple tasks (Kalaria et al., 
2008).  
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Despite the above-mentioned obstacles to performing longitudinal research in 
ageing in developing countries such as South Africa, this type of research is important 
because it may yield useful information regarding possible predictors of, or contributors 
to, cognitive change and/or decline in older adults from LAMICs. The ways in which 
these factors interact to increase risk for AD (and for cognitive decline in healthy older 
adults) in LAMICs might be different to that in HICs. For instance, individuals living in 
South Africa, particularly in less affluent rural areas, are more likely to experience 
traumatic life events and continuing psychosocial stress, with fewer resources to help 
them deal with this. Furthermore, although not yet formally studied, people living in 
LAMICs have a greater probability of experiencing negative events in early life 
(Kalaria et al., 2008) which may translate into an increased risk of AD in later life. So, 
if the predictors of, or contributors to, cognitive decline in older adults are different in 
LAMICs than in HICs, then this may provide insight into avenues for future 
preventative or intervention strategies.  
On a more local level, there is also a lack of resources for diagnosing and 
treating AD in South African older adults. South Africa’s ageing population will result 
in an increase in the prevalence and societal burden of cognitive impairment and 
various kinds of dementia, of which AD is likely to account for the majority. Thus, 
future intervention strategies might be guided by knowledge about risk factors for 
cognitive impairment and subsequent cognitive decline. 
 
Summary 
The literature demonstrates that there is variability around factors associated 
with cognitive decline. Findings pertaining to the physiological factors, namely cortisol 
and APOE-є4, are contradictory. A common aspect in the literature regarding cortisol 
and APOE-є4, however, is that their roles in AD appear to be most prominent in the 
preclinical and early stages of the disease. Psychosocial stress seems to confer an 
association with cognitive decline, although this association is greater in individuals 
who are already cognitively impaired, compared with controls. The evidence for age 
and education as contributors to cognitive decline is strong, with several studies 
reporting results in support of this. 
Overall, longitudinal studies of AD are needed to develop a more conclusive 
and accurate understanding of the combined role that certain factors can play in the 
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progression of cognitive decline. Of particular interest in this LAMIC population 
longitudinal study is the impact of physiological (cortisol and APOE-є4), psychosocial 
(psychosocial stress), and sociodemographic (age and education) factors on the 
progression of cognitive change and decline across a spectrum of healthy cognition to 
impaired cognition in AD.  
 
Aims and Hypotheses 
The purpose of this longitudinal study was to investigate cognitive change and 
cognitive decline over a period of 3 years across two samples: participants who were 
cognitively healthy at baseline measurement, and patients with AD. As noted in the 
literature review above, assessing participants longitudinally allows investigation of the 
predictive value of certain risk factors for cognitive change in healthy older adults, and 
for cognitive decline as AD progresses (Gomar, Bobes-Bascaran, Conejero-Goldberg, 
Davies, & Goldberg, 2011; Musicco et al., 2010; Wattmo, Wallin, Londos, & Minthon, 
2011). The particular factors under consideration here were baseline psychosocial (self-
perceived) stress and physiological stress (cortisol), as well as APOE-є4 carrier status. I 
also considered the predictive value of age and education for determining cognitive 
change and decline in this sample of older South African adults, given that both of those 
variables were established by the Study 1 data analyses as factors associated with 
cognitive function in the sample.  
After the baseline testing described in Study 1, participants were re-
administered a cognitive test battery on an annual (12 ± 2 months) basis for 2 years. 
These re-assessments constituted the first follow-up (after one year; Time 1) and the 
second follow-up (after two years; Time 2).  
I tested three hypotheses using the sociodemographic, physiological, and 
cognitive data collected at baseline and the physiological and cognitive data collected at 
Time 1 and Time 2. The first two hypotheses relate to psychosocial and physiological 
stress. Hypothesis 1 stated that, across the entire sample, baseline levels of psychosocial 
stress (as measured by the PSS) and baseline levels of cortisol (log transformed values) 
would be significant predictors of cognitive change (as measured by CAMCOG-R total 
scores at each time point), even after taking into account individual differences in age, 
education, and APOE-є4 carrier status. Hypothesis 2 stated that participants with 
cognitive decline (as measured by a drop of one point or more on the MMSE) would 
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have higher baseline levels of psychosocial stress (as measured by the PSS) and higher 
baseline levels of cortisol (log transformed values), across the entire sample and relative 
to those participants who did not show cognitive decline. Hypothesis 3 stated that 
participants who were APOE-є4 carriers would be more likely to experience cognitive 
decline than participants who were not carriers.
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Methods 
 
Participants 
Participants enrolled in the cross-sectional study were enrolled automatically in 
the longitudinal study if they were willing and/or able to continue their involvement in 
the research programme. Figure 10 illustrates the number of participants enrolled in the 
longitudinal study at the first and second follow-up visits. It also shows the number of 
participants who withdrew voluntarily, those controls who converted to MCI, those 
mild to moderate AD patients who declined to the severe stage of disease and who were 
therefore excluded from the follow-up visits, and those participants who did not have a 
follow-up visit. The latter, included participants who enrolled in the study at such a 
point that they were ineligible for a first or second follow-up assessment as data 
collection had ceased by the time they would have had the follow-up assessment. 
Participants were enrolled in the study even if they were going to have only the 
Baseline assessment because I wanted to have as large a group as possible at Baseline 
in order to have sufficient numbers to perform the regression model. 
Participants involved in the longitudinal study included possible or probable AD 
patients (nAD = 43 at first follow-up, nAD = 19 at second follow-up). These participants 
had been recruited into the cross-sectional study from a variety of sources: a non-
governmental agency nursing home located near Cape Town, Groote Schuur Hospital’s 
Memory Clinic or geriatric outpatient clinic, and GP referrals. These patients had been 
diagnosed, prior to entering the study, as mild to moderate or possible or probable AD 
in terms of NINCDS/ADRDA criteria (McKhann et al., 1984). Most of these patients 
remained, across the follow-up period, in the mild to moderate stages of possible or 
probable AD, and were able to consent to procedures and to complete the cognitive 
tests. However, some of the AD patients enrolled in Study 1 withdrew or subsequently 
declined to a more severe stage of disease and were thus unable to be tested further (1 
patient prior to the first follow-up and 6 patients prior to the second follow-up 
withdrew). 
Control participants (nHC = 52 at first follow-up, nHC = 27 at second follow-up) 
were healthy, community-dwelling, independent volunteers. The control participants 
had been recruited into Study 1 via word-of-mouth advertising.  
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Figure 10. Diagram illustrating the number of participants (healthy controls and AD 
patients) enrolled in Study 2, as well as details relating to exclusion. Data collection and 
follow-up assessments ceased in October 2012. Some participants who were enrolled in 
the study during the later parts of 2010 and 2011 were not enrolled long enough to have 
a first and/or second follow-up assessment and therefore fall into the ‘No follow-up’ 
category. 
  
Individuals screened 
and enrolled for 
participation as per 
protocol 
n = 152 
Individuals who decided 
against participation and 
therefore excluded prior to 
Baseline visit 
n = 4 
Participants enrolled 
for Baseline visit 
(July 2008 –  
Oct 2012) 
n = 148 
Participants excluded 
post-diagnosis 
(total n = 14): 
Epilepsy n = 1 
Depression n = 4 
Parkinson’s disease n =2 
Psychiatric symptoms n = 2 
Dementia not Alzheimer’s type  
n = 3 
Decided against participation  
n = 2 
Study 1 
Baseline 
Controls  
n = 69 
 
Enrollment in 
Study 2 
Time 1 
follow-up  
n = 43 
Study 1 
Baseline 
AD Patients  
n = 65 
Study 2 
Time 2 
follow-up 
n = 19 
 
Total participants  
at Baseline in Study 1  
n = 134 
Enrollment in 
Study 2 
Time 1 
follow-up  
n = 52 
Study 2 
Time 2 
follow-up 
n = 27 
 
Participants not  
followed up 
n = 17 
Deceased n = 1 
Withdrawn/no longer 
testable n = 0 
Converted to MCI n = 2 
No follow-up n = 14 
 
Participants not 
followed up 
n = 22 
Deceased n = 1 
Withdrawn/no 
longer testable n = 1 
No follow-up n = 20 
 
Participants not 
followed up 
n = 25 
Deceased n = 1 
Withdrawn/no longer 
testable n =1 
No follow-up n = 23 
 
Participants not 
followed up 
n = 24 
Deceased n = 2 
Withdrawn/no 
longer testable n = 6 
No follow-up n = 16 
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Research Design and Setting 
Standardized study procedures were conducted in the Division of Neurology at 
Groote Schuur Hospital, at a non-governmental agency nursing home, or at the 
participant’s residence. Regardless of the venue, all participants were tested in an 
isolated, quiet room at similar times of day, between the hours of 09h00 and 11h30. 
 
Materials  
At the two follow-up visits, namely Time 1 and Time 2, I used a subset of the 
measures used in Study 1. The sociodemographic, psychosocial stress (LTE-Q and 
PSS), affective, behavioural and adaptive functioning questionnaires (DECO, BADLS, 
CD-RISC, and GDS) used in Study 1 were not re-administered at the follow-up visits.  
Neuropsychological test battery. This battery included some of the tests used 
in Study 1 that have demonstrated good test-retest reliability and have been used to 
track cognitive decline, namely: the CAMCOG-R, MMSE, TMT, and CLOX. Further 
descriptions of these instruments, including details regarding their psychometric 
properties and previous use in South Africa, can be found in the Methods section of 
Study 1. The TPT was not re-administered at the follow-up visits as its test-retest 
properties have not yet been demonstrated.  
Physiological measures. At each follow-up visit I administered Sarstedt 
Salivette® Cortisol devices to participants so that they could collect saliva samples 
from which cortisol levels would be determined. Further details relating to the salivettes 
are in the Methods section of Study 1. 
 
Procedures.  
Figure 11 presents an outline of the procedure for those participants involved in 
Study 2. The follow-up procedure was identical for both the first and second follow-up 
visits. Approximately 1 and 2 years (± 2 months) after participants’ initial baseline visit, 
the researcher contacted the participants and their family members to arrange a follow-
up appointment for the participant and his/her informant in the Division of Neurology at 
GSH. The day before the test session, the researcher contacted the participant and/or the 
informant to remind them of their GSH appointment. This session was arranged such 
that the participants were tested at the same times of day as for the baseline 
assessments, between the hours of 09h00 and 11h30. On the day of the testing session, 
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when the participant and informant arrived at GSH, they were met by the researcher and 
escorted to the testing venue in the Division of Neurology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Diagram of participant study procedure through the first and second follow-
up visits.  
 
Neuropsychological testing. During the testing session the researcher 
administered the neuropsychological test battery (i.e. CAMCOG-R, including the 
MMSE, TMT, and CLOX). The duration of each follow-up neuropsychological test 
session usually lasted between 30 and 60 minutes. 
At the end of the testing session, the researcher again provided the participant 
and/or the informant with two sets of salivettes and instructions for using them. For 
those participants with memory problems, the instructions and salivettes were given to 
the informant, who was also instructed how to assist the participant in obtaining the 
saliva sample. Participants were required to collect their saliva samples at 09h00 on two 
mornings in succession. Once both saliva samples had been taken, the participant, or the 
informant, called the research team to let us know that the samples were ready for 
collection. After the researcher collected the salivettes, they were stored in a freezer at -
20°C at GSH before being taken for analysis at the hospital’s Chemical Pathology 
Laboratory, where a standard assay was performed to determine salivary cortisol levels. 
1-year follow-up (Time 1) 
2-year follow-up (Time 2) 
Neuropsychological  
testing 
 
Salivary cortisol  
collections 
 
Neuropsychological  
testing 
 
Salivary cortisol  
collections 
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Analytical procedures for saliva samples. Once a batch of salivettes had been 
collected and stored in a freezer at -20°C, the researcher took them to the hospital’s 
Chemical Pathology Laboratory, where a standard assay was performed to determine 
salivary cortisol levels. 
 
Ethical and Safety Considerations 
All study procedures were approved by the Research Ethics Committees of the 
University of Cape Town’s Department of Psychology and the Faculty of Health 
Sciences (REC REF 346/2008). The study was conducted according to the ethical 
guidelines and principles of the International Declaration of Helsinki, the South African 
Guidelines for Good Clinical Practice and the MRC Ethical Guidelines for Research.  
All participants were provided with thorough and detailed written and verbal 
information about the study; their anonymity was assured and they were informed of 
their right to withdraw from the study at any given point, without prejudice. Participants 
were informed about all the relevant study procedures and what their role in the study 
would entail.  
 
Data Management and Statistical Analyses 
I sorted and cleaned the data and checked for any missing items. I used 
Statistica 10 or SPSS version 19.0 for all analyses. For measures taken at Time 1 and 
Time 2, I performed descriptive statistical analyses of all the data and calculated 
measures of central tendency (mean and median) and dispersion (range, standard 
deviation, and variance) for all variables. I also constructed boxplots for all the 
continuous predictor variables (age, education, psychosocial stress, and cortisol) in 
order to detect outliers that may have influenced the measures of central tendency. For 
the inferential statistical analyses that followed, I set the alpha level at .05. Where 
necessary (i.e., where assumptions of sphericity were not satisfied), I used Greenhouse-
Geisser corrected degrees of freedom. I used Cohen’s d or ηp
2
 as estimates of the effect 
sizes for parametric data; Cohen’s r as an estimate of effect size for non-parametric 
data; and φ as an estimate of effect size for the chi-square (χ2) analyses. 
Deriving outcome variables. Statistical analyses assessed predictors of 
cognitive change and of cognitive decline. The reason for exploring both cognitive 
change and cognitive decline is that cognitive change over time does not necessarily 
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denote decline; especially in controls, scores at the follow-up assessments could have 
remained constant, or even improved slightly because of practice effects or reduced 
anxiety due to increased familiarity with the assessment situation.  
Cognitive change was defined, simply, as change in CAMCOG-R total score 
across the three CAMCOG-R administrations. Hence, this construct measures cognitive 
performance along a continuum. 
In contrast, to assess cognitive decline, I compared groups of participants who 
declined against those who did not. To define these groups, I first compiled a list of 
participants whose MMSE score decreased by 1 point or more from Baseline to Time 1, 
or by 2 points or more from Baseline to Time 2. As a reminder, the sample size at 
Baseline was, N = 134; nHC = 69, nAD = patients 65. Each participant who had cognitive 
data for all three time points (N = 43; nHC = 27, nAD = 19) therefore had two cognitive 
decline scores: one for Time 1 score subtracted from Baseline score, and one for Time 2 
score subtracted from Baseline score. Those participants who dropped out of the study 
before Time 2 had only one cognitive decline score (Baseline minus Time 1). The 
sample size at Time 1 was, N = 95; nHC = 52, nAD = 43. Those participants who dropped 
out of the study before Time 1 did not have a cognitive decline score. For each of Time 
1 cognitive decline (i.e., Baseline minus Time 1) and Time 2 cognitive decline (i.e., 
Baseline minus Time 2), I divided participants into two groups: those who declined 
(Decliners) and those who did not decline (Non-decliners) between the two 
measurement points. 
  The choice to define Time 1 cognitive decline as a decrease of ≥ 1 point per year 
on the MMSE has precedent in several previously published studies (Kalmijn et al., 
1999; Ng, 2008; Niti, Yap, Kua, & Ng, 2009; Kalmijn, Janssen, Pols, Lamberts, & 
Breteler, 2000; Volpato et al., 2002). A year-to-year drop of ≥ 1 point on the MMSE 
corresponds to a drop of ≥ 2 points over 3 or more years of follow-up, and represents 
considerable cognitive decline (Ng, Feng, Niti, Kua, & Yap, 2008).  
  Inferential statistical analyses. Before testing the three hypotheses listed 
above, I sought to characterise the sample by conducting several statistical analyses of 
between-group differences in demographic and cognitive variables at Time 1 and Time 
2. I used either t-tests or Mann-Whitney U tests, depending on whether the data met the 
assumptions underlying parametric statistical analyses. 
 Testing Hypothesis 1. A general linear model with repeated measures (GLM-
RM) examined whether psychosocial stress and cortisol predicted cognitive change 
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across the three measurement points, taking into account age, education, and APOE-є4. 
I entered Time (Baseline; Time 1; Time 2) as the within-subjects factor, CAMCOG-R 
total score at each measurement point as the outcome variable, and age (in years), 
education (number of completed years), APOE-є4 carrier status (with or without), log 
transformed cortisol values, PSS scores for psychosocial stress, and group status 
(healthy control versus AD patient) as predictors. The first three variables were 
included in this model based on their demonstrated associations with cognitive 
functioning (in Study 1 and in previously published studies), and because, in the current 
sample, there were significant between-group differences for each of these variables.  
Testing Hypothesis 2. An optimal solution for examining whether psychosocial 
stress and cortisol predicted cognitive decline would have been to perform one large 
regression or general linear model, including as predictors: age, education, APOE-є4 
carrier status, cortisol level, and PSS scores; and as the outcome variable, cognitive 
decline (from Baseline to Time 1, or from Baseline to Time 2). However, given the 
small numbers at Time 1 and especially at Time 2, there was insufficient power to 
include all of these predictors in one model. For example, a model including age, 
education, APOE-є4, cortisol, and PSS scores as predictors and Baseline to Time 1 
cognitive decline as the outcome variable, had insufficient power (with N = 38) to 
detect a medium-sized effect. A post-hoc power analysis for this model indicated actual 
power of 0.06, with ideal power (1 - β) set at .80 and α = .05, two-tailed, and a small 
effect size of 0.01. 
As the next best solution for testing Hypothesis 2, I divided participants into two 
groups based on whether or not they had demonstrated cognitive decline from Baseline 
to Time 1 and from Baseline to Time 2. I then performed t-tests to determine whether 
there were between-group (Decliners versus Non-decliners) differences for 
psychosocial stress and cortisol.  
Testing Hypothesis 3. Two separate χ2 tests of contingency tested this 
hypothesis. In each, APOE-є4 carrier status (with or without) was one dichotomous 
variable and decline status (yes or no) was the other. The only difference between the 
two tests was that the first described the contingency between the variables when 
decline was defined as a decrease in MMSE score of ≥ 1 point from Baseline to Time 1, 
and the second described the contingency between the variables when decline was 
defined as a decrease in MMSE score of ≥ 2 points from Baseline to Time 2.  
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Exploratory analyses. As noted earlier, each participant provided two 
consecutive samples of salivary cortisol at Baseline, at Time 1, and at Time 2. Because 
previous studies suggested that cortisol levels increased as people age (see, e.g., 
Deuschle et al., 1997; Otte et al., 2005; Vgontzas et al., 2003), I was interested in 
analysing the changes in salivary cortisol levels over time in this study sample.  
I took the average value of each of the two samples from each visit to represent 
cortisol levels at, respectively, Baseline, Time 1, and Time 2. The raw scores of those 
average values were not normally distributed, however. Hence, I performed a log 
transformation of these data, and used those log transformed values in the analyses 
described next. I used a GLM-RM to examine how cortisol levels changed in the 
sample across three measurement points. In this model, I entered Time (Baseline, Time 
1, Time 2) as the within-subjects predictor, Group (controls versus AD patients) and 
age as between-subjects predictors, and the three cortisol levels as outcome variables.
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Results 
 
The results are presented under three broad headings: Sample Characteristics, 
Hypothesis Testing, and Exploratory Analyses. The first section, which includes Tables 
15-20, presents the demographic and cognitive characteristics of the Time 1 and Time 2 
sub-samples (recall that not every participant for whom I obtained data at Baseline 
returned at Time 1, and not every Time 1 participant returned at Time 2). For each of 
Time 1 and Time 2, I first present the sample’s demographic characteristics and then I 
present the cognitive data. I then present data pertaining to those participants who 
remained in this study through Time 2, those who withdrew, and those who died 
(Tables 20-21). 
The second section presents results pertaining to tests of Hypotheses 1-3. The 
third section presents results of the exploratory analyses related to cortisol levels, as 
described above. 
 
Sample Characteristics at Time 1 and Time 2 
Demographic and Cognitive Data. Table 16 shows the demographic data for 
the Time 1 participants. Consistent with the demographic data for the Baseline sample 
(N = 134; nAD patients = 65, nHC = 69) presented in Study 1, there were significant 
between-group differences with regard to age, distribution of race, education, and 
household income. AD patients were older, had fewer years of education, and had a 
lower monthly income. Regarding APOE-є4 carrier status, which was measured at 
baseline, there was a strong trend toward a significant between-group difference: Of the 
participants who remained in the study at Time 1, most AD patients had the є4 allele 
and most controls did not. 
Table 17 shows, for the Time 1 participants, descriptive statistics and between-
group comparisons for the CAMCOG-R (total score and subscale scores), MMSE, 
TMT, and CLOX. Because data were not normally distributed, I present medians and 
inter-quartile ranges rather than means and standard deviations. Consistent with results 
from analyses reported in Study 1 for the Baseline sample, these results show that, at 
Time 1, AD patients had significantly poorer cognitive functioning (both overall and 
within specific domains) than controls 
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Table 16 
Time 1: Sample Demographic Data (N = 95) 
                            Group    
 Controls AD Patients  
 
  
Variable (n = 52) (n = 43) df t / χ2 p ESE 
Age 72.35 (8.23) 77.19 (8.55) 93 -2.80
a
 .006** 0.58 
Sex (M:F) 12:40 12:31 1 0.29
b
 .59 -0.06 
Race (W:B:C:I) 28:1:23:0 4:1:37:1 1 21.61
b
 < .001*** 0.48 
Education (years) 13.87 (4.51) 8.72 (3.02) 93 6.39
a
 < .001*** 1.34 
Handedness  
(Right:Left) 
47:5 42:1 1 2.11
b
 .15 -0.15 
Body Mass Index 28.00 (6.44) 26.35 (5.47) 78 1.21
a
 .23 0.28 
APOE-є4 (With:Without) 20:31 25:17 1 3.80b .05 -0.20 
Monthly household income        
< ZAR2500:≥ ZAR2500 10:42 37:6 1 42.04b < .001*** 0.67 
Note. For the variables Age, Education, and Body Mass Index, means are presented with standard deviations in  
parentheses. APOE-є4 = apolipoprotein є4. For the variable Race, W = White, B = Black African, C = Coloured,  
I = Indian. 
a
Test statistic for t-test. 
b
Test statistic for Mann-Whitney U test. ESE = effect size estimate; in this case,  
either Cohen’s d for t-tests or φ for χ2 tests. 
*p < .05. **p < .01. ***p < .001. 
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Table 17 
Time 1: Sample Cognitive Data (N = 95) 
  Group   
  Controls  AD Patients   
 
Variable 
Max. Attainable Score (n = 52)  (n  = 43) Z 
Z 
p 
p 
ESE 
ESE CAMCOG-R 105 94.00 (7.00)  63.50 (24.00) 8.22 < .001*** 0.84 
 Memory 27 22.50 (4.00)  9.00 (8.00) 8.08 < .001*** 0.83 
 Orientation 10 10.00 (0.00)  7.00 (5.00) 6.96 < .001*** 0.71 
 Language 30 27.00 (2.00)  22.00 (6.00) 7.01 < .001*** 0.72 
 Attention 7 7.00 (1.00)  3.00 (4.00) 5.82 < .001*** 0.60 
 Calculation 2 2.00 (0.00)  1.00 (1.00) 4.81 < .001*** 0.49 
 Praxis 12 11.00 (2.00)  9.00 (3.00) 5.34 < .001*** 0.55 
 Abstract Thinking 8 7.00 (2.00)  4.00 (4.00) 6.52 < .001*** 0.67 
 Perception 9 8.00 (2.00)  5.00 (2.00) 6.58 < .001*** 0.68 
Learning 17 14.00 (2.00)  7.00 (6.00) 7.42 < .001*** 0.76 
MMSE 30 29.00 (2.00)  20.50 (6.00) 7.97 < .001*** 0.82 
TMT-A  90 seconds 42.00 (16.00)  90.00 (106.00) -6.99 < .001*** -0.72 
TMT-B  300 seconds 93.50 (35.50)  300.00 (66.00) -7.38 < .001*** -0.76 
CLOX 1 15 13.00 (2.00)  10.00 (4.00) 5.69 < .001*** 0.58 
CLOX 2 15 14.00 (1.00)  13.00 (3.00) -2.53 < .001*** -0.26 
Note. Medians are presented with interquartile ranges in parentheses. Z = test statistic for Mann-Whitney U test.  
CAMCOG-R= Cambridge Cognitive Examination-Revised; MMSE = Mini-Mental State Examination. TMT-A = Trail  
Making Test (Part A); TMT-B = Trail Making Test (Part B); CLOX 1 = Executive Clock Drawing Task (Part 1); CLOX 2  
= Executive Clock Drawing Task (Part 2). For both TMT trials, the outcome variable is time, in seconds. For each  
between-group comparison, degrees of freedom = 93. Z = Test statistic for Mann-Whitney U test. ESE = effect size estimate;  
in this case, Cohen’s r (for non-parametric data). 
*p < .05. **p < .01. ***p < .001. 
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 Table 18 shows the demographic data for the Time 2 participants. Significant 
differences between the groups were found for education and income, where the AD 
patients had fewer years of education and a lower level of income.  
Table 19 shows, for the Time 2 participants, the descriptive statistics and 
between-group comparisons for the CAMCOG-R (total score and subscale scores), 
MMSE, TMT, and CLOX. Because data were not normally distributed, I present 
medians and inter-quartile ranges rather than means and standard deviations. Consistent 
with results from analyses reported in Study 1 for the Baseline sample, and with the 
results from Time 1, these results show that AD patients had significantly poorer 
cognitive functioning (both overall and within specific domains) than controls.
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Table 18 
Time 2: Sample Demographic Data (N = 46) 
 Group    
 Controls AD Patients  
 
  
 (n = 27) (n = 19) df t / χ2 p ESE 
Age 73.85 (9.09) 75.89 (9.62) 44 -0.73
a
 .47 0.22 
Sex (M:F) 7:20 8:11 1 1.33
b
 .25 -0.17 
Race (W:B:C:I) 9:0:18:0 2:0:16:1 1 4.31
a
 .23 0.31 
Education (years) 13.04 (4.75) 9.26 (3.25) 44 2.30
b
 .004** 0.93 
Handedness (Right:Left) 2:25 1:18 1 .08
b
 .77 0.04 
APOE-є4 (With:Without) 9:18 11:8 1 2.74b .10 -0.24 
Body Mass Index 27.65 (5.59) 26.69 (5.95) 41 .05
a
 .60 1.14 
Monthly household income        
< ZAR2500:≥ ZAR2500 6:21 18:1 1 17.17b <.001*** -0.61 
Note. For the variables Age, Education, and Body Mass Index, means are presented with standard deviations in parentheses.  
For the variable Race, W = White, B = Black African, C = Coloured, I= Indian. 
a
Test statistic for t-test. 
b
Test statistic for  
Mann-Whitney U test. ESE = effect size estimate; in this case, either Cohen’s d for t-tests or φ for χ2 tests.  
*p < .05. **p < .01. ***p < .001. 
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Table 19 
Time 2: Sample Cognitive Data (N = 46)  
  Group   
  Controls  AD Patients    
 
Variable 
Max. Attainable 
Score 
(n = 27)  (n  = 19) Z p 
Z 
ESE 
p 
 
ESE 
CAMCOG-R 105 94.00 (5.00)  68.00 (27.00) 5.66 < .001*** 0.83 
 Memory 27 22.00 (2.00)  7.00 (9.00) 5.57 < .001*** 0.82 
 Orientation 10 10.00 (0.00)  8.00 (3.00) 3.90 < .001*** 0.57 
 Language 30 27.00 (2.00)  22.00 (7.00) 4.84 < .001*** 0.71 
 Attention 7 7.00 (1.00)  3.00 (4.00) 3.16 < .001*** 0.47 
 Calculation 2 2.00 (0.00)  1.00 (1.00) 3.22 < .001*** 0.47 
 Praxis 12 11.00 (1.00)  9.00 (5.00) 2.93 .003** 0.43 
      Abstract 
      Thinking                 
8 7.00 (1.00)  6.00 (5.00) 2.78 .005** 0.40 
 Perception 9 8.00 (1.00)  5.00 (2.00) 3.98 < .001*** 0.59 
Learning 17 15.00 (2.00)  5.00 (8.00) 5.14 < .001*** 0.76 
MMSE 30 28.00 (2.00)  22.00 (8.00) 5.24 < .001*** 0.77 
TMT-A 90 seconds 42.00 (24.00)  72.00 (54.00) -3.30 < .001*** -0.49 
TMT-B 300 seconds 118.00 (75.00)  300.00 (150.00) -3.76 < .001*** -0.56 
CLOX 1 15 13.00 (1.00)  10.50 (4.00) 3.52 < .001*** 0.52 
CLOX 2 15 14.00 (2.00)  11.50 (4.00) 3.78 < .001*** 0.56 
Note. Medians are presented with interquartile ranges in parentheses. Z = test statistic for Mann-Whitney U test.  
CAMCOG-R= Cambridge Cognitive Examination-Revised; MMSE = Mini-Mental State Examination. TMT-A = Trail  
Making Test (Part A); TMT-B = Trail Making Test (Part B); CLOX 1 = Executive Clock Drawing Task (Part 1); CLOX 2  
= Executive Clock Drawing Task (Part 2). For both TMT trials, the outcome variable is time, in seconds. For each  
between-group comparison, degrees of freedom = 44. Z = Test statistic for Mann-Whitney U test. ESE = effect size  
estimate; in this case, Cohen’s r (for non-parametric data). 
*p < .05. **p < .01. ***p < .001. 
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Table 20 shows between-group comparisons for the AD patients who remained 
in the study through Time 2 (the Remained group) and those who withdrew/were no 
longer testable/had died either before Time 1 or before Time 2 (the Withdrew group). 
This analysis does not include controls because there were so few who withdrew/were 
no longer testable/had died (n = 5). This analysis also does not include those AD 
patients who were not enrolled in the study long enough to have had follow-up 
measurements. Patients in the Withdrew group were significantly older and had lower 
baseline MMSE and CAMCOG-R scores than those in the Remained group.  
 
Table 20 
Between-Group Differences at Baseline for AD Patients who Remained in the Study and 
those who Withdrew (N = 29) 
                    Group     
Remained Withdrew     
(n = 19) (n = 10) df t / χ2 p ESE 
Age 73.89 (9.62) 79.40 (8.13) 27 1.54 .14 0.62 
Sex (M:F) 8:11 1:9 1 3.16 .08 0.33 
Education  9.26 (3.25) 7.70 (2.21) 27 -1.36 .19 0.56 
Body Mass Index 26.69 (5.95) 25.34 (4.24) 21 -0.54 .60 0.26 
APOE-є4 
(With:Without) 
11:8 6:4 1 0.01 .91 -0.02 
CAMCOG-R 69.47 (11.17) 57.00 (19.40) 27 -2.21 .04* 0.78 
MMSE 22.21 (3.36) 17.80 (5.41) 27 -2.72 .01* 0.98 
PSS 18.47 (9.02) 23.10 (8.23) 27 1.35 .19 0.54 
Cortisol 0.65 (0.37) 0.69 (0.37) 17 -0.23 .83 0.11 
Note. The group of AD patients who withdrew also includes patients who were no 
longer testable or who had died. Means are presented with standard deviations in 
parentheses for parametric data. All the variable measurements are from the Baseline 
assessment. Age = years. Education = years of completed education. CAMCOG-R = 
Cambridge Cognitive Examination-Revised; MMSE = Mini-Mental State Examination; 
PSS = Perceived Stress Scale – measure of psychosocial stress. Cortisol is the average 
of the two cortisol collections at Baseline; this is the log transformed data. ESE = effect 
size estimate; in this case, Cohen’s d. 
*p < .05. **p < .01. ***p < .001. 
 
Table 21 presents data on those participants (n = 5; 2 controls and 3 AD 
patients) who died during the study. The observed z-scores indicate that most of these 
participants were older, and had fewer years of education, than their respective group 
means. Except for participant D5, scores for cognition (CAMCOG-R and MMSE) and 
general functioning (DECO) for these participants were all below their respective group 
means, indicating a relatively high degree of impairment. However, the magnitude of z-
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scores for each variable and for each participant varies substantially and so did not 
suggest that any particular constellation of cognitive and functional characteristics 
distinguished individuals who died during the study.  
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Table 21 
Baseline Data Z-scores for Participants Who Died during the Study 
 Group Age Education BMI CAMCOG-R MMSE Cortisol PSS DECO 
D1 Control 2.01 -0.36 -.10 -1.30 -1.43 -0.58 -1.22 0.59 
D2 
Control 3.28 -1.20 - -1.68 -2.65 - 0.88 -2.00 
D3 Patient 0.50 -0.47 -0.77 -1.54 -1.16 -1.08 0.42 -0.49 
D4 Patient 1.64 -1.40 1.42 -1.77 -2.05 0.48 0.55 -0.73 
D5 Patient 0.74 -0.47 0.74 0.22 0.39 - -0.67 0.24 
Note. Z-scores are based on the separate group means and standard deviations for controls and AD patients. BMI = Body Mass Index; 
CAMCOG-R = Cambridge Cognitive Examination-Revised; MMSE = Mini-Mental State Examination. PSS = Perceived Stress Scale – measure 
of psychosocial stress. DECO = Deterioration Cognitive Observee – measure of cognitive and physical functioning. If the z-score is positive, its 
corresponding raw score is above the mean; if the z-score is negative, its corresponding score is below the mean.  
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Hypothesis 1: Psychosocial Stress, Cortisol, and Cognitive Change 
To investigate the extent to which PSS scores and cortisol levels (both as 
measured at Baseline; log transformed data) contributed to cognitive change (as 
measured by CAMCOG-R total score at Baseline, Time 1, and Time 2) I performed a 
GLM-RM. This model also included age, education, APOE-є4 carrier status, and group 
status (healthy control versus AD patient) as predictors. The analysis included data 
from the 46 participants who completed assessment at the three measurement points 
(nHC = 27, nAD = 19). 
Table 22 summarises the data on which the analysis was conducted. Figure 12 
shows, for each group separately, changes in CAMCOG-R total score from Baseline to 
Time 1 to Time 2. As the Table and Figure show, the mean CAMCOG-R scores of 
controls remained fairly consistent across the three time points. Figure 12, panel (a) 
shows the mean CAMCOG-R total scores for healthy controls and AD patients at 
Baseline, Time 1, or Time 2. In other words, panel (a) includes data for all participants 
who had at least a Baseline CAMCOG-R score; some did not have data for all three 
measurement points. Figure 12, panel (a) suggests that the mean scores in AD patients 
decreased from Baseline to Time 1, and increased slightly from Time 1 to Time 2. This 
increase is likely to have been an artifact of selective attrition: Some of the patients with 
the lowest scores at Baseline or at Time 1 dropped out before the Time 2 follow-up. As 
a result, the mean AD patient score at Time 2 is higher than that at Time 1 increase, but 
this estimate of functioning is likely based on a healthier sample than that measured at 
Baseline and at Time 1. This inference is supported by the data presented earlier (see 
Table 20), which shows that the AD patients who died during the study had 
significantly lower Baseline CAMCOG-R total and MMSE scores than their group 
means. Furthermore, the AD patients who were no longer involved in the study at Time 
2 (due to voluntary withdrawal, disease severity, or death) tended to have lower 
baseline MMSE, CAMCOG total, and DECO scores than those patients who remained 
in the study (see Table 20). 
Figure 12, panel (b), therefore provides a more accurate reflection of the 
trajectory of cognitive functioning across time in this sample. The data presented in that 
figure are based only on scores from the controls and AD patients who had complete 
cognitive data at all three measurement points. The figure shows that, whereas the mean 
score for controls remained largely consistent, that for AD patients decreased over time. 
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As expected, the GLM-RM detected significant main effects of age, F(1, 36) = 
5.65, p = .02, ηp
2
 = .14, education, F(1, 36) = 6.33, p = .02, ηp
2
 = .15, and of group, F(1, 
36) = 65.78, p < .001, ηp
2
 = .65 on cognitive change. The analysis also detected a 
significant time x group interaction, F(1.59, 57.09) = 9.71, p = .001, ηp
2
 = .21; this 
interaction is depicted in Figure 12, panel (b). 
The analysis detected no significant main effect of APOE-є4 carrier status, F(1, 
36) = 1.44, p = .24, ηp
2
 = .04, cortisol levels, F(1, 36) = 0.29, p = .59, ηp
2
 = .008, or PSS 
score, F(1, 36) = 0.08, p = .78, ηp
2
 = .002. It also detected no other significant two-way 
interactions involving time, each F(1.46, 54.14) < 1.30, each p > .30, each ηp
2
 < .04. 
 
Table 22 
Descriptive Data at Baseline for Predictor Variables in the GLM-RM for Cognitive 
Change 
 Total Controls AD Patients 
 (N = 46) (n = 27)  (n = 19) 
Age 72.51 (9.01) 71.67 (9.09) 73.94 (8.96) 
Education 11.86 (4.66) 13.33 (4.67) 9.38 (3.52) 
APOE-є4 (With:Without) 19:27 9:18 10:9 
Cortisol 0.68 (0.33) 0.69 (0.33) 0.65 (0.37) 
PSS 16.69 (8.38) 16.67 (8.77) 17.00 (7.97) 
CAMCOG-R Total Score    
Baseline 82.98 (13.17) 90.78 (5.49) 69.81 (11.80) 
Time 1 83.26 (14.78) 92.30 (4.51) 68.00 (13.45) 
Time 2 82.37 (16.59) 92.94 (6.12) 60.71 (14.02) 
Note. For all variables, means are presented with standard deviations in parentheses. 
APOE-є4 = apolipoprotein є4. PSS = Perceived Stress Scale – measure  
of psychosocial stress. CAMCOG-R = Cambridge Cognitive Examination-Revised.  
Data are presented for all three measurements of the CAMCOG-R.
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(a)                                                                                                     (b)       
              
Figure 12. Panel (a) shows mean CAMCOG-R total scores, with standard error bars, for participants who completed assessment at Baseline  
(nHC = 69, nAD = 65), at Time 1 (nHC = 52, nAD = 42), or at Time 2 (nHC = 27, nAD = 19). Panel (b) shows mean CAMCOG-R total scores,  
with standard error bars, for only those participants who completed assessment at all three measurement points (nHC = 27, nAD  = 19). 
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Hypothesis 2: Psychosocial Stress, Cortisol, and Cognitive Decline 
Tables 23 and 24 show results of the between-group comparisons investigating 
differences between the Decliners and Non-decliners from Baseline to Time 1 and from 
Baseline to Time 2, respectively. Regarding Time 1 cognitive decline, there were no 
significant between-group differences at the Bonferroni-corrected p-value (.01), 
although age (p = .07) and PSS scores for psychosocial stress (p = .09) tended toward 
significance. Results showed that there was no significant difference in baseline cortisol 
levels for those who declined and those who did not decline. Regarding Time 2 
cognitive decline, there were no significant differences for any of the variables, namely 
age, education, cortisol, and PSS. 
 
Table 23 
Between-group Comparisons for Decliners and Non-decliners at Time 1 Cognitive 
Decline (N = 95) 
                            Group    
 Decliners Non-decliners  
 
  
Variable (n = 41) (n = 54) df t  p ESE 
Age 75.46 (7.88) 72.25 (9.03) 94 -1.82 .07 0.38 
Education 11.59 (4.59) 11.62 (4.76) 94 0.03 .97 0.01 
Cortisol .81 (.32) .80 (.34) 87 -.16 .87 0.03 
PSS 20.17 (7.45) 17.33 (8.46) 94 -1.71 .09 0.36 
Note. For all variables, means are presented with standard deviations in parentheses. A 
Bonferroni correction was applied as multiple t-tests were used. All the variable 
measurements are from the Baseline assessment. Age = years. Education = years of 
completed education. Cortisol is the average of the two cortisol collections at Baseline; 
this is the log transformed data. PSS = Perceived Stress Scale – measure of 
psychosocial stress. ESE = effect size estimate; in this case, Cohen’s d. 
*p < .05. **p < .01. ***p < .001. 
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Table 24 
Between-group Comparisons for Decliners and Non-decliners at Time 2 Cognitive 
Decline (N = 46) 
                            Group    
 Decliners Non-decliners  
 
  
Variable (n = 32) (n = 14) df t  p ESE 
Age 73.43 (9.91) 72.22 (9.13) 44 -0.40 .69 0.13 
Education 11.29 (4.49) 11.81 (4.49) 44 0.36 .72 0.11 
Cortisol 0.70 (0.30) 0.70 (0.34) 43 0.01 .99 0.00 
PSS 19.43 (8.20) 16.00 (7.91) 43 -1.33 .19 0.43 
Note. For all variables, means are presented with standard deviations in parentheses. A 
Bonferroni correction was applied as multiple t-tests were used. All the variable 
measurements are from the Baseline assessment. Age = years. Education = years of 
completed education. Cortisol is the average of the two cortisol collections at baseline; 
this is the log transformed data. PSS = Perceived Stress Scale – measure of 
psychosocial stress. ESE = effect size estimate; in this case, Cohen’s d.  
*p < .01. **p < .001.  
 
 
Hypothesis 3: Apolipoprotein є4 and Cognitive Decline 
Tables 25 and 26 show the contingency tables upon which the analyses here 
were based. For both Time 1 and Time 2 cognitive decline, the analyses showed that 
participants who were APOE-є4 carriers were not more likely to decline than 
participants who were not, χ2(1) = 1.75, p = .19, φ = .14, and χ2(1) = 0.94, p = .33, φ = 
.15, respectively. 
 
Table 25 
Contingency Table for Time 1 Cognitive Decline and APOE є4 Carrier Status (N = 93) 
 APOE є4+ APOE є4- 
Decliners 23 18 
Non-decliners 22 30 
Note. APOE-є4 = apolipoprotein є4. Decliners = those participants who declined by 
≥ 1 point on the Mini-Mental State Examination (MMSE). Non-Decliners = those 
participants whose MMSE scores either remained the same or increased over time. 
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Table 26 
Contingency Table for Time 2 Cognitive Decline and APOE є4 Carrier Status (N = 43) 
 APOE є4+ APOE є4- 
Decliners 6 6 
Non-decliners 11 20 
Note. APOE-є4 = apolipoprotein є4. Decliners = those participants who declined by 
≥ 2 points on the Mini-Mental State Examination (MMSE). Non-Decliners = those 
participants whose MMSE scores either remained the same or increased over time.  
 
 
Exploratory Analyses  
Changes in cortisol levels over time. Figure 13, panel (a) shows the mean log 
transformed cortisol levels for healthy controls and AD patients who provided salivary 
cortisol samples at Baseline, Time 1, or Time 2. Figure 13, panel (b) shows the mean 
log transformed cortisol levels for healthy controls and AD patients who provided 
salivary cortisol samples at Baseline, Time 1, and Time 2. In other words, panel (a) 
includes data for all participants who provided at least one set of samples; some did not 
have data for all three measurement points. This may be reflected by the slight decrease 
in cortisol levels at Time 2 in the controls. 
In contrast, panel (b) includes data for only those participants who had complete 
cortisol data for all three measurement points. Therefore, this graph provides a more 
accurate indication of the trajectory of salivary cortisol levels over time. In both groups, 
panel (b) shows a small initial increase in cortisol from Baseline to Time 1 with a 
subsequent plateau at Time 2. The Baseline cortisol levels shown in panel (b) are lower 
than the Baseline cortisol levels in panel (a).  
A GLM-RM examined the data depicted in Figure 13, panel (b). The GLM-RM 
detected no significant main effect of group, F(1, 26) = .31, p = .58, ηp
2
 = .01, or age, 
F(1, 26) = .15, p = .70, ηp
2
 = .006. The analysis did not detect a time x group 
interaction, F(2, 26) = .02, p = .95, ηp
2
 = .001, or a time x age interaction, F(1, 26) = 
.11, p = .83, ηp
2
 = .004. 
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(a)    (b) 
           
Figure 13. Panel (a) shows mean log transformed cortisol levels, with standard error bars, for participants who provided salivary  
cortisol samples at Baseline (nHC = 66, nAD = 51), at Time 1 (nHC = 36, nAD  = 23), or at Time 2  
(nHC = 25, nAD = 12). Panel (b) shows mean log transformed cortisol levels, with standard error bars, for only those  
participants who provided salivary cortisol samples at all three measurement points; (nHC = 20, nAD = 9). 
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Summary of Results  
 
This longitudinal study investigated cognitive change and cognitive decline 
across a continuum of cognitive functioning, i.e. in participants who were cognitively 
healthy at Baseline measurement and patients with AD, over a period of 3 years. The 
main aim of this longitudinal study was to investigate cognitive change and cognitive 
decline over a period of 3 years across a continuum of cognition in participants who 
were cognitively healthy at Baseline measurement and patients with AD. 
The particular factors of interest in this study were Baseline psychosocial (self-
perceived) stress and physiological stress (cortisol), as well as APOE-є4 carrier status. I 
also explored the predictive value of age and education for determining cognitive 
change and decline in this sample of older South African adults, given that both of those 
variables were established by the Study 1 data analyses as factors associated with 
cognitive function in the initial sample.  
The main finding from this longitudinal study was that Baseline psychosocial 
stress, Baseline cortisol levels, and APOE-є4 were not significant predictors of 
cognitive change or cognitive decline. Age, education, and group status contributed 
significantly to cognitive change but not to cognitive decline. 
In the following section I shall first briefly summarize the sample characteristics 
from the Time 1 and Time 2 follow-up assessments. Then I shall summarize the 
findings for each hypothesis. Lastly, I will summarize the result from the exploratory 
analysis. As with Study 1, the purpose of this section is merely to provide an overview 
of the main findings from this longitudinal study. I shall interpret and discuss these 
results in the General Discussion, together with the findings from Study 1.  
 
Sample Characteristics for Time 1 and Time 2 
Participants were followed up from Baseline to Time 1 and Time 2. At Baseline 
there were 134 participants (nHC = 69, nAD = 65). At Time 1 there were 95 participants 
(nHC = 52, nAD = 43). At this time point, the AD patients were still older, had fewer 
years of education, and a lower level of income than the controls. At Time 2 there were 
46 participants (nHC = 27, nAD = 19), the groups were similar in terms of age, but AD 
patients still had significantly fewer years of education and a lower level of income.  
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The number of participants decreased from Baseline to Time 1 and from Time 1 
to Time 2. The reasons for this attrition will be discussed in more detail in the General 
Discussion. In general, across the three measurement points, the AD patients were 
older, had fewer years of education, and a lower household income. AD patients also 
had consistently lower cognitive scores than controls, as could be expected.  
 
Hypothesis-Driven Analyses 
Hypothesis 1 was not confirmed: Baseline levels of psychosocial stress and 
cortisol did not predict cognitive change. Cognitive change was measured by the 
change in CAMCOG-R total scores across the three measurement points, namely, 
Baseline, Time 1, and Time 2. Across the entire sample, change in cognitive 
performance, as measured by the CAMCOG-R total score, was not significantly 
different across these measurement points. 
A GLM-RM explored whether Baseline age (in years), education (in years), 
APOE-є4 carrier status (as a dichotomous variable, i.e. with or without), cortisol (log 
transformed data), psychosocial stress (as measured by PSS scores), and group status 
(healthy control versus AD patient) predicted cognitive change. This model indicated 
that age, education, and group status contributed significantly to cognitive change: older 
participants with fewer years of education and with AD were more likely to 
demonstrate cognitive change than younger participants with more years of education 
and no cognitive impairment. There was also a significant time x group interaction; AD 
patients had greater cognitive change than controls. No significant main effect of 
APOE-є4 carrier status, cortisol levels or PSS scores was found and there were no other 
significant two-way interactions.  
Baseline levels of psychosocial stress as measured by the PSS were not 
significant predictors of cognitive change. Similarly, Baseline levels of log transformed 
cortisol as measured by the average of two morning measurements did not predict 
cognitive change. When analysed over the three time points, cortisol levels were not 
found to change significantly from one time point to another, although graphic 
representation of these levels shows a mild increase from Baseline to Time 1, with a 
subsequent plateau from Time 1 to Time 2. This pattern was seen in controls and AD 
patients.  
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Hypothesis 2 was not confirmed: Baseline levels of psychosocial stress and 
cortisol did not predict decline. Cognitive decline was defined as a drop of 1 or more 
point(s) on the MMSE from Baseline to Time 1, and a drop of 2 or more points from 
Baseline to Time 2. Based on such decline, participants were divided into two groups: 
Decliners and Non-decliners. Baseline levels of psychosocial stress tended to be higher 
in Decliners than Non-decliners. Baseline cortisol levels were not found to be higher in 
Decliners than Non-decliners.  
Hypothesis 3 was not confirmed: Participants who were APOE-є4 carriers were 
not more likely to have cognitive decline than participants who were not carriers. This 
result was found for measurements at Baseline to Time 1 and from Baseline to Time 2. 
 
Exploratory Analyses 
 Based on reports in the literature of cortisol increasing with age, levels of 
cortisol in this study were examined over the three year time period. Not all participants 
provided salivary cortisol samples for all three measur ment points; some provided for 
only one or two measurement points. Cortisol levels were not found to change 
significantly with age; this was common to both the controls and AD patients.  
 In summary, the findings from this longitudinal study did not confirm my 
hypotheses. Baseline psychosocial stress, Baseline cortisol levels, and APOE-є4 were 
not significant predictors of cognitive change or cognitive decline. Age, education, and 
group status contributed significantly to cognitive change but not to cognitive decline. 
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CHAPTER FOUR: GENERAL DISCUSSION 
 
The primary aim of this thesis was to investigate the role of stress (and other 
well-established stress- and dementia-related vulnerabilities) in predicting age-related 
cognitive impairment and cognitive decline in older South African adults. Despite the 
fact that South Africans have high rates of exposure to traumatic life events and 
psychosocial stress (Williams et al., 2007), and that the country has a growing 
population of older adults, this is the first such investigation in this low- and middle-
income country, 
The dissertation presented two studies. The first was of a cross-sectional design 
(Study 1), and the second of a longitudinal design (Study 2). In both, cognition was the 
main outcome variable. Throughout, I treated it as a continuous variable, ranging across 
a healthy control group and an Alzheimer’s disease group, because I wanted to capture 
a spectrum of cognitive functioning in healthy adults and in patients with mild to 
moderate AD.   
The purpose of Study 1 was to explore, in a sample of cognitively healthy older 
adults and AD patients, associations between cognitive functioning, and factors 
established in previously published literature as being stress- and dementia-related 
vulnerabilities. These factors included self-perceived psychosocial stress, levels of 
circulating cortisol, APOE-є4 carrier status, plasma beta-amyloid concentrations, and 
hippocampal volume. I explored bi- and multivariate relationships among these 
variables, as well as their predictive role in cognitive functioning. The investigation also 
included sociodemographic (e.g., age, sex, and level of complete education) and 
personality (e.g., resilience) variables. 
A major reason driving the inclusion of so many variables of interest, and of 
pursuing such a wide-ranging investigation, is that there is no single factor that, in 
isolation, causes age-related cognitive decline and/or sporadic AD. Hence, it made 
sense to examine several factors simultaneously, in one large model. Using hierarchical 
regression analyses, I was able to identify those factors most strongly related to 
cognitive functioning in this sample.  
Study 2 built on the results of Study 1; variables that significantly predicted 
cognitive functioning in Study 1 were explored as potential predictors of longitudinal 
cognitive change and cognitive decline in Study 2. In the latter, I assessed participants’ 
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cognition annually over 3 years (the Baseline measurement taken in Study 1, and then 
two follow-ups). Study 2 also had a particular interest in investigating the role of 
psychosocial and physiological stress in cognitive change/decline over time.  
Given the primary aims and the design elements described above, the main set 
of results discussed here are those from Study 1’s hierarchical regression model – the 
largest model examined in this research (i.e., the one that included the biggest set of 
predictors). Discussion of these regression results is combined with the results from 
Study 2 pertaining to predictors of longitudinal cognitive change and decline.  
The rest of this General Discussion is divided into several discrete sections. The 
first is a brief review of the sample characteristics. Then, I discuss each factor of 
interest in order of its entry into the regression model in Study 1 (i.e., age, sex, 
education, APOE-є4, cortisol, and psychosocial stress). That discussion focuses on each 
factor in terms of its role in both the cross-sectional and longitudinal studies (that is to 
say, its impact on cognitive functioning at Baseline and on subsequent cognitive change 
and decline), and in terms of its association with stress. I then discuss resilience, Aβ, 
and hippocampal volumes separately because they were not included in the hierarchical 
regression model. Resilience was not included in the model due to its correlation with 
psychosocial stress, and only a subset of participants was included for the Aβ and 
neuroimaging components of the study. This General Discussion section concludes 
with brief considerations of the management of stress, contextual factors, 
methodological limitations, reflections, future recommendations, and a summary and 
conclusion.  
  
Cross-Sectional and Longitudinal Results in the Context of the Literature 
Sample characteristics. At baseline, the sample comprised 134 older adults, of 
whom 69 were cognitively healthy controls and 65 were patients with possible or 
probable AD, diagnosed according to the NINCDS/ADRDA and the DSM-IV-TR 
criteria. On average, controls were younger than AD patients and had significantly more 
years of education. In both groups there was almost double the number of female than 
male participants, although this difference was not significant in either group. 
Regarding SES status, AD patients had a lower socioeconomic status in terms of 
monthly household income than controls.  
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This sample was followed up over a period of up to 3 years. A number of 
participants were lost to follow-up, however. This attrition occurred because some (a) 
were no longer willing to participate, (b) were no longer testable because of ailing 
health, or (c) had died. Another reason for the decline in sample size from Baseline to 
subsequent assessments was that several people were enrolled in the study in the final 
year of recruitment and therefore had not been in the study long enough to have a 
follow-up assessment. The reason for enrolling these participants even though they 
would be ineligible for follow-up assessment was that I wanted to have the largest 
possible sample size at baseline so as to be able to include a substantial number of 
predictors in the regression model. 
Across the entire sample, the only significant difference between the 
participants who remained in the study relative to those who withdrew was age; 
younger participants were more likely to remain in the study than older participants. 
Five participants died during the study; two were controls and three were AD patients. 
There did not appear to be any particular pattern of cognitive or functional indicators 
that characterized these participants.  
Models of cognitive functioning at Baseline and over time. This next section 
will discuss the findings in relation to each main factor of interest. These factors will be 
discussed in order of their entry into the regression model, followed by the remaining 
factors that were explored outside the regression model. In other words, the factors will 
be discussed in this order: age, sex, level of education, APOE-є4, cortisol, and 
psychosocial stress. I shall then discuss the results pertaining to resilience, Aβ, and 
hippocampal volumes. 
Predictor 1: Age. This was the first predictor variable entered into the cross-
sectional hierarchical regression model, and it proved to be a significant predictor of 
cognitive functioning. This result is not surprising because (a) numerous previous 
studies have established that cognitive functioning is vulnerable to the effects of ageing 
(Gunstad et al., 2006; Greenwood, 2000), and (b) even cognitively healthy older adults 
perform more poorly than young adults on cognitive tests (Gunstad et al., 2006; Tsang 
& Shaner, 1998; Verhaeghen & Cerella, 2002; Ferstl, 2006; Mata, Schooler, & 
Rieskamp, 2007).  
Over the 3-year study period, including three annual measurement points, the 
cognitive performance of controls remained largely consistent whereas that of AD 
patients declined over time. This finding was not unexpected; i.e. cognitive 
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performance in the healthy controls was likely to remain fairly constant but the AD 
patients would decline over time, given that progressive cognitive decline is a key 
feature of, and a diagnostic criterion for, AD (Dubois et al., 2007; McKhann et al., 
1984; Morris, 2006).  
Data analyses in the longitudinal study also confirmed that age was a significant 
predictor of cognitive change; specifically, those who were older at Baseline 
demonstrated more cognitive change over time. Similarly, in terms of cognitive decline, 
those participants who declined compared to those who did not decline tended to be 
older; although this result did not reach statistical significance, a small-to-moderate 
effect size was achieved. This finding was not unexpected because increasing age has 
been associated with accelerated cognitive decline (Alley et al., 2007).  
In terms of the relationship between age and self-reported current psychosocial 
stress, in both controls and AD patients there was a negative association. This finding 
may seem strange in light of the fact that older adults are likely to experience several 
stressors later in life, especially related to, for instance, the experience of chronic health 
conditions or the loss of a spouse (Krause, 1999). However, a decrease in self-perceived 
stress with advancing age may not actually reflect fewer experiences of stress. Instead, 
it is more likely to reflect the way in which older adults appraise stressful situations 
(Boeninger, Shiraishi, Aldwin, & Spiro, 2009). Another suggestion is that the nature of 
stress changes as people get older; stressful events are more likely to be of a chronic 
than episodic nature, thus providing individuals with more time to come to terms with 
their problems and to use previously successful strategies in managing them (Aldwin, 
Sutton, & Lachman, 1996).  One might also suggest that, as disease progresses in AD 
patients, their insight may become impaired to the point that their self-reported level of 
psychosocial stress might not be an accurate reflection of their actual experienced levels 
of psychosocial stress. This latter situation might have arisen in the current study. 
However, at Baseline, the AD patients in this sample were in the mild to moderate 
stages of AD, where insight is, generally speaking, relatively well preserved. 
 In summary, age was an important predictor of cognitive functioning in both the 
cross-sectional and longitudinal studies. Additionally, age was negatively correlated 
with levels of self-perceived psychosocial stress. Both these findings are consistent with 
previously published studies.  
Predictor 2: Sex. This dichotomous variable was the second predictor entered 
into the cross-sectional hierarchical regression model. At Baseline and across the entire 
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sample, there were no significant sex differences in CAMCOG-R performance; 
similarly, in the regression model, sex was not a significant predictor of cognitive 
functioning. This finding is inconsistent with previous reports demonstrating that 
cognitively healthy men and women perform differently on cognitive tasks (Meinz & 
Salthouse, 1998; Reilly, 2012; Torres et al., 2006; Voyer, Voyer, & Bryden, 1995). 
Most studies reporting differences in cognitive function between men and women have 
investigated different domains of cognitive function; i.e. women have been found to 
perform more strongly than men on verbal tasks and men outperform women on 
visuospatial tasks (Weiss et al., 2003). In my study I examined men’s and women’s 
cognitive performance on a general measure of cognitive functioning and not on 
specific cognitive domains. Therefore the ability to detect sex differences in cognition 
may have been lost because all the cognitive domains were explored together.  
There was a significant association between sex and self-reported current 
psychosocial stress in both the AD patient and control groups. Specifically, male AD 
patients had significantly higher levels of psychosocial stress than female AD patients. 
A possible explanation for this pattern of data may relate to sex differences in stress 
appraisal and coping mechanisms in the context of chronic illness; biological sex plays 
a role in the determinants and consequences of poor health (Vlassoff, 2007). To my 
knowledge, levels of psychosocial stress between male and female AD patients have 
not been reported. I would propose that the male AD patients, in the early-to-moderate 
disease stage that they were in and thus with relatively preserved insight, had higher 
levels of psychosocial stress because they felt that their disease threatened their role as a 
“provider”. Related to this, they may also have had financial concerns.  
In the control group, females had higher levels of psychosocial stress than 
males. This result is consistent with reports from other studies of cognitively healthy 
older adults (Cohen & Janicki-Deverts, 2012). It is likely that environmental factors are 
likely to account for this difference. Healthy older females may be caregivers to sick 
family members or a spouse. They may also have concerns related to performing 
domestic work and maintaining a household even though they themselves are getting 
older and may have their own health concerns. Many of the female control participants 
in my study still lived independently and were responsible for many household chores, 
in addition to caring for a sick husband or looking after their grandchildren during the 
day. 
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There were no sex differences across the sample or within each group 
separately, on any of the other measures of stress (viz., lifetime traumatic experiences 
or morning cortisol levels). Regarding cortisol, the non-significant difference between 
males and females contradicts what has been reported elsewhere for older adults. For 
instance, Kudielka et al. (1998) showed that elderly men have higher free salivary 
cortisol levels than elderly women. Most studies of sex differences in salivary cortisol 
levels have been performed in relation to HPA axis reactivity. My study examined sex 
differences in unstimulated salivary cortisol levels. This methodological difference may 
account for the lack of a difference between male and female cortisol levels in my 
study.   
In summary, findings from the cross-sectional study suggested that sex was not 
a significant predictor of cognitive functioning, but that there were sex differences in 
terms of self-reported psychosocial stress, and that the pattern of these differences was 
different in AD patients to that in controls. This difference may be accounted for by sex 
differences in stress appraisal and coping mechanisms between healthy older adults and 
older adults with chronic disease. I did not examine the predictive value of sex in the 
longitudinal study because (a) it was not part of any of my specific hypotheses, and (b) 
in this sample, it was not a significant predictor of cognitive functioning at Baseline. 
Predictor 3: Level of education. This was the third predictor variable entered 
into the cross-sectional hierarchical regression model, and it proved to be a significant 
predictor of cognitive functioning. This finding supported the significant bivariate 
correlation between education and cognition in this sample (regardless of group status, 
participants with more years of education had higher cognitive scores). In fact, in the 
regression model, years of completed education contributed the largest amount of 
variance to the outcome. This finding is consistent with those reported in numerous 
studies describing strong associations between education and cognitive performance in 
older adults (Ganguli et al., 2010; Muniz-Terrera, Matthews, Dening, Huppert, & 
Brayne, 2009; Schneider et al., 2012). 
In the longitudinal study, education also contributed significantly to the variance 
in cognitive change. Specifically, participants with higher levels of education scored 
better on the CAMCOG-R across time than participants with lower levels of education.  
In contrast to the significant role of education in predicting cognitive change 
across the three measurement points, it was not a significant factor in predicting 
cognitive decline between Baseline and Time 1, and between Baseline and Time 2. In 
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other words, there was no difference in years of education between those who did and 
those who did not decline between those time points. One way to account for this 
apparent discrepancy is that, across time, there was more attrition of participants with 
low education; these individuals, therefore, were not present at Time 1 and Time 2 (see 
Table 20), and hence there was less variation in education in the cognitive decline 
models. Furthermore, the effect sizes for these analyses were small, suggesting that the 
sample was not large enough to detect a significant effect.  
Nonetheless, this pattern of findings is consistent with previous reports showing 
that education level is highly correlated with cognitive performance at Baseline but is 
not associated with cognitive decline after that (Muniz-Terrera et al., 2009; Schneider et 
al., 2012; Wilson et al., 2009). Higher Baseline cognitive performance of individuals 
with more education might account for the lower rates of cognitive decline in those 
individuals. This may be as a result of education masking the effects of such decline. 
As noted earlier, at Baseline measurement, controls had significantly higher 
levels of education than AD patients. This between-group difference remained at Time 
1 and Time 2. This finding is consistent with the cognitive reserve hypothesis (Stern, 
2009), which proposes that education is a proxy for a ‘reserve’ (associated with more 
flexibility and efficiency in handling adaptive problems) that protects against the 
clinical manifestation of neuropathology. The current finding also corresponds with 
those presented by Roe et al. (2007), who reported that a diagnosis of AD was less 
likely to be found in older adults with higher levels of education. However, this 
beneficial effect of education seems not to be consistent across time as education has 
been shown not to be a significant predictor of cognitive decline (Wilson et al., 2009; 
Woodard et al., 2010).  
I also examined the association between level of education and (a) resilience and 
(b) self-reported current psychosocial stress. Across the entire sample, there was a 
significant correlation between education and resilience. This finding is consistent with 
previous studies suggesting that higher levels of education are associated with increased 
resilience and better coping mechanisms (Frankenberg et al., 2013). Individuals with 
more years of education may have developed better coping mechanisms and may have 
more access to resources that help them to deal with problems. For example, they may 
have an enhanced sense of control over their life which is likely to act as a 
psychological buffer against potential stressors (Fast, Gruenfeld, Sivanathan, & 
Galinsky, 2009).  
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In this sample, there was a trend for participants with higher levels of education 
to have lower psychosocial stress scores. This finding is consistent with previous 
reports suggesting that better-educated adults, partly as a result of higher SES status, 
have lower stress levels (Baum, Garofalo, & Yali, 1999; Grzywacz et al., 2004). This 
pattern of data could also be considered in light of the cognitive reserve hypothesis. For 
instance, if individuals with higher levels of education are better equipped to cope with 
pathological brain changes than individuals with lower levels of education (Meng & 
D'Arcy, 2012), they may also be more able and better prepared to cope with 
psychosocial stress. This may be because they have developed enhanced problem-
solving skills and reasoning ability, for instance, and therefore may be better equipped 
to deal with problems that may arise. Higher levels of education are also likely to lead 
to improved occupational attainment and an increased level of income; these factors 
may ameliorate the negative effects of stress by preventing certain stressors from 
occurring, such as those related to severe financial stress due to a low level of 
occupation, or living in a less advantaged area where levels of crime are high.  
In summary, findings from the cross-sectional study suggest that level of 
education was a strong predictor of cognitive performance. In the longitudinal study, 
however, education was not associated with cognitive decline. It is possible that the 
effect of education on cognitive decline might have been masked because several 
participants with lower levels of education were lost to follow-up. The general trend for 
education not to be a contributor to cognitive decline, however, has been reported in 
studies elsewhere. Finally, in a finding that was consistent with previously published 
studies, there was a negative correlation between years of completed education and self-
reported current psychosocial stress.  
Predictor 4: APOE-є4. This was the fourth predictor variable entered into the 
cross-sectional hierarchical regression model. In this sample that was representative of 
the heterogeneous population of the Western Cape, the overall APOE-є4 allelic 
frequency was 26%, and was significantly higher in AD patients (35%) than in controls 
(19%). This patient:control ratio is consistent with findings from other research studies, 
mostly conducted using European and North American populations (Farrer et al., 1997; 
Hua et al., 2008; Raygani et al., 2005; Tsai et al., 1994).  
The allelic frequency of APOE-є4 is known to be higher in African populations, 
generally, and in sub-Saharan Africa, particularly. In fact, the Khoi-San population of 
southern Africa has the highest reported є4 allelic frequency in the world, at 37% 
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(Sandholzer, et al., 1995). Joska et al. (2010) reported an є4 allelic frequency of 30% in 
a predominantly black African Xhosa-speaking population from the Western Cape 
region of South Africa. 
The APOE-є4 allelic frequency found for cognitively healthy controls in this 
study (19%) is higher than that reported in North American and European studies 
(Farrer et al., 1997; Sando et al., 2008b; Singh, Singh, & Mastana, 2006), but is similar 
to that reported in other studies of African populations. In Americans of European 
ancestry, the population allelic frequency is estimated at 10-12% (Farrer et al., 1997).  
In contrast, the APOE-є4 allelic frequency found for AD patients in this study 
(35%) is similar to that reported for samples of European and North American ancestry. 
The latter has been estimated at 40% (Mayeux, 2003; Sando et al., 2008b; Tsai et al., 
1994), but it is markedly higher than frequencies reported in AD patients of African 
descent from West African studies (Gureje et al., 2006; Osuntokun et al., 1995).  
How, then, can these results be explained? The population of the Western Cape 
region of South Africa is heterogeneous. This diversity arises from the establishment of 
a people of mixed ancestry that today is known as the South African Coloured 
population. Today, that group is estimated to comprise about 54% of the population of 
the Western Cape Province (Adhikari, 2005; de Wit et al., 2010). Most people classified 
as Coloured under the previous system of “race” classification have a mixed genetic 
ancestry, with significant contributions from the indigenous African populations as well 
as from the European settler populations. Recently, a genome-wide analysis of the 
structure of the Coloured population in the Western Cape was performed. This analysis 
revealed that the major ancestral components of this population comprised mainly 
Khoi-San, Bantu-speaking Africans, European, and a smaller Asian contribution (de 
Wit et al., 2010). Because 55% (25 controls and 49 AD patients) of the participants in 
the current sample self-identified as Coloured, the high background allelic frequency of 
є4 in the sample might be explained by this indigenous ancestry. 
From an evolutionary perspective, the є4 allele of the APOE gene has been 
considered a ‘thrifty’ allele (Corbo & Scacchi, 1999). This means it has an evolutionary 
advantage in conditions of nutrient deprivation and starvation. It may also be protective 
against infectious diseases (Wozniak et al., 2002), and it may protect cognition in 
children in LAMIC rural areas where the burden of enteric disease is high (Oria et al., 
2005). However, the allele appears to become disadvantageous when the human 
lifespan increases, and when the same population it protected under challenging 
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conditions, is exposed to an industrialized “Western” environment where relatively 
cheap, processed, low-fibre and high saturated fat foods are available more readily. 
Hence, the allele that was once protective becomes a risk factor for certain medical 
conditions, including AD (Corbo & Scacchi, 1999). The data presented here support 
this argument: the AD patients had a significantly higher APOE-є4 frequency than 
controls. 
 The є4 allele, already present in a higher frequency in our study population, 
may increase susceptibility to developing AD in this ageing, urbanised population. 
Indeed, this phenomenon has been reported for other industrialized countries. Other 
African studies, including one comparing a Yoruba population in Nigeria with that of a 
genetically related African-American population in Indianapolis, USA, did not find an 
association between presence of APOE-є4 and AD in the Nigerian population (Gureje 
et al., 2006; Osuntokun et al., 1995), but such an association was found in the African-
American population (Murrell et al., 2006). The lack of association between presence of 
APOE-є4 and AD in the Nigerian population is probably accounted for by genetic, 
environmental, and dietary factors, as well as genetic/environmental interactions (Hall 
et al., 2006). In my study, I did not explore the role of other genetic (non-APOE), 
environmental, or dietary factors on the relationship between APOE-є4 and AD. Future 
research could examine whether such factors play a role in this population.  
The biological mechanisms underlying the increased susceptibility to AD 
conferred by possession of the APOE-є4 allele are not the primary focus of my study. 
However, mechanisms that have been postulated include a greater susceptibility of the 
E4 isoform of the protein, compared with the E2 and E3 variants, to oxidative damage 
(Lane & Farlow, 2005). The damaged or oxidised APOE-є4 could then result in 
defective cholesterol transport to damaged CNS structures during the process of cell 
repair. Also, the clearing of beta-amyloid from the brain by the oxidized APOE-є4 may 
be less efficient than that by the E2 or E3 isoforms (Mahley, Weisgraber, & Huang, 
2009).  
Data from the cross-sectional study suggested that APOE-є4 carrier status was a 
significant predictor of cognitive functioning: Those with the є4 allele performed more 
poorly on the CAMCOG-R than those without the allele. Although AD patients had a 
significantly higher є4 allelic frequency than controls, within the AD patient group 
there was no significant difference, at Baseline, in cognitive performance between those 
patients with and without є4. 
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Data from the longitudinal study suggested that APOE-є4 carrier status was not 
a significant predictor of cognitive change across time. Furthermore, there was a 
relatively equal distribution of APOE-є4 carriers and non-carriers among participants 
who demonstrated cognitive decline between Baseline and Time 1, or between Baseline 
and Time 2. The lack of an association between APOE-є4 carrier status and cognitive 
change/decline stands in contrast to the findings of Cosentino and colleagues (2008); in 
their study, APOE-є4 carrier status was associated with faster cognitive decline in an 
incident population-based AD group. Those authors proposed that the effect of APOE-
є4 on cognitive decline is prominent in the earliest stages of AD. APOE-є4 has also 
been associated with cognitive decline in non-pathological ageing (Schiepers et al., 
2012). 
In contrast to the relationship between APOE-є4 and cognitive decline in 
cognitively healthy adults, there are recent data to support the current findings of a lack 
of association between APOE-є4 and cognitive decline. Bunce et al. (2013) examined 
APOE genotype and cognitive change in a longitudinal population-based study of 
cognitively healthy adults in their 20s, 40s, and 60s. They reported that without 
dementia-related neuropathology, the APOE genotype had no effect on cognitive 
change in early, middle, or late adulthood. Where they did find an є4-related cognitive 
decline in older adults, they suggested it was linked to a preclinical period of dementia 
that had not yet been identified as such. 
In summary, the APOE-є4 allelic frequency in this sample was relatively high 
and can be explained by the partial African ancestry of the population from which the 
sample was drawn. In the current sample, APOE-є4 carrier status was a significant 
predictor of cognitive functioning at Baseline, but not of cognitive decline over the 
follow-up period. Furthermore, there were no APOE-є4 by cortisol interaction effects 
with regard to cognitive functioning. Other environmental factors not explored in this 
study (e.g., diet and increased longevity within the population) are likely to interact 
with the APOE-є4 allele and increase the susceptibility to developing AD. APOE-є4 
was also explored in relation to psychosocial stress and cortisol; these findings are 
discussed in the relevant sections below. 
Predictor 5: Cortisol. The log transformed salivary cortisol data constituted the 
fifth predictor variable entered into the cross-sectional hierarchical regression model. 
As noted earlier, a major driving component of the research described in this 
dissertation is the concept that stress is linked to cognitive impairment via changes that 
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occur in HPA-axis functioning. A marker of HPA-axis activity is the hormone cortisol 
(Aguilera, 2011; Foley & Kirschbaum, 2010; Henry, 1992; McEwen & Sapolsky, 1995; 
McEwen & Stellar, 1993; Sapolsky, 1996; Selye, 1976; Tsigos & Chrousos, 2002). 
There is strong evidence that chronically elevated cortisol levels can cause damage to 
the brain and contribute to age-associated pathology such as neurodegeneration 
(Aguilera, 2011; McEwen & Stellar, 1993; Sapolsky, 1999). 
Several studies have explored the association between chronically elevated 
cortisol levels and cognitive functioning in ageing. In my cross-sectional study, 
morning salivary levels of circulating cortisol did not predict cognitive functioning. 
This lack of association was found in controls, in AD patients, and when analysed 
across the entire sample; it was true in bivariate correlational analyses and in the 
regression model. This set of findings disconfirmed my initial hypotheses, and stands in 
contrast to some previous studies (see Lee et al., 2007; Lupien at al., 1994). A possible 
reason for this discrepancy may relate to the cortisol measurements themselves, i.e. the 
time of day and the number of measurements obtained. In the studies mentioned above, 
several cortisol measurements were obtained throughout the day. In my study, I 
obtained one 9am measurement of cortisol per day for two consecutive days at each 
time point. It is possible that obtaining several measurements of cortisol may have 
produced a different result. However, another study using the 9am salivary cortisol 
measurement reported an inverse association between cortisol and memory recall in 
older adults with mild cognitive impairment but this association was not found in 
controls or AD patients (Wolf, Convit, Thorn, & de Leon, 2002). One could also 
speculate about the role of the inverted U-shaped function in regard to why I did not 
find an association between cognition and cortisol (Diamond, Bennett, Fleshner, & 
Rose, 1992). This inverted U-shape relationship implies that very high or very low 
levels of cortisol impair cognition, while moderate levels may facilitate memory 
(Lupien & McEwen, 1997). The association between cognition and cortisol levels 
reported by Lupien et al. (1994) was for high cortisol levels. The cortisol levels of 
participants in this study may not have been high enough to impair cognition. However, 
this is rank speculation because I did not have a measure of the AD patients’ pre-
morbid basal cortisol levels against which to compare their current levels and thus 
based on these data I cannot provide support for a U-shaped relationship. 
However, it could also be argued that an association between morning salivary 
cortisol levels and cognitive functioning just does not exist. For example, Peavy et al. 
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(2007) found a lack of association between cortisol levels and performance on memory 
tests. Additionally, Schrijvers et al. (2011) reported that morning serum levels of 
cortisol were not related to cognitive functioning in the Rotterdam study, a large 
prospective population based cohort study. One might question the fact that the 
Rotterdam study used serum and not salivary cortisol, as in mine and the study of Peavy 
et al. However, studies that have used serum cortisol as opposed to salivary cortisol are 
comparable because serum and salivary cortisol are well correlated and salivary cortisol 
levels have been shown to be a surrogate for serum cortisol (Dorn, Lucke, Loucks, & 
Berga, 2007).  
In the cross-sectional study, the lack of a significant between-group difference 
for controls and AD patients in terms of morning levels of salivary cortisol was 
unexpected. In my a priori hypothesis I predicted that cortisol levels would be higher in 
AD patients than in controls. The association between AD and cortisol levels has been 
reported elsewhere (Csernansky et al., 2006; Giubilei et al., 2001). Cortisol levels in 
AD patients have been shown to be higher compared to cognitively healthy controls 
(Umegaki et al., 2000; Swanwick et al., 1998).  One way to account for the non-
significant between-group difference in my study may relate to a flattening of the HPA 
axis diurnal amplitude. HPA-axis activity is known to flatten with age, and particularly 
in older adults with dementia (Ferrari et al., 2000; Deuschle, 1997). The AD patients in 
my study were older than the controls; a combination of older age and disease 
progression may have produced a flattened HPA-axis profile in the AD patients, thus 
possibly explaining similar cortisol levels between the groups. However, this is a 
tentative suggestion because I did not have knowledge of whether the AD patients’ 
HPA axis profiles differed from controls at Baseline.  
Findings from the longitudinal study showed a small but statistically non-
significant increase from Baseline in morning levels of circulating cortisol over the 3-
year follow-up period in both controls and AD patients. Baseline cortisol levels had no 
predictive effect on either cognitive change or cognitive decline over time. These data 
are not consistent with the glucocorticoid hypothesis of the pathophysiology of mild to 
moderate AD. A lack of support for this hypothesis does, however, confirm similar 
previous reports (Schrijvers et al., 2011; Swanwick et al., 1998). In the study by 
Swanwick et al., they reported that, although HPA-axis dysfunction correlated with 
severity of AD at Baseline, it did not increase at follow-up. A possible reason for this 
finding in my study relates to evidence which suggests that the effects of elevated 
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cortisol are only noticeable when those levels are sustained over an extended period of 
time (Lupien et al., 1998). In this sample, controls and AD patients reported similar 
levels of lifetime stress. Therefore, it could be speculated that if there were no between-
group differences for lifetime stress then there may not have been between-group 
differences in levels of cortisol. However, the relationship between the experience of 
psychosocial stress and the release of cortisol and its circulating levels is not 
straightforward. For example, chronic stress may evoke adaptive physiological 
mechanisms so that cortisol levels may not increase proportionately to stress levels (de 
Kloet, Joels, & Holsboer, 2005). Another possible explanation for the lack of significant 
change in cortisol over time relates to reports of high intra-individual stability of 
salivary cortisol (Shirtcliff et al., 2012). Researchers in this field have hypothesized that 
cortisol may be regarded as a psychological trait which may account for its stability 
over time (Wust, Federenko, Hellhammer, & Kirschbaum, 2000). Furthermore, cortisol 
and individual vulnerability to the negative effects of stress on cognitive functioning 
may thus be influenced to some degree by genetic factors (Kreek, Nielsen, Butelman, & 
LaForge, 2005; Polk, Cohen, Doyle, Skoner, & Kirschbaum, 2005; van Santen et al., 
2011; Wust, et al., 2000).  
One such genetic factor that has been associated with stress and with AD is 
APOE-є4. Study 1’s data analysis detected no significant main effect of either cortisol 
or APOE-є4, and no significant interaction effect of the two variables, on cognitive 
functioning. These findings, then, are not consistent with reports in previous studies 
suggesting that the interaction between higher stress levels and presence of APOE-є4 is 
associated with poorer cognitive functioning (Gerritsen, Comijs, Deeg, Penninx, & 
Geerlings, 2011; Lee et al., 2008; Peavy et al., 2007). Possible reasons for the 
discrepancy may relate to the measurement of cortisol. For instance, Lee and colleagues 
(2008) measured salivary cortisol at the time of cognitive testing, therefore measuring 
HPA-axis reactivity to the assessment situation. However, in my study I measured 
unstimulated morning cortisol levels and did not measure HPA-axis reactivity. The 
APOE-є4 by cortisol interaction may be stronger when HPA axis reactivity rather than 
unstimulated cortisol levels is measured. Hence, Lee et al. may have shown a stronger 
association of cortisol and APOE-є4 with cognition because they measured the actual 
response to stress and the sensitivity of the HPA axis feedback system. 
Another reason for the lack of an APOE-є4 by cortisol interaction may relate to 
the measures of cognition employed in various studies. Those studies that have found 
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significant APOE-є4 by cortisol interaction effects have used discrete measures of 
memory. In my study, however, I used a measure of general cognitive functioning and 
did not have a discrete measure of memory. One might suggest that using a specific 
measure of memory might have produced a different result, given that cortisol affects 
the hippocampus which plays a crucial role in new learning and memory. Thus, larger 
differences in memory performance than in general cognitive performance may have 
demonstrated a significant APOE-є4 by cortisol interaction. On the other hand, though, 
one could argue that this effect should still have been seen in my study because 
glucocorticoid receptors are distributed throughout the brain and thus several domains 
of cognition may be affected by such an interaction, as shown by Lee et al. (2008). 
The discussion above has focused on the factors of interest in this study and 
their association with cortisol. There are, however, several other factors known to be 
associated with salivary cortisol levels, such as age and BMI (Daniel et al., 2006), mood 
(Het, Schoofs, Rohleder, & Wolf, 2012; Polk, Cohen, Doyle, Skoner, & Kirschbaum, 
2005), activity level (West, Otte, Geher, Johnson, & Mohr, 2004; Rimmele et al., 2009), 
and medical conditions (Roberts, Wessely, Chalder, Papadopoulos, & Cleare, 2004). 
Hence, even though there were no between-group differences in terms of BMI in my 
study, and age was controlled for, it is possible that other factors contributed to the lack 
of association between salivary cortisol levels and cognition. Furthermore, it must be 
noted that I only measured morning salivary cortisol levels which do not reflect the 
circadian rhythm of cortisol secretion. Future studies may benefit from including 
several measurements of cortisol throughout the day to obtain an indicator of the HPA 
axis functioning. 
In summary, in the current sample there was no significant association between 
cortisol and cognitive functioning at Baseline, or between cortisol and cognitive 
change/decline over time. This finding, while inconsistent with some studies, has been 
reported in other studies. There are several possible reasons for this lack of association 
which may relate to the measurement of cortisol itself (i.e. the time of day and the 
number of measurements), measurement of unstimulated cortisol, flattening of the HPA 
axis diurnal amplitude in the AD patients, or the possibility, as demonstrated in this 
sample and in other studies, that morning levels of cortisol are not predictors of 
cognitive functioning or decline.  
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Predictor 6: Psychosocial stress. This was the sixth, and final, predictor 
variable entered into the cross-sectional hierarchical regression model. It proved to be a 
non-significant predictor of cognitive functioning. 
Regarding measurement of ‘psychosocial stress’, in this study scores on the 
Perceived Stress Scale (PSS) captured the construct. In other words, these scores 
provided an indicator of how stressful participants perceived their lives to have been 
over the past month. This self-perceived psychosocial stress resulted primarily from the 
experience of minor daily stressors and agitations. One might question, then, whether 
AD patients were reliably able to report experiencing such stress, given their memory 
impairment. These patients were, however, in the mild to moderate stages of AD and 
were capable of recalling how stressful their life had felt over the past month. In several 
cases, relatives of the patients confirmed that the answers provided by the patients were 
veridical, to the best of their knowledge.  
In the current sample, AD patients had significantly higher levels of Baseline 
psychosocial stress than controls. Clearly, one can make no inferences of causation 
based on this limited dataset and design. One possible interpretation of the data, 
however, is that AD patients may have had higher levels of psychosocial stress 
throughout their lifetimes, and this may have contributed to their development of the 
disease. This interpretation is supported by longitudinal studies that have tracked 
psychosocial stress and risk of developing AD over several years (Johansson et al., 
2010; Wilson et al., 2003; Wilson, Begeny, Boyle, Schneider, & Bennett, 2011). For 
example, in a 35 year longitudinal study, Johansson et al. (2010) examined mid-life 
stress and the risk of dementia (105 of the 161 dementia cases were AD). Reports of 
frequent/constant stress at one, two, or three time points during this period were related 
to risk of developing dementia, including AD. This interpretation is also supported by 
reviews which implicate stress as a role player in the development of AD (Lupien, 
McEwen, Gunnar, & Heim, 2009; Sotiropoulos et al., 2008). 
An alternative interpretation is that the AD patients may have reported higher 
levels of psychosocial stress because their memory (and other cognitive) problems 
concerned them greatly. This interpretation is supported by findings that AD patients 
experience and demonstrate high levels of anxiety (Ferretti, McCurry, Logsdon, 
Gibbons, & Teri, 2001; Porter et al., 2003; Teri et al., 1999). Furthermore, recent 
studies have found that AD patients report lower levels of quality of life compared with 
reports from caregivers. AD patients with the lowest ratings of quality of life had a 
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better cognitive status and more depression (Conde-Sala et al., 2013; Xing et al., 2012). 
The latter is known to be associated with stress (Sotiropoulos et al., 2008). 
A third interpretation is that higher levels of psychosocial stress in AD patients 
might be attributable to their lower SES status levels (recall that, in this sample, AD 
patients reported having a significantly lower monthly household income than controls). 
Cohen and Janicki-Deverts (2012) studied the distributions of psychological stress in 
the United States in a series of probability samples. They found that adults with low 
SES status were most likely to experience the highest levels of stress and associated 
disease risk. However, given that those findings (and those reported here) are strictly 
correlational, one should be cautious in suggesting that increased financial concerns 
have a significant causal impact on self-reported levels of psychosocial stress, and that 
this chain then represents a risk for AD. 
Of course, the three interpretations outlined above might not (and probably do 
not) exist in isolation from one another. In other words, accepting one interpretation 
does not mean one has to discard the other two. Rather, it is possible that all three (and, 
perhaps, other factors) contribute in some degree to the observed relationship between 
SES status and psychosocial stress in AD patients. Distinguishing the precise 
mechanisms underlying the relationship is, clearly, a complex task, and one that was not 
the focus of this investigation. Here, it must suffice to say that, in the current sample, 
AD patients reported experiencing more psychosocial stress and lower income than 
controls. Psychosocial stress did not play a significant role in predicting cognitive 
functioning in the sample. SES status was not specifically explored with psychosocial 
stress because SES status was highly correlated with education. Rather, education and 
psychosocial stress relationships were examined and those have already been discussed.  
As mentioned earlier, psychosocial stress was not a predictor of cognitive 
functioning. Of note, however, is that this lack of association between psychosocial 
stress and cognitive functioning is not consistent with some previous reports. For 
example, Neupert and colleagues (2006) found, in a sample of 333 older adults in the 
VA Normative Aging Study, that daily stressors were associated with everyday memory 
failures. Similarly, research involving a cohort of older men from the Normative Aging 
Study found similar associations between psychosocial stress (as measured by the PSS) 
and MMSE score (Peters et al., 2010). The authors reported that participants with 
higher PSS scores had a 0.57-point lower MMSE score. 
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Results from the longitudinal study suggested that Baseline levels of 
psychosocial stress did not have any effect on cognitive change over time. Again, this 
finding stands in contrast to results reported by Wilson et al. (2007), who found, in a 
sample of 1, 256 cognitively healthy individuals (mean age: 76.8 years) that individuals 
who were more prone to experience psychological distress experienced more cognitive 
change over a 12-year period. 
In terms of cognitive decline, there was no significant difference in Baseline 
levels of psychosocial stress between those participants who declined and those who did 
not. My finding does not correspond with those from epidemiological studies that have 
demonstrated that cognitive decline is accelerated by chronic psychological stress 
(Peavy et al., 2009; Wilson et al., 2007). 
A possible explanation for the discrepancy between the current findings and 
those of Peavy et al. (2009) and Wilson et al. (2007) relates to the stage of cognitive 
functioning that participants were in. Peavy et al. only found an association between 
stress and cognitive decline in participants who were already cognitively impaired, 
while Wilson and colleagues only examined stress and worsening cognitive function in 
healthy adults. It is possible that the effects of stress differ depending on the level of 
cognitive functioning or stage of cognitive decline at which one is. The differential 
effects of stage may have been lost if all participants were regarded as one category. 
However, in my study, post-hoc analyses indicated a similar non-significant finding 
between cognitive decline and psychosocial stress when examined in the control and 
AD patient groups separately. A post-hoc power analysis for the entire sample showed 
that there was insufficient power (N = 95) to detect a medium-sized effect; actual power 
of 0.40, with ideal power (1 - β) set at .80 and α = .05, two-tailed, and a small-to-
medium effect size of 0.36.  
In summary, the data analyses reported here suggest that current levels of 
psychosocial stress do not have a significant effect on (a) the baseline cognitive 
functioning of older adults, and (b) subsequent cognitive change or decline. These 
findings contrast with several previous studies which have found such associations. 
Furthermore, these findings were unexpected because South Africa has high levels of 
community and interpersonal violence, as well as a history of severe socio-political 
instability (Barber, 1999; Finchilescu & Dawes, 1999; Hamber & Lewis, 1997). Thus, it 
is likely that older adults who have lived in this country for all or most of their lives 
would have experienced numerous traumatic life events and would have relatively high 
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levels of psychosocial stress (Williams et al., 2007). One might expect, then, given 
previous literature, that a stress-cognitive function link would be clear in a South 
African sample. 
Findings regarding resilience. Levels of resilience may account for some of 
the individual differences in the response to psychosocial stress and adversity. Although 
resilience (as measured by the CD-RISC) was not included as a predictor variable in the 
cross-sectional hierarchical regression model, I did conduct a subset of analyses 
featuring it because of its purported link to lifetime trauma and current psychosocial 
stress. 
In controls, AD patients, and across the entire sample, there was a significant 
inverse relationship between levels of resilience and psychosocial stress, indicating that 
participants with lower levels of resilience had higher levels of psychosocial stress. This 
finding was expected and is consistent with similar results found elsewhere in older 
adults (Yehuda & Flory, 2007; Wagnild, 2003). Furthermore, across the entire sample, 
education and resilience were positively correlated, indicating that participants with 
higher levels of education had higher levels of resilience. This finding is not surprising 
because higher levels of education are likely to lead to a better occupation and living 
conditions, which in turn may provide a more supportive environment than one might 
have with lower levels of education and poor job prospects. However, any causal 
inference regarding the relationship between level of education and resilience in later 
life in this study cannot be drawn. Furthermore, education and income are closely 
intertwined, and the single effect of one variable over another on resilience cannot be 
determined. It is likely that both these factors affect levels of resilience, independently 
and interactively (Muller, 2002; Taylor, et al., 2010).  
Findings regarding beta-amyloid. The literature indicates that changes in the 
levels of the different Aβ peptides that are produced are detectable in the plasma, occur 
in a preclinical stage of AD, and they persist with disease progression. 
In this study, AD patients had a lower plasma Aβ1-42/Aβ1-40 ratio than age-
matched controls. Although this between-group difference was not statistically 
significant, the comparison was associated with a relatively large effect size (d = 1.05). 
Current opinion in the literature suggests that a lower plasma Aβ1-42/Aβ1-40 ratio 
predicts the development of AD (Graff-Radford et al., 2007; Koyama et al., 2012; van 
Oijen, Hofman, Soares, Koudstaal, & Breteler, 2006). Furthermore, a lower plasma 
Aβ1-42/Aβ1-40 ratio has been observed in AD patients with established disease 
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compared with healthy controls (Lui et al., 2010). A recent study confirmed the decline 
of this ratio in AD patients over a period of 18 months (Rembach et al., 2013). The data 
reported here were generally consistent with this literature in that the plasma Aβ1-
42/Aβ1-40 ratio in my study correlated positively and significantly with cognitive 
performance. No inference can be made, however, regarding the causal role of the 
plasma Aβ1-42/Aβ1-40 ratio in cognitive performance. It was not surprising, though, 
that the plasma Aβ1-42/Aβ1-40 ratio in this study was lower in AD patients compared 
with controls. The AD patients were in the mild to moderate stages of the disease and 
one could speculate that they had already experienced this decline in the Aβ1-42/Aβ1-
40 ratio. 
Regarding the specific concentrations of Aβ1-42 and Aβ1-40, I found lower 
levels of plasma Aβ1-42 and slightly higher levels of Aβ1-40 in AD patients relative to 
controls, but these results were not statistically significant. Previous findings with 
regards to the independent roles of Aβ1-42 and Aβ1-40 in AD have been contradictory: 
Some studies have reported elevated levels of Aβ1-42 and Aβ1-40 in the early stages of 
AD (Mayeux et al., 2003), whereas others reported that only Aβ1-40 was higher in AD 
patients than in controls (Mehta et al., 2000). Consistent with the current findings, Lui 
et al. (2010) reported lower plasma Aβ1-42 levels in AD patients relative to controls. 
Furthermore, a meta-analysis of 12 cross-sectional studies concluded that AD patients 
had marginally but non-significantly lower plasma Aβ1-42 levels compared with 
cognitively normal individuals; there was also no significant difference in Aβ1-40 
levels (Song et al., 2011).   
A study investigating the predictive value of Aβ in an elderly population without 
dementia (N = 1, 125) found that higher plasma Aβ1-42 levels at the onset of the study 
related to a threefold increased risk of AD (Schupf et al., 2008). However, a decline in 
Aβ1-42 and a decreased Aβ1-42/Aβ1-40 ratio was linked with conversion to AD. In my 
study, the AD process had already begun in the cognitively impaired AD participants 
and plasma Aβ1-42 may have already declined from previous levels.  
Murine studies have reported relationships between psychosocial stressors, 
HPA-axis response to stress, elevated glucocorticoids, and increased production of Aβ 
(Carroll et al., 2011; Dong & Csernansky, 2009; Green et al., 2006). The direction of 
the relationship is a positive one, where increased stress is associated with increased Aβ 
production. For example, Kang et al. (2007) demonstrated that chronic and acute stress 
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increased Aβ levels in the brain interstitial fluid in amyloid precursor protein transgenic 
mice. 
In this study, when analysing the entire sample, I found that there were no 
significant correlations between any of the Aβ levels and psychosocial stress, between 
Aβ1-42 and cortisol, and between Aβ1-40 and cortisol. There was, however, a 
significant negative correlation between cortisol levels and the Aβ1-42/Aβ1-40 ratio 
(i.e. lower Aβ1-42/Aβ1-40 ratios were associated with higher cortisol levels). This 
finding is interesting because, as noted above, lower Aβ1-42/Aβ1-40 ratios are also 
strongly related to the presence of AD. This set of findings raises the question about 
whether there might be an interactive role of stress and Aβ in humans with AD. 
However, all the nuances of this question make it a complex one, and it would need 
examination in a longitudinal design featuring a much larger sample of older adults than 
that reported on here. Aβ is known to change over time; future studies that monitor the 
trajectory of plasma Aβ levels in cognitively healthy and AD individuals are likely to 
yield reliable information in this regard.  
To my knowledge, this is the first study to determine plasma Aβ peptide 
concentrations in older adults from an African population. The results from my study 
did not show any obvious relationships between Aβ and psychosocial stress. However, 
the significant negative correlation between cortisol levels and the Aβ1-42/Aβ1-40 ratio 
was interesting and raises questions for future research. Although previously published 
studies have found some associations between plasma Aβ and the presence and 
progression of AD, it remains an open question as to whether a plasma-based test for 
the detection of Aβ is going to become a useful diagnostic marker for AD. One could 
speculate that if well-designed longitudinal studies of plasma Aβ and risk of AD 
showed promising results, this could pave the way for a valid, non-invasive method in 
which to diagnose AD.  
Findings regarding hippocampal volume. The hippocampal formation is 
important to research in the cognitive neuroscience of ageing, and to current research, 
because (a) it is one of the earliest brain structures to be affected in AD, (b) it may incur 
structural and functional damage as a result of stress and cortisol levels (Bremner, 
2006), and (c) hippocampal damage can impair learning and memory performance 
(Lupien et al., 1997b). To my knowledge, this is the first African study that reports 
results of manual tracing of the hippocampi of older adults with and without cognitive 
impairment. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
179 
 
In this sample, AD patients had significantly smaller right, left, and total 
hippocampal volumes than controls. These findings are consistent with those of 
previously published studies (Jack, Jr. et al., 1997; Pennanen et al., 2004). Other 
findings were as follows: First, across the entire sample, ICV-adjusted hippocampal 
volumes (right, left, and total) were significantly associated with MMSE and Learning 
subscale scores. Second, AD patients with the є4 allele had smaller ICV-adjusted total 
hippocampal volumes than those without the є4 allele. This latter finding is consistent 
with those reported by several previous MRI studies (Geroldi et al., 1999; Hashimoto et 
al., 2001; Pievani et al., 2011; Spampinato, Rumboldt, Hosker, & Mintzer, 2011).  
Review of the literature indicates evidence for the relationship between stress 
and hippocampal volume. In animals, a body of literature supports the notion that the 
hippocampus is selectively vulnerable to the effects of chronic stress (Lee, Jarome, Li, 
Kim, & Helmstetter, 2009; Magarinos, McEwen, Flugge, & Fuchs, 1996; McEwen & 
Sapolsky, 1995; Watanabe, Gould, & McEwen, 1992). Similarly, in humans, elevated 
cortisol levels are associated with and predictive of hippocampal atrophy (Lupien et al., 
1998; Lupien et al., 2009; McEwen & Sapolsky, 1995; Sapolsky, 2000). The current 
data analyses did not detect such associations, however. There was no main effect of 
cortisol (and no cortisol by APOE-є4 interaction) on ICV-adjusted hippocampal 
volumes. Furthermore, there was no significant association between psychosocial stress 
and hippocampal volume.  
There remains controversy surrounding the question of whether, in humans, 
encounters with stressors, and consequent activation of the physiological stress 
response, causes reduced hippocampal volumes. A relatively large body of literature 
has shown that, in comparison with controls, individuals diagnosed with post-traumatic 
stress disorder (PTSD) have smaller hippocampal volumes (Bremner, 2005; Gurvits et 
al., 1996; Smith, 2005; Villarreal et al., 2002). This finding suggests that reduced 
hippocampal volume may result from repeated exposure to stress and a consequent 
increase in glucocorticoid levels. However, it is also possible that smaller hippocampal 
volume may predispose individuals to the development of pathological post-traumatic 
stress responses, such as those seen in PTSD (Sapolsky, 2002; Wignall et al., 2004; 
Woodward et al., 2006). The latter idea is supported, for example, by the finding that, in 
monozygotic twins with different trauma exposure histories, smaller hippocampi 
constituted a pre-existing vulnerability for the development of stress-related 
psychopathology (Gilbertson et al., 2002). The current state of the literature supports a 
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role for stress in hippocampal atrophy. This is well demonstrated in animals; evidence 
in humans is becoming increasingly convincing. However, regarding the human studies, 
there is no conclusive evidence for the direction of the relationship between stress and 
hippocampal atrophy. 
In summary, findings from my study indicated that hippocampal volumes in AD 
patients were significantly smaller than in controls. This finding is in agreement with 
MRI studies globally. In AD patients, smaller hippocampal volumes were associated 
with the APOE-є4 allele. Such findings suggest a role for APOE-є4 in hippocampal 
atrophy in AD; however, the role at this point is purely one of association, as causation 
cannot be established. Cortisol levels were not associated with hippocampal volumes.  
 
Results in Terms of the Research Framework 
Having now discussed the results pertaining to investigation of all the variables 
of interest in this study (i.e., their relationships with cognitive functioning, with 
cognitive change, with cognitive decline, and with stress), I refer back to Figure 3 
(Study 1, page 61). That figure was a schematic representation of the research areas of 
interest in this study, namely, age, education, resilience, psychosocial stress, cortisol, 
APOE-є4, beta-amyloid, and hippocampal volume, and it addressed a key theme: that 
there are several factors associated with cognitive impairment, and that some of these 
factors are inherent and some are modifiable in early life but less so in later life. The 
methods employed in this dissertation have shown that the possible effects of these 
factors, on cognitive functioning and on each other, are measureable through the use of 
neuropsychological testing, neuroradiological imaging, and biochemical tests of blood 
samples.  
The results presented in Study 1 and Study 2 are in keeping with the general 
framework of this dissertation illustrated by that figure: multiple factors are associated 
with cognitive functioning in older adults, and some of those factors are associated with 
cognitive decline post-baseline. With the interplay among different factors, the results 
show that there is no single profile of factors predictive of cognitive functioning or 
cognitive decline.  
Furthermore, the figure alluded to the lasting effects that stress (psychosocial 
and physiological) can have on cognitive function and on brain structure. In this 
sample, however, stress was not a significant predictor of cognitive functioning at the 
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Baseline assessment or of cognitive change/decline over time. However, in participants 
with measured cognitive impairment (i.e., those in the AD patient group), levels of 
psychosocial stress were significantly higher than in controls. 
 
The Significance of Stress in the Context of Cognition: Can it be Managed?  
Even though my study did not find stress to be a significant contributor to 
cognitive functioning or change/decline, this result appears somewhat anomalous in the 
context of the broader literature. Hence, it remains an important factor for consideration 
especially because it is potentially modifiable. In this section, I focus briefly on the 
importance of stress in cognitive functioning and ways in which stress can be dealt with 
in order to minimise its adverse effects on cognition.  
All human beings experience stress-inducing events during their lifetime. Some 
of these events are completely out of the individual’s control, especially when they 
occur early in life. Human and animal studies have shown that early developmental 
stress, which can even occur during the intra-uterine and neonatal periods, can have 
long-lasting effects that influence ageing (McEwen, 2008; Solas et al., 2010).  
 On the other hand, even though we are perhaps unable to control the occurrence 
of traumatic life events and daily stressors, we might be able to control our response to 
stress. In other words, the physiological response to an event that might otherwise be 
stressful is a potentially modifiable variable among the numerous factors 
(sociodemographic, environmental, genetic, personality, etc.) that affect the way in 
which we age. 
Pharmacological manipulation and psychosocial management are two ways of 
modifying or controlling the physiological stress response. An example of the former is 
the use of beta-blockers (e.g., propranolol). The experience of stressors activates, 
among others, the locus coeruleus-noradrenergic system. This activation results in the 
release of norepinephrine, a stress hormone (Berridge & Waterhouse, 2003; 
Charmandari, Tsigos, & Chrousos, 2005; Tsigos & Chrousos, 2002). This hormone 
increases the state of arousal, which precipitates further physiological changes as part of 
the stress response (Morilak et al., 2005). One of the roles of beta-blockers is to inhibit 
the action of norepinephrine (Aston-Jones, Gonzalez, & Doran, 2007; Chavey, 2000; 
Dodt, Breckling, Derad, Fehm, & Born, 1997).  
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The use of beta-blockers to inhibit the negative effects of stress on the brain has 
been examined in experimental studies. For example, in a sample of participants who 
had recently experienced a traumatic event (motor vehicle accident or physical assault), 
some of the participants were prescribed a non-selective beta blocker, propranolol, 2-20 
hours post-trauma (Vaiva et al., 2003). The results indicated that PTSD rates were 
higher in participants who did not take the drug compared with those who did take it. 
Based on those results, the authors suggested that immediate treatment with propranolol 
post-trauma might have a mitigating or even preventative effect on subsequent 
development of PTSD. Similarly, a Cochrane Review assessed findings in 35 short-
term randomised controlled trials of pharmacotherapy for PTSD (Stein, Ipser, & Seedat, 
2006). The types of pharmacotherapy reviewed included several different lines of 
treatment, such as anti-depressive agents, monoamine oxidase inhibitors, selective 
serotonin reuptake inhibitors, or tricyclic drugs. The review reported that symptom 
severity for 17 trials was significantly reduced in the medication groups, compared to 
the placebo groups.  
The effects of stress are also amenable to social interventions and 
psychotherapeutic strategies. Such non-pharmacological management of stress includes 
developing coping strategies, such as relaxation or social skills, to deal with anxiety- 
and stress-evoking experiences (Cottraux, 2002). Cognitive therapy is also effective in 
the management of stress (Baddeley & Gros, 2013; Granath, Ingvarsson, von, & 
Lundberg, 2006; Jenni & Wollersheim, 1979). Regular exercise, healthy diet, and social 
support have also been shown to be targets for behavioural interventions that moderate 
the effects of chronic stress and provide beneficial effects for brain and body health 
(Cohen & Wills, 1985; Duman, 2005; McEwen & Wingfield, 2010; Petruzzello, 
Landers, Hatfield, Kubitz, & Salazar, 1991; Scully, Kremer, Meade, Graham, & 
Dudgeon, 1998). 
The literature provides support for the potential modification of stress. This is 
encouraging in light of the fact that stress has been linked to several health conditions, 
including mental health. Although stress, in isolation, did not have an influence on 
cognitive functioning in my study, it was related to other factors which may then affect 
cognitive functioning. Thus, finding effective ways to manage stress may have benefits 
on several areas of health, which in turn may then benefit cognition. 
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The Broader Social Perspective 
As is the case in most LAMICs, South Africa will, over the next few decades, 
continue to experience urbanisation and an increase in life expectancy (United Nations 
Population Division, 2006). Age-related diseases in South Africa are going to become 
more prevalent because people are living longer. The South African healthcare system 
is currently ill-equipped to deal with the burden of age-related disease, and there are 
few community-based and residential care facilities for people with AD and dementia 
(Kalula et al., 2010). Furthermore, Baiyewu and Potocnik (2005) reported that, at their 
count, there were only six outpatient psychiatric facilities for older adults in South 
Africa. This scarcity of such resources is not unusual in the African context or in 
LAMICs in general, and the responsibility of caring for older adults falls on relatives 
(Prince, 2004). For example, Ogunniyi et al. (2005) emphasised that, for older adults 
with dementia in Nigeria, support and care comes from the family, with limited public 
assistance.  
With these contextual factors in mind, the social and economic implications of a 
rising AD prevalence are considerable. There are costs associated with medical care, 
social costs incurred by carers who are forced to stop work, and costs associated with 
informal care (Prince, 2004). Linked with these costs, and experienced in HICs and 
LAMICs, is the burden placed on the families and informal caregivers of patients with 
dementia; they are faced with overwhelming emotional and physical pressures (Clay, 
Roth, Wadley, & Haley, 2008; Gronning et al., 2013; Ogunniyi et al., 2005; Okoye & 
Asa, 2013; Richardson, Lee, Berg-Weger, & Grossberg, 2013).  
Furthermore, older adults play an especially important role in South African 
society. In many cases, they help alleviate household financial strains by caring for (or 
even raising) grandchildren, caring for household members who are sick, disabled, or 
frail, and providing material and financial support for their offspring (Legido-Quigley, 
2003). In particular, they care for family members affected by HIV/AIDS, and for the 
dependents of those family members (Ferreira, Keikelame, & Mosaval, 2001).  
The valuable role that older adults play in South African society, therefore, 
highlights the importance of focusing on diseases that occur in this group. This study 
has contributed to awareness-creation around age-related cognitive impairment, and 
Alzheimer’s disease, in South Africa. Creating awareness about these topics will be 
useful in assisting policymaking decisions in SA. AD research in South Africa (and in 
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LAMICs generally) has the potential for researchers and policy makers to work together 
to shape governmental policies for meeting the needs of its growing population of older 
adults. It is becoming increasingly obvious that a plan of action for AD in South Africa 
is urgently required. In the United States, a recent report (NIH Research Portfolio 
Online Reporting Tools, 2012) stated that in HICs, research funding from public 
sources for AD research is currently one-tenth of the funding for cancer research. It is 
likely that a similar, if not worse, trend is to be found in LAMICs such as South Africa. 
Raising awareness and thus promoting the profile of AD may boost funding for 
research into age-related neurodegenerative diseases of all kinds. 
Creating awareness and enhanced understanding of AD is also important in 
dispelling the myths and superstitious beliefs that are commonly held about this disease, 
and therefore to reduce concealment of this disease as a result of these misconceptions 
(Kabir, Iliyasu, Abubakar, & Aliyu, 2004). Mental illness is still associated with 
significant stigma, and family members do not always encourage the pursuit of 
conventional treatment (Corrigan & Kleinlein, 2005). In Nigeria, it has been reported 
that in community-dwelling individuals, the preferred option in seeking treatment for 
mental illness is to visit spiritual and traditional healers, followed lastly by hospitals and 
Western medicine (Adewuya & Makanjuola, 2009). 
In conversations with older adults, particularly those from rural and township 
areas, I was told that when older adults begin to behave oddly and become forgetful, 
they are sometimes cast out from the community, or they are hidden away by the 
family. These older adults are often considered to be bewitched or possessed. Studies 
have demonstrated that symptoms of mental illness are considered by members of the 
public and by traditional healers to be caused by supernatural factors (Adelekan, 
Makanjuola, & Ndom, 2001; Makanjuola, Adelekan, & Morakinyo, 2000). Such 
attitudes towards mental illness create a barrier to seeking health care. Furthermore, 
negative attitudes towards individuals with mental illness have been reported 
(Igbinomwanhia, James, & Omoaregba, 2013).The Alzheimer’s Disease International 
World Alzheimer Report 2012 (Batsch & Mittelman, 2012) focused specifically on 
overcoming the stigma of dementia. Reducing the stigma associated with dementia is 
more likely to be achieved with well-developed and implemented political and public 
campaigns to encourage a society-level shift towards acceptance, inclusion, and proper 
treatment for people with dementia.  
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Methodological Limitations, Reflections, and Future Recommendations 
No research study is without its difficulties and void of limitations; this one was 
no exception. Finding appropriate individuals to participate was not easy, particularly in 
the case of the AD patients. There were several reasons for this. First, I sought AD 
patients who were in the mild to moderate stages of the disease. This specificity was 
problematic because, in general, patients who present at the local memory and geriatric 
outpatient clinics are often already in the moderate-to-late stages of the disease. The 
reason for this relatively late presentation is that the early cognitive symptoms of AD 
are often regarded by individuals and their relatives as part of normal ageing. Only 
when there are challenging behavioural and difficult personality changes do patients 
(or, more often, their family members) seek medical attention. In some cases, even if 
the patient was willing to participate in this study, the family members were not keen 
for their relative to enroll in the study. This was sometimes due to the fact that there 
were logistic difficulties related to relatives or caregivers working full-time, with no-
one available to accompany the individual to the study assessment (recall that a reliable 
informant was an inclusion criterion of the study). Sometimes, there were transport 
problems (e.g., a lack of access to personal transport). In such cases, where possible, we 
the research team, did our best to accommodate such individuals by arranging a 
personal driver to collect and return participants and their informants from their homes, 
and for a member of the research team to escort them between the hospital entrance and 
the clinic room.  
 In an attempt to overcome, or at least minimise, the difficulty I experienced in 
finding appropriate cases of patients with mild to moderate AD, I contacted GPs and 
asked if they were willing to assist by (a) allowing the research team to place approved 
advertisements in their practice rooms, and (b) referring potential early AD patients, 
with prior consent from the patient and his or her relative(s). Although GPs did not refer 
large numbers of AD patients, they were still a worthwhile recruitment source. 
Another methodological limitation relates to psychosocial stress. This is, to 
some degree, an abstract concept; the experience of stress is entirely subjective, and 
there is great inter- and intra-individual variation in its experience. Although the stress 
measures I used in this study assessed a combination of lifetime and recent stress, as 
well as measuring the self-perceived impact of that stress, it is not certain that these 
measures captured the entirety of the participants’ experiences of life stress. However, 
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the PSS and LTE-Q measures that I used have good psychometric properties, and the 
PSS, specifically, is the most widely used instrument for the appraisal of self-perceived 
current stress.  
Even though stress itself is an abstract concept, the effects of stress can be 
measured physiologically. I used the collection of morning salivary cortisol to provide a 
general indicator of physiological stress. However, I encountered some difficulty in 
relation to the collection of the saliva samples using the salivette devices. Even though 
we provided participants with clear and simple instructions about how to collect their 
saliva samples using the salivettes, there were still errors. One such error included not 
chewing on the sponge long enough for it to absorb enough saliva. The saliva sample 
collection procedure was particularly problematic with AD patients who did not always 
have someone available to assist with collection of their samples. In addition, resource 
and financial constraints permitted the collection of only two salivary cortisol 
measurements per person for each visit. Future research may benefit from the collection 
of several measurements across the day. Lastly, due to a laboratory error, one batch of 
saliva samples was spoiled; thus accounting for the reduced number of cortisol samples 
at Time 1 and Time 2 in addition to the participant attrition. 
 The generalizability of the findings from this study to the South African 
population as a whole may be limited because the participants in this sample all resided 
in the Western Cape province of the country. As mentioned previously, the Western 
Cape is a heterogeneous population; population groups in the other provinces of the 
country may vary due to different lineages and migration patterns (Statistics South 
Africa, 2013). Furthermore, the Western Cape has been shown to have the highest 
prevalence of mental disorders, with anxiety disorders being the most common 
disorder, compared with the other provinces of South Africa (Herman et al., 2009). The 
findings from my study should, therefore, be interpreted with caution when attempting 
to generalize about cognitive ageing in South Africa, let alone all of Africa. 
Although these methodological obstacles were challenging at the time, they 
provided opportunities to learn and encouraged creative thinking about how to adapt to 
these situations. One of the benefits of this study was that it contributed to raising 
awareness about AD in the local community. Many of the participants heard about the 
study by word of mouth: Friends or relatives were participating and, upon hearing about 
their participation, they too wanted to become involved. Most of the participants and 
informants involved in this study did not have much prior knowledge about AD; they 
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gained much through their involvement in the study. They understood better what the 
warning signs of AD are, what symptoms could be expected with disease progression, 
and whom they should consult with. Caregivers received advice about caring for 
patients with AD, and referrals to local support groups. Another positive point resulting 
from participation in the study was that some of the participants and/or their relatives 
felt that they had a voice in the context of a disease that was largely ignored in the 
South African public health sector. They appreciated that AD and its symptoms were 
not a normal part of ageing, that several symptoms were likely to occur, and that these 
symptoms were part of the disease and were not due to the patient being purposefully 
difficult. The latter enabled relatives and caregivers to be more tolerant and 
understanding towards the behaviours exhibited by the patient. So on an individual 
level, benefit from participation in this study appears to have been achieved.  
Obviously, there should be further research in the area of age-related cognitive 
functioning and AD in South Africa, especially in light of increasing longevity. The 
general recommendation for future research would be to increase the Baseline sample 
size and increase the time of follow-up. In the case of a neurodegenerative disease such 
as AD, a longitudinal study design is likely to elicit the most useful and applicable 
findings. Ideally, this design should include a large number of older adults who are 
cognitively healthy at Baseline. Such a design element would allow for the 
determination of risk factors for cognitive impairment and AD by monitoring factors 
associated with conversion to AD. 
Recommendations for future research also include tracking structural brain 
changes over time, with repeated MRI scans and measurement of hippocampal 
volumes. Had resources allowed, I should have liked to incorporate this design element 
into my study as it would have been useful to examine factors associated with 
hippocampal atrophy over time, instead of just at one cross-sectional measurement. 
Due to financial constraints, I was only able to investigate plasma Aβ in a small 
sample of participants. The initial results from this investigation suggest that this is an 
area worth further exploration, particularly because obtaining blood samples for the 
determination of plasma Aβ concentrations is easier and less invasive than obtaining 
CSF. Specifically, it would be interesting to examine longitudinally whether an 
interaction between lower Aβ1-42/Aβ1-40 ratios and higher cortisol levels increases the 
risk for developing cognitive impairment and AD. 
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The stress-related findings in my study did not confirm a priori predictions. 
South Africa has high levels of crime and violence, and levels of psychosocial stress are 
high. Within this population, it might be useful to assess levels of psychosocial stress 
across several time points, to monitor changes in stress levels over time. A study that 
employs multiple measurements of cognition, and of physiological and psychological 
stress, over several years may detect relationships that the current analyses did not. 
 
Summary and Conclusions 
To my knowledge, this is the first African study to investigate psychosocial 
stress, cortisol, APOE-є4, beta-amyloid, and hippocampal volume in a sample of older 
adults with and without cognitive impairment. It replicated established methods used in 
research studies emerging from high-income countries. The findings suggest that the 
Alzheimer’s disease profile found in this sample of older adults from the Western Cape 
in South Africa is similar to that found in previously published studies, most of which 
have emerged from high-income countries in Europe and North America.  
The conceptual framework upon which this study was based related to the multi-
factorial profile of age-related cognitive impairment in older adults. The findings 
support the concept that several factors, to varying degrees, contribute to cognitive 
impairment and change in cognition over time. Increasing age and fewer years of 
education played the most prominent role in this regard. In the cross-sectional study, 
increasing age, fewer years of education, and presence of APOE-є4 were significant 
predictors of cognitive functioning. However, when these factors were examined in the 
longitudinal study, they were not found to play a significant role in cognitive decline 
over a period of 3 years, although they contributed to cognitive change over that time 
period. This set of findings suggests that increasing age, lower education, and presence 
of APOE-є4 may contribute to the development of the disease, but that once the disease 
process has begun, their role in predicting cognitive decline is less clear. 
Stress, measured both subjectively (psychosocial) and objectively 
(physiological), was a focus of this research because it (a) has been shown to be 
associated with cognitive impairment and decline, and (b) was especially relevant to 
examine this factor in a LAMIC where the experience of psychosocial stress is known 
to be high. In the current sample, however, stress was not a significant predictor of 
Baseline cognitive functioning or subsequent cognitive change/decline. Although AD 
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patients did report higher levels of current psychosocial stress than controls, it remains 
an open question whether patients had higher levels of premorbid psychosocial stress, 
or whether they appraised their lives to be more stressful because they were 
experiencing the clinical symptoms of AD, such as memory loss and disorientation.  
The beta-amyloid and hippocampal volume analyses, although performed for 
small subsets of participants, showed associations with cognition, and with stress in the 
case of beta-amyloid. These findings suggest that future research in these areas in this 
population might be worthwhile.  
In conclusion, this study has set the platform for further research to be 
undertaken in this field and in this geographic context. This study has also gone some 
way toward creating awareness about age-related cognitive impairment and 
Alzheimer’s disease in the Western Cape province of South Africa. The profile of 
factors associated with cognitive functioning in this sample of older South African 
adults was similar to that found in studies from high-income countries. In this sample, 
however, neither psychosocial nor physiological stress was related to Baseline cognitive 
function or to subsequent cognitive decline. The discrepancy between the findings 
reported here and the previously published findings in this area of the literature may 
relate to between-study variance in (a) the stage of disease in the AD patient samples, or 
(b) the way in which cortisol was measured (i.e., the time of day at which 
measurements were taken, or differences in the number of measurements taken).  
This study provides novel information about South African older adults, and 
contributes more generally to knowledge about cognitive ageing and AD in low- and 
middle-income countries. Perhaps most importantly, the study highlights the 
importance for public health of understanding, treating, and (as far as possible) 
preventing age-associated cognitive disorders, particularly on a continent where they 
have largely been ignored. 
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Appendix A 
 
Sociodemographic Questionnaire 
 
1. Age: __________ 
2. Date of Birth (d/m/y): ______________ 
3. Sex (circle one):   Male  Female 
4. Race (circle one):   White  Black  Coloured  
Indian  Other: specify: ________________ 
5. Handedness (circle one):  Left  Right  Ambidextrous 
6. Home Language: 
________________________________________________________________ 
7. Do you speak any other languages? Please specify: 
____________________________________ 
8. Who was/were your primary caregiver(s) during your childhood? (E.g., parents, 
mother, father, grandmother, grandfather, uncle, aunt, etc.) 
____________________________________________ 
 
9.  Are you a caregiver? (Who do you care for?) 
______________________________________ 
10.  What is the total monthly income of the household in which you live? If you are a 
student please take care to put your immediate caregivers monthly income not your 
own (circle one):  
 
R0 – R499   R500 – R999   R1000 - R2499
   
R2500 – R5499  R5500 – R9999  R10 000+ 
11. What term best describes the kind of neighbourhood in which you grew up? 
SUBURBAN 
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URBAN 
TOWNSHIP 
INTERMEDIATE 
 
12. What is the name of the neighbourhood in which you grew up? 
___________________________________________________________________
_ 
Section A. Education 
 
13. Education (highest degree or grade completed): 
________________________________ 
 
14. What are the names of the schools you attended during your schooling career? 
 
Junior school    
 
 
High School  
 
 
15. If you attended multiple schools in high school, how many months/years roughly 
did you spend at each and which schools were they? 
 
 
16. Was most of your school education completed in a rural or urban setting (circle 
one)? 
 RURAL  URBAN 
17. In which language was most of your school education completed? 
_________________________ 
18. Did you have to repeat any grades?   YES  NO 
 If yes, please specify which grade(s): 
_____________________________________________ 
19. Did you receive a matric certificate?  __________________________ 
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20. If so, at which school did you complete your matric? 
__________________________ 
 
21. Did you matriculate from a public high school or a private high school (circle one)? 
 PUBLIC  PRIVATE 
 
22. Roughly how many students were there per teacher in high school (that which you 
matriculated from)? 
 
 
23. Did you, or are you presently, attending any tertiary education?  
YES             NO 
If yes, what are you studying? 
_______________________________________________________ 
Where are you studying? 
___________________________________________________________ 
 
Please only answer the following questions if you currently are NOT receiving any level 
of education  
24. Did you receive any further education post-matric? YES  NO  
 If yes, please specify at which institution/college etc. this was received:
 
 ________________________________________________________________
_ 
25. How many years of education did you receive post-matric? _________________ 
26. What field of study was this in? __________________________ 
27. Education (highest degree or grade completed):  ________________________ 
 
Section B: Health 
(Please circle the appropriate answer for each of the questions below) 
 
28. Would you say your birth was: Normal Abnormal  Don’t know 
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29. Have you ever experienced a head injury? (e.g., being hit on the head with an object 
and losing consciousness as a result)       
           YES
  NO  
 If yes, please specify: 
__________________________________________________________ 
30. Have you ever been involved in a motor vehicle accident?   
          YES 
 NO 
 If yes, how old were you at the time? 
______________________________________________ 
 
31. Have you ever had surgery?    YES   NO 
 If yes: 
What type of surgery? 
___________________________________________________ 
 
How old were you at the time of surgery? 
____________________________________ 
 
32. Do you now, or have you ever, experienced any of the following medical 
conditions: 
32.1. Allergies      YES  NO 
 If yes, please specify: 
__________________________________________________________ 
32.2. Asthma      YES  NO 
32.3. Tuberculosis      YES  NO 
32.4. Hypertension (high blood pressure)   YES  NO 
32.5. Epilepsy (i.e., seizures or fits)   YES  NO 
32.6. Neurological problems    YES  NO 
If yes, please specify: 
__________________________________________________________ 
32.7. Depression      YES  NO 
32.8. Treated for/ diagnosed with any memory problems or disorders  
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YES  NO 
If yes, please specify: 
__________________________________________________________ 
32.9. Learning difficulties (dyslexia, ADD/ADHD) YES  NO 
If yes, please specify: 
__________________________________________________________ 
32.10. Problems with your vision    YES  NO 
If yes, please specify: 
__________________________________________________________ 
32.11. Problems with your hearing    YES  NO 
If yes, please specify: 
__________________________________________________________ 
 
33. Do you have any family history of any of the above medical conditions? 
          YES 
 NO 
 If yes, please specify: 
__________________________________________________________ 
__________________________________________________________ 
 
34. Are you currently taking any prescription medication(s)?   
          YES 
 NO 
If yes, what medication(s)? 
______________________________________________________ 
 
35. Do you participant in mental activity?   YES  NO 
 
36. Do you participate in physical activity?   YES  NO 
 
37. Do you participant in religious activity?   YES  NO 
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Appendix B 
 
Altered CAMCOG-R Items for Use in a South African Population 
Question number Original question Revised question 
144 Can you tell me where we are 
now? For instance, what county 
(state) are we in? 
Can you tell me where we are 
now? For instance, what 
province are we in? 
146 What are two main streets 
nearby (or near your home)? 
What country are we in? 
155 Was there wireless/radio in this 
country before television 
was invented? 
Was there radio in this country 
before television was invented? 
157 I am going to show you some 
objects. Please tell me the name 
of each one. Show ‘Pictures for 
naming’ in booklet.  
[Pictures: (1) shoe, sandal; (2) 
typewriter; (3) scales; (4) 
suitcase, portmanteau;  
(5) barometer; (6) table lamp; 
lamp] 
I am g ing to show you some 
objects. Please tell me the 
name of each one. Show 
‘Pictures for naming’ in 
booklet. 
[Pictures: (1) shoe, sandal; (2) 
screwdriver; (3) clothes iron; 
(4) suitcase, portmanteau;  
(5) clock; (6) table lamp; lamp] 
164 Can you tell me what were the 
objects in the coloured pictures I 
showed you a little while ago? 
[Answer: (1) shoe, sandal; (2) 
typewriter; (3) scales; (4) 
suitcase, portmanteau;  
(5) barometer; (6) table lamp; 
lamp] 
Can you tell me what were the 
objects in the coloured pictures 
I showed you a little while ago?  
[Answer: (1) shoe, sandal; (2) 
screwdriver; (3) clothes iron; 
(4) suitcase, portmanteau;  
(5) clock; (6) table lamp; lamp] 
165 Which of these objects did I 
show you below? [Answer: (1) 
shoe, sandal; (2) screwdriver; 
(3) clothes iron; (4) suitcase, 
Which of these objects did I 
show you below? [Answer: (1) 
shoe, sandal; (2) screwdriver; 
(3) clothes iron; (4) suitcase, 
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portmanteau;  
(5) barometer; (6) table lamp; 
lamp] 
portmanteau;  
(5) clock; (6) table lamp; lamp] 
169 Who was the leader of the 
Russians in the Second World 
War? [Correct answer: Stalin] 
Who was the Prime Minister 
of South Africa during the 
Second World War? 
[Correct answer: Jan Smuts] 
170 What was Mae West famous 
for? 
[Correct answer: Entertainer, 
Film Star, life jacket] 
What was Louis Armstrong 
famous for? 
[Correct Answer: Singer, 
Saxophonist, Jazz Singer] 
171 Who was the famous flyer 
whose son was kidnapped? 
[Correct answer: Lindbergh] 
Which famous film, starring 
Vivien Leigh and Clark Gable 
was released in the 1930s? 
[Correct answer: Gone with the 
Wind] 
166a Who was the US President 
who was shot in Texas?  
[Correct answer: John F. 
Kennedy] 
What is the name of the South 
African prime minister who 
was stabbed in parliament? 
[Correct answer: Hendrik 
Verwoed] 
167a What is Yoko Ono famous for? 
[Correct Answer: Wife of 
Beatle, John Lennon] 
What is Steve Biko famous for? 
[Correct answer: Black 
activist, died in police custody] 
169a What was Edmund Hilary 
famous for? 
[Correct answer: First to reach 
summit of Mt Everest] 
Who was the first South African 
to win a Nobel Peace Prize? 
[Correct answer: Albert Luthuli] 
170a Who was the first woman Prime 
Minister of India? 
[Correct answer: Indira Ghandi] 
Who was the first surgeon to 
perform a heart transplant? 
[Correct answer: Christiaan 
(Chris) Barnard] 
171a Who was the famous cinema Which island off the coast of 
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actress who married Prince 
Rainier of Monaco? 
[Correct Answer: Grace 
Kelly] 
South Africa was used as a 
leper colony, military base and 
prison? 
[Correct answer: Robben 
Island] 
172 What is the name of the present 
King or Queen? 
What is the name of the present 
President of South Africa? 
173 Who is likely to be the next 
King or Queen? 
What was the full date when 
two planes flew into the Twin 
Towers in New York? 
[Correct answer: 11 September 
2001] 
174 What is the name of the Prime 
Minister? 
Who is the president of USA? 
176 Name the following three 
objects taking one second to say 
each: apple, table, penny. 
Name the following three 
objects taking one second to say 
each: apple, table, pen. 
180 What were the three objects I 
asked you to repeat a little while 
ago? 
[Correct answer: apple, table 
penny] 
What were the three objects I 
asked you to repeat a little while 
ago? 
[Correct answer: apple, table 
pen] 
190 Write this name and address on 
the envelope: 
Mr. John Brown 
42 West Street, Bedford 
Write this name and address on 
the envelope: 
Mr. John Brown 
42 West Street, Bellville 
195 If someone went shopping and 
was given 15 pence as change 
from £1, how much did they 
spend? 
If some went shopping and 
was given 15 cents as change 
from R1, how much did they 
spend? 
201 Who is this? 
[Show picture of (1) Queen; 
(2) Pope, Archbishop, Bishop] 
Who is this? 
[Show picture: (1) Archbishop 
Desmond Tutu; (2) Nelson 
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Mandela] 
203 Can you tell me who this is, or 
what he/she does? 
[Indicate any two people 
Available] 
Can you tell me who this is, or 
what he/she does?  
[Turn to the last section of the 
CAMCOG picture booklet and 
show any two pictures of people 
in service professions: 
policeman, doctor, nurse, 
fireman, priest] 
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Appendix C 
 
Participation Information Leaflet and Consent Form 
 
TITLE OF THE RESEARCH PROJECT: Risk factors for the development of 
cognitive 
impairment in the elderly  
 
PROTOCOL NUMBER:   
 
PRINCIPAL INVESTIGATOR: Dr Marc I Combrinck 
 
ADDRESS:   Divisions of Neurology and Geriatric Medicine, Department of 
Medicine, E7 Room 63, Groote Schuur Hospital, Private Bag X3, Observatory, Cape 
7935 
 
CONTACT NUMBER: +27 21 404 3198 or 404 3120 
 
We are inviting you to participate in a research project. Please take some time to read 
the information presented here. It explains the details of the project. If there are any 
aspects of the project you do not understand, please do not hesitate to ask the study staff 
or doctor.  It is important that you are fully satisfied that you clearly understand what 
this research entails and how you could be involved.  Your participation in the study is 
entirely voluntary and you are free to decline to participate.  If you say no, this will not 
affect you negatively in any way whatsoever.  It will not affect any future medical 
treatment you may need. You are also free to withdraw from the study at any point, 
even if you did initially agree to take part. You do not have to give a reason for 
withdrawing. 
 
This study has been approved by the Research Ethics Committee of the Faculty of 
Health Sciences of the University of Cape Town. It will be conducted according to the 
ethical guidelines and principles of the International Declaration of Helsinki, the South 
African Guidelines for Good Clinical Practice and the Medical Research Council 
(MRC) Ethical Guidelines for Research. 
 
This trial is being run by the Division of Neurology and the Institute of Ageing in 
Africa in the Department of Medicine at the University of Cape Town. We aim to 
recruit a total of 150 participants over a period of 3 years. 
 
 
What is this research study all about?  
 
Some people develop memory problems as they get older. Many elderly people have 
mild memory difficulties.  However, in a few, the problem may be more severe. We are 
interested in finding out more about what causes the difficulties with memory and other 
higher brain functions.  In order to do so, we should like to investigate these possible 
causes using a number of methods. These include blood tests, questions you would need 
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to answer about yourself, tests of memory and other higher brain functions, a CT scan 
of the brain, and tests of your saliva. In some instances we may, with your special 
permission, perform tests on the fluid covering your brain and spine by doing a lumbar 
puncture.  We shall also ask some of you to undergo a special scan known as an MRI at 
our research facility at Tygerberg Hospital. 
 
We are interested in testing people both with memory difficulties and those without, so 
that we can compare the two groups. In this way we might be able to identify causes of 
memory impairment. Our research findings may help to prevent, or to better diagnose 
and treat, these conditions in the future. 
 
Procedures 
 
If you agree to take part in the study and you meet all the conditions required to enter 
the study, you will be invited to visit our clinic on two separate days.  At these visits to 
our clinic we shall: 
 
(1) take a detailed history.  
(2) interview your relative/friend (someone who knows you well) to find out 
whether he/she thinks you have any memory difficulties. 
(3) perform a full physical examination. This will include measuring your 
blood pressure, listening to your heart and chest, examining the nervous 
system and testing your urine. 
(4) take approximately 36 ml (7 tablespoons) of blood to look for possible 
causes of memory impairment. These will include: 
 
(i) a blood sugar (glucose) (for diabetes) 
(ii) a blood cholesterol level 
(iii)tests of liver, kidney and thyroid gland function 
(iv) haemoglobin, blood cell counts 
(v) tests for vitamins or vitamin deficiencies (vitamin B-12 and 
homocysteine) 
(vi) a test for syphilis. (This test is routinely performed in hospital 
clinics because syphilis used to be a common cause of impairment of 
higher brain function in the past)  
(vii) a sample to measure inflammation in the blood 
(cytokines) 
 
(viii) one sample will be used to prepare DNA from your 
blood. We shall test this for a gene called apolipoprotein E (APOE). 
Some forms of this gene may be associated with a higher risk of 
developing memory problems. However, this test does not diagnose 
that you have, or will necessarily develop, memory problems. We are 
doing it purely for research; it may help us to better understand some 
causes of memory difficulties.  
 
(ix) A test for a chemical in the blood known as clusterin.  This 
chemical may be increased in people with memory difficulties. 
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(5) We shall ask you to complete questionnaires about yourself and we shall 
perform tests of your memory and other higher mental functions. These will be 
conducted in a quiet, relaxed atmosphere. We expect that these tests will be of 
about two hours’ duration. However, there will be opportunities to rest in-
between tests. 
 
(6) We shall perform a MRI scan of the brain. This is a special X-ray 
photograph that will show us the structure of your brain. It can detect lumps or 
masses inside the head and it might also give us some idea about brain 
shrinkage.  It will also show any obvious strokes that you might have had. If 
you like, we shall show you the pictures of your brain scan. 
 
(7) In some instances we may wish to perform a lumbar puncture to obtain a 
sample of the fluid (the cerebrospinal fluid or CSF) that surrounds the brain 
and the spinal cord. We shall only perform this test with your special 
permission and if we think the test will help diagnose and treat the cause of 
your memory problems.  We shall send the sample to the laboratory to test for 
infection or inflammation. We shall also store a sample in the freezer to be 
analysed at a later stage for chemicals related to inflammation (cytokines). 
   
 
If we think a lumbar puncture is necessary and if you agree, the test will be performed 
in our Neurology Ward at the Groote Schuur Hospital. You will need to rest in bed, 
lying flat, for a couple of hours afterwards. The test is usually well tolerated, especially 
in elderly people, and there are usually no side-effects. Occasionally some people 
develop headaches after the test, often a day or two later. We generally advise people to 
have a restful two days after the procedure and to drink plenty of fluids.  Should 
headaches occur, they are usually relieved by lying down flat and taking simple pain-
killers like paracetamol. Very rarel , some people (usually young adults) develop quite 
bad headaches and for this we may need to re-admit you to our hospital ward for pain 
relief.  We shall telephone all participants a day or two after the lumbar puncture to 
make sure they are okay. 
 
 
(8) We shall measure the levels of a stress hormone, cortisol, in your saliva 
(“spit”).  You or your relative will be asked to swab a sample of your saliva on 
three consecutive mornings at 09h00 a.m. We shall provide the swabs and the 
containers as well as clear instructions about how to collect and store the 
samples. The samples need to be kept refrigerated and one of the staff of our 
study group will collect them from you. 
 
 
If we find any abnormal results that we think will need further treatment, we shall 
contact you. With your permission, we shall refer you to the appropriate health services. 
For example, we may diagnose hypertension or diabetes mellitus for the first time. If we 
find that you or your relative/friend has a significant memory problem that is interfering 
with your daily living activities, we shall refer you to a Memory Clinic. Your 
permission will always be sought first. 
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(9) Some participants in the study will be asked to undergo a special type of 
brain scan which will be performed at the Cape Universities Brain Imaging 
Centre (CUBIC) at Tygerberg Hospital. This scan is called an MRI (magnetic 
resonance imaging) scan. It provides a detailed picture of the brain including 
the parts involved in memory. We are also able to measure chemicals in parts 
of the brain using what’s known as magnetic resonance spectroscopy (MRS).  
We shall provide transport for you to the facility at Tygerberg Hospital where 
necessary. On arrival we shall ask you and your relative questions regarding the 
following: whether you have had a cardiac pacemaker, a neuro-stimulator, previous eye 
injuries or a foreign body, previous neurosurgery, previous other surgery involving 
metal implants, a cochlear implant, whether you have been a welder or metal grinder 
and whether you are claustrophobic or not. The scan will require you to lie on your 
back on a table that will move into the scanning machine for the 30 to 40 minutes it will 
take for the scan to be completed. 
During this time you will be able to close your eyes and rest. You will also be able to 
talk to the study doctor/assistant at all times during the scan should you experience any 
discomfort. The scan is a safe procedure if you have been screened correctly for the 
presence of any magnetic material on or inside your body. As the scan is done in a 
relatively confined space, occasionally some people become anxious. This does not 
happen often, and if you feel anxious beforehand, we will spend time allowing you to 
get used to the surroundings before we begin. When the magnet in the machine is 
switched on, it will make some loud banging noises, but you will be clearly warned 
when this will take place. At this time you will feel nothing and the noise is not harmful 
to you in any way. To minimise the possible discomfort associated with this, we will 
give you some soft earplugs and will also put earphones on so that you can listen to 
music if you so choose.  
After the two baseline visits and the three collections of saliva, we would like to re-
assess your memory functions again at one, two and three years later, respectively, 
provided you continue to consent to participation in the study. 
 
 
What will your responsibilities be? 
 
You will be required to attend the study visit at the appropriate time and to participate 
as fully as you can with the tests and questionnaires. You should answer the questions 
as fully and honestly as you can. If there are any questions that you cannot, or do not 
wish to answer, you should tell us so. 
 
Will you benefit from taking part in this study? 
 
You will receive little direct benefit from the study. 
However, you will undergo a thorough medical check-up as part of the research 
protocol. As previously indicated, we shall, with your permission, refer you to the 
appropriate medical services if any treatable abnormalities are found. 
 
 
Are there any risks in your taking part in this research? 
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You may feel uncomfortable about answering some of the questions about yourself or 
your friend/relative. Some people don’t like talking, or knowing about, problems related 
to memory or thinking. You should feel free to mention your feelings or concerns to 
any member of the study team. 
 
If you do not agree to take part, what alternatives do you have? 
 
You are free not to participate in the study or to refuse parts of the study.  
 
Who will have access to your medical records? 
 
The information collected about you will be treated as confidential and protected.  If it 
is used in a publication or thesis, your identity will remain anonymous.  Only the direct 
study team will have full access to the information. If we need to refer you to a clinic 
for treatment, we will provide them with the relevant information needed to treat your 
condition.  
 
Will you be paid to take part in this study and are there any costs involved? 
 
You will not be paid to take part in the study but your transport costs will be covered 
for the study visit. You will be re-imbursed for the sum of R150-00. There will be no 
costs involved for you, if you do take part. 
 
 
Is there anything else that you should know or do? 
 You should inform our family practitioner or usual doctor that you are 
taking part in a research study.   
 You can contact Dr Marc Combrinck at tel (021) 404 3198 or 404 3120 
if you have any further queries or encounter any problems. 
 You can contact the Research Ethics Committee of the Health Sciences 
Faculty of the University of Cape Town 021-4066338 if you have any concerns 
or complaints that have not been adequately addressed by your study doctor. 
 You will receive a copy of this information and consent form for your 
own records. 
 
Declaration by participant and/or friend/relative/guardian 
By signing below, I …………………………………..…………., hereby agree to take 
part in the research study entitled: “Risk Factors for Cognitive Impairment in the 
Elderly” 
 
I declare that: 
 
 I have read or had read to me this information and consent form and 
it is written in a language with which I am fluent and comfortable. 
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 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have 
not been pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised 
or prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study 
doctor or researcher feels it is in my best interests, or if I do not follow the 
study plan, as agreed to. 
 
Signed at (place) ......................…........…………….. on (date) 
…………....……….. 2012. 
 
 .....................................................................   ...................................................................  
Signature of participant Signature of witness 
 
 
 .....................................................................   ...................................................................  
Signature of relative/friend/guardian Signature of witness 
 
 
 If the study doctor considers that I or my friend/relative should undergo 
a lumbar puncture, I shall agree to the test: 
 
      YES          NO 
                                                                       
 (Tick whichever box is appropriate) 
 
 I agree to undergo an MRI scan at Tygerberg Hospital 
 
 
                          YES          NO    
                                                                       
 (Tick whichever box is appropriate)  
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to 
………………………………….. 
 I encouraged him/her to ask questions and took adequate time to 
answer them. 
 I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
 I did/did not use an interpreter. (If an interpreter is used then the 
interpreter must sign the declaration below). 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 
2012. 
 
 
 .....................................................................   ...................................................................  
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) 
………………………………………. to explain the information in this 
document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans / Xhosa (delete whichever is not applicable). 
 We encouraged him/her to ask questions and took adequate time to 
answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of 
this informed consent document and has had all his/her question 
satisfactorily answered. 
 
Signed at (place) ......................…........…………….. on (date) …………....……………... 
 
 
 .....................................................................   ...................................................................  
 
Signature of interpreter Signature of witness 
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Appendix D 
 
Salivette Instructions 
 
 
Thank you again for agreeing to participate in this study. The following are the 
instructions for submitting 2 saliva samples, 2 consecutive days in a row at 9:00AM.  
 
12 hours before collecting a sample, the participant must not: 
1. Drink any alcohol/smoke cigarettes  
2. Have any dairy products, e.g., cheese, yoghurt, milk 
3. Have any fizzy drinks, oranges, lemons, pineapples (no citrus), sweets, 
chocolates 
4. Ingest or inhale any steroids, e.g., prednisone, prednisolone, 
methylprednisolone 
 
When taking the sample at 9:00AM: 
1. Make sure you have had breakfast by 7:30AM or otherwise only have breakfast 
after you have taken your sample i.e. after 9:00AM. 
(It is sometimes easier to avoid eating or drinking anything other than 
water before taking the sample). 
2. Wash out your mouth with water 10 minutes before taking the sample. 
3. Remove the saliva “sponge” collection device from container and chew on it for 
a minute. 
4. Place the sponge back in the container and make sure it is tightly closed/sealed. 
5. Place in freezer 
6. Once your sample has been taken you may eat or drink anything you wish 
 
After you have taken the sample: 
1. If both samples are collected please call Katharine James for collection: 021 404 
7750  
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Appendix E  
MRI Volunteer Screening Form and Consent 
 
 
Volunteer Information:   
                                
Name Contact number 
Date of Birth Project name 
Weight Principle investigator 
 
The following information is very important to ensure your safety and to prevent any interference during 
the MR procedure. 
Please answer the following questions (mark with an X):                      Yes            No     Don’t 
know 
Pacemaker    
Aneurism clips    
Artificial heart valve    
Vena cava filter    
Prosthesis (e.g. eye, breast etc.)    
Shrapnel in eye or body    
Neurostimulator    
Cochlear implant (ear) or hearing aid    
? Diabetic    
? Renal impairment    
? Asthma    
? Allergies    
? Any other implants (e.g. screws, plates, joint 
replacements) 
   
? Pregnant    
? Previous MRI investigation with intravenous contrast    
Is there any other device implanted or are there 
any other ailments that you think that we should be 
aware of? 
   
                                                                                                                      
I hereby acknowledge that the potential risks of the examination have been explained to me and that 
during the course of the investigation it may be necessary for the intravenous injection of a contrast 
agent. 
Attention: It is the policy of this institution not to discuss results of the MR investigation with the patients 
for ethical reasons. All enquiries in this regard should be directed to the referring physician. 
 
Signature:                                                                     Date:
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Appendix F 
 
Preliminary Results for the Structural Equation Model 
 
 Table F1 shows the results from the preliminary analyses that were explored in 
the SEM. The outcome variable was cognition which was further divided into 
Cognition Affected and Cognition Unaffected groups. These groups refer to the sum of 
scores from domains of cognition, as measured by the CAMCOG-R, which one would 
expect to be associated with mild to moderate AD (Memory, Orientation, Language), 
and those domains one would not expect to be affected in mild to moderate AD 
(Attention, Calculation, Praxis, Abstract Thinking, and Perception). As can be seen in 
this table, several variables were strongly correlated with both Cognition Affected and 
Cognition Unaffected.  
 
Table F1 
Correlations: Cognition affected and cognition unaffected with age, education, APOE-
є4, cortisol, psychosocial stress, and resilience at Baseline (N = 115)  
Variable 
Group 
Cognition Affected Cognition Unaffected 
  
Age -.33*** 
.52*** 
-.21* 
-.06 
-.18 
.41*** 
-.36*** 
.59*** 
-.21* 
-.06 
-.11 
.33*** 
Education  
APOE-є4 
Cortisol 
PSS 
Resilience 
Note. Values presented are for Pearson’s r. The variables Age and Education are 
measured in years. APOE-є4 = apolipoprotein є4; Cortisol = log transformed values. 
PSS = Perceived Stress Scale – measure of psychosocial stress; CD-RISC = Connor-
Davidson Resilience Scale – measure of resilience. 
*p < .05. **p < .01. ***p < .001. 
 
 
 
